STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 185452

TO: Alton Pryor **Location:** **Art Unit: 1616** **April 14, 2006** **Case Serial Number: 10/036546**	**From: P. Sheppard** **Location: Remsen Building** **Phone: (571) 272-2529** **sheppard@uspto.gov**

Search Notes

FOR OFFICIAL USE ONLY (T) ACCESS DB # _____

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Alton Pryor Examiner #: 74458 Date: 4/10/06

Art Unit: 1616 Phone Number: 2-0624 Serial Number: 10/036,546

Location (Bldg/Room#): REM4B39 Mailbox #): 4th FL Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

Search claim 34

a) L3 s propylene glycol ?caprylate? or Capax or Henkel or Edenol or Hodag or Inolex or Lexol or lipo or liponate or Miglyol or ~~Stepl~~ Stepan or neobee or trivent or unitolate or UPI

b) L4 s glycerol tris 2-ethylhexanoate or trioctanoin or ~~glycerin~~ triester of glycerin and 2-ethylhexanoic acid or Kyoei or Hexalan or Nikko or Nisshin or Nomcort or trivent

c) L5 s aerosol? or spray?

d) L11 s incapacit? or inflam? or compounds of claim 45

e) L3 a + L5 c + L11 d or L3 a (p) L5 c (p) L11 d

f) L4 b + L5 c + L11 d or L4 b (p) L5 c (p) L11 d

g) L3 a + L4 b + L5 c + L11 d or L3 a (p) L4 b (p) L5 c (p) L11 d

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:47:41 ON 14 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Apr 2006 VOL 144 ISS 17
FILE LAST UPDATED: 13 Apr 2006  (20060413/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que
L1        21941 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE(L)GLYCOL OR CAPRYL
                OR CAPAX OR KENKEL OR EDENOL OR HODAG OR INOLEX OR LEXOL OR
                LIPO OR LIPON? OR MIGL? OR STEPAN OR NEOBEE OR TRIVENT OR
                UNITOL? OR UPI
L2         2232 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLYCEROL(L)ETHYLHEXAN? OR
                TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR
                HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
L3       484872 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 OR PROPYLENE(2A)GLYCOL OR
                ?CAPRYL? OR CAPAX OR KENKEL OR EDENOL OR HODAG OR INOLEX OR
                LEXOL OR LIPO OR LIPON? OR MIGL? OR STEPAN OR NEOBEE OR
                TRIVENT OR UNITOL? OR UPI
L5       215163 SEA FILE=HCAPLUS ABB=ON  PLU=ON  AEROSOLS/CV OR AEROSOL? OR
                MIST OR SPRAY
L6         4600 SEA FILE=REGISTRY ABB=ON  PLU=ON  NONENAMIDE OR OCTAMIDE OR
                DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR CAPSANTHI
                N OR UNDECANAMIDE OR PAAIPER
L7        10495 SEA FILE=REGISTRY ABB=ON  PLU=ON  CAPSAICIN OR DIBENZOXAZEPINE
                OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR CAPSCIUM
                OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L8        14988 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6 OR NONENAMIDE OR OCTAMIDE
                OR DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR
                CAPSANTHIN OR UNDECANAMIDE OR PAAIPER
L9           13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  PAAI?
L10       68025 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7 OR CAPSAICIN OR DIBENZOXAZE
                PINE OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR
                CAPSCIUM OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L11      318578 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INCAPACIT? OR INFLAM? OR L8
                OR L9 OR L10
L33     1172689 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 OR GLYCEROL(L)ETHYLHEXAN?
                OR TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR
                HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
```

```
L34         138 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L33 AND L5 AND L11
L35          58 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L34 AND PD=<FEBRUARY 24, 2002


=> d ibib abs hitstr l35 1-58

L35  ANSWER 1 OF 58  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:934158  HCAPLUS
DOCUMENT NUMBER:          141:384328
TITLE:                    Transdermal or transmucosal malodorous-free and
                          irritation-free formulations for topical delivery of
                          effective therapeutic compositions
INVENTOR(S):              Carrara, Dario Norberto R.; Grenier, Arnaud; Besse,
                          Celine; Simes, Stephen M.; Lehman, Leah M.
PATENT ASSIGNEE(S):       Switz.
SOURCE:                   U.S. Pat. Appl. Publ., 31 pp., Cont.-in-part of U.S.
                          Ser. No. 343,570.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2004219197         A1    20041104    US 2004-798161          20040310
     WO 2002011768         A1    20020214    WO 2001-EP9007          20010803 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1323430            A2    20030702    EP 2003-3313            20010803
     EP 1323430            A3    20030806
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     EP 1323431            A2    20030702    EP 2003-3316            20010803
     EP 1323431            A3    20030806
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, LT, LV, FI, RO, MK, CY, AL, TR
     EP 1325752            A2    20030709    EP 2003-3317            20010803
     EP 1325752            A3    20030806
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     US 2003199426         A1    20031023    US 2003-343570          20030519
     AU 2004220498         A1    20040923    AU 2004-220498          20040311
     WO 2005039531         A1    20050506    WO 2004-EP11175         20041006
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
```

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

WO 2000-EP7533	A	20000803
WO 2001-EP9007	W	20010803
US 2003-453604P	P	20030311
US 2003-343570	A2	20030519
US 2003-510613P	P	20031010
EP 2001-960619	A3	20010803
US 2004-798161	A	20040310
WO 2004-US7291	A	20040311

AB The present invention relates to transdermal or transmucosal malodorous-free and irritation-free formulations comprising an active agent and delivery vehicle. In particular, the formulation comprises at least one active agent; and a delivery vehicle, which may comprise a C2 to C4 alkanol, a polyalc., and a permeation enhancer of monoalkyl ether of diethylene glycol present in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces. The formulation is substantially free of long-chain fatty alcs., long chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compds. during use of the formulation. Thus, advantageously, the formulations of the present invention do not include the undesirable-odor causing and irritation causing permeation enhancers that were once thought to be necessary for such transdermal or transmucosal formulations.

IT **57-55-6**, **Propylene glycol**, biological studies
57-83-0, Progestin, biological studies **9003-11-6**, Polyoxyethylene polyoxypropylene copolymer **11138-66-2**, Xanthan **25322-69-4**, Polypropylene glycol.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal or transmucosal malodorous-free and irritation-free formulations for topical delivery of effective therapeutic compns.)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9003-11-6 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI)
(CA INDEX NAME)



L35 ANSWER 2 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:396254 HCAPLUS
DOCUMENT NUMBER: 138:390940
TITLE: Buccal, polar and non-polar **spray** or capsule containing drugs for treating metabolic disorders
INVENTOR(S): Dugger, Harry A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003095925	A1	20030522	US 2002-230084	20020829
WO 9916417	A1	19990408	WO 1997-US17899	19971001 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

EP 1029536 A1 20000823 EP 2000-109347 19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

EP 1036561 A1 20000920 EP 2000-109357 19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

CA 2497114 AA 20040311 CA 2003-2497114 20030827
WO 2004019903 A1 20040311 WO 2003-US26855 20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003262916 A1 20040319 AU 2003-262916 20030827
EP 1549290 A1 20050706 EP 2003-791858 20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006502148 T2 20060119 JP 2004-531571 20030827
US 2005025714 A1 20050203 US 2004-928989 20040827

PRIORITY APPLN. INFO.:
WO 1997-US17899 A2 19971001
US 2000-537118 A2 20000329
EP 1997-911621 A3 19971001
US 2002-230084 A 20020829
WO 2003-US26855 W 20030827

AB Buccal **aerosol sprays** or capsules using polar and non-polar solvent were developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant. Lingual **sprays** contained cyclosporine, water, ethanol, PEG, and flavors.

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, **Propylene glycol**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal, polar and non-polar **spray** or capsule containing drugs for treating metabolic disorders)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



IT **9029-60-1**, Lipoxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; buccal, polar and non-polar **spray** or capsule containing drugs for treating metabolic disorders)
RN 9029-60-1 HCAPLUS
CN Oxygenase, lip- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L35 ANSWER 3 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:319266 HCAPLUS
DOCUMENT NUMBER: 138:343857
TITLE: Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
INVENTOR(S): Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill, Steven L.; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 898,553.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077297	A1	20030424	US 2002-74687	20020211
US 6294192	B1	20010925	US 1999-258654	19990226 <--
US 6267985	B1	20010731	US 1999-345615	19990630 <--
US 6248363	B1	20010619	US 1999-447690	19991123 <--
US 2003064097	A1	20030403	US 2001-800593	20010306
US 6569463	B2	20030527		
US 2002032171	A1	20020314	US 2001-877541	20010608
US 6761903	B2	20040713		
US 2002012680	A1	20020131	US 2001-898553	20010702 <--
US 6451339	B2	20020917		
WO 2003068186	A1	20030821	WO 2003-US4195	20030211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003213020	A1	20030904	AU 2003-213020	20030211
PRIORITY APPLN. INFO.:			US 1999-258654	A1 19990226
			US 1999-345615	A2 19990630
			US 1999-447690	A3 19991123
			US 2001-800593	A2 20010306
			US 2001-877541	A2 20010608
			US 2001-898553	A2 20010702
			US 1999-375636	A2 19990817
			US 2000-751968	A2 20001229
			US 2002-74687	A 20020211
			WO 2003-US4195	W 20030211

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

IT **57-83-0**, Progesterone, biological studies **1335-30-4**, Aluminum silicate **1343-88-0**, Magnesium silicate **9005-37-2**, **Propylene glycol** alginate **11138-66-2**, Xanthan gum **23288-49-5**, Probucol **31637-97-5**, Etofibrate **31694-55-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1335-30-4 HCAPLUS
CN Silicic acid, aluminum salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1343-88-0 HCAPLUS
CN Silicic acid, magnesium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-37-2 HCAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)-
(9CI) (CA INDEX NAME)



RN 31637-97-5 HCAPLUS
CN 3-Pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-
oxopropoxy]ethyl ester (9CI) (CA INDEX NAME)



RN 31694-55-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-

propanetriyltris[ω-hydroxy- (9CI) (CA INDEX NAME)



L35 ANSWER 4 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:367171 HCAPLUS
DOCUMENT NUMBER: 136:374541
TITLE: Cosmetic and pharmaceutical dispersions containing liposome-encapsulated active agent and modified starch
INVENTOR(S): Vollhardt, Jurgen; Malkan, Nisha; Manzo, Robert P.
PATENT ASSIGNEE(S): Dragoco Gerberding & Co. A.-G., Germany
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. 6,045,823.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6387398	B1	20020514	US 1999-365033	19990802
US 6045823	A	20000404	US 1998-120269	19980722 <--
PRIORITY APPLN. INFO.:			US 1998-120269 A2	19980722
			US 1996-715962 B1	19960919
			US 1997-962906 A2	19971103

AB Cosmetic or pharmaceutical formulations, such as (a) anhydrous cosmetic stick formulations and (b) anhydrous **aerosol spray** formulations, comprise an anhydrous solid or liquid dispersion medium and about 0.01-20% by weight of solid particles dispersed in the medium. Solid particles are preferably prepared by a process comprising **spray**-drying a mixture of liposome-encapsulated active agent, modified starch, and optionally a hydrocolloid gum, such as maltodextrin. For example, a water-free antiperspirant stick was prepared containing stearyl alc. 20.0%, Cremophor RH 40 2.0%, silica 0.80%, cyclomethicone 54.7%, glycol stearate 2.0%, aluminum zirconium AZG-369 powder 20%, talc 0.5%, and encapsulated fragrance 2.0%. The encapsulated fragrance particles do not dissolve or disappear in the formulation, which would yield a homogeneous distribution of the perfume oil.

IT **142-91-6**, Isopropyl palmitate
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(dispersions containing solid particles prepared by **spray**-drying of mixture of liposome-encapsulated active agent and modified starch)
RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



IT **11138-66-2**, Xanthan gum
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersions containing solid particles prepared by **spray**-drying of mixture of liposome-encapsulated active agent and modified starch)
RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **89-78-1**, Menthol
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(perfume containing; dispersions containing solid particles prepared by **spray**-drying of mixture of liposome-encapsulated active agent and modified starch)
RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 5 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:241244 HCAPLUS
DOCUMENT NUMBER: 136:267932
TITLE: Sunscreen composition containing sol-gel microcapsules
INVENTOR(S): Lapidot, Nao; Magdassi, Shlomo; Avnir, David; Rottman, Claudio; Gans, Orit; Seri-Levy, Alon
PATENT ASSIGNEE(S): Israel
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. 6,238,650.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002037261	A1	20020328	US 2001-840456	20010424
US 6468509	B2	20021022		
US 6238650	B1	20010529	US 1999-318828	19990526 <--
PRIORITY APPLN. INFO.:			US 1998-215136 A2	19981218
			US 1999-318828 A2	19990526

AB The present invention generally relates to safe and stable sunscreen compns. comprising of at least one sunscreen active ingredient in the form of an inert sol-gel microcapsules encapsulating UV absorbing compds. in any acceptable cosmetic vehicle. The composition according to the present invention can comprise several UV absorbers that may be encapsulated in the same sol-gel microcapsule or in different capsules. The

hydrophobicity/hydrophilicity character of the sol-gel microcapsules can be controlled by selecting suitable sol-gel precursors and suitable reaction conditions and can be chosen to be compatible with the cosmetic vehicle to be used in the sunscreen composition, thus, the present invention facilitates an easy incorporation of the composite sol-gel encapsulated sunscreen in all types of cosmetic vehicles including oil free compns., with no necessary steps of heating or high shear forces. The sunscreen compns. of the present invention can comprise any acceptable UVA and/or UVB absorbing compds. at any desired ratio to obtain a desired accumulative UV screening spectrum. An aqueous suspension of silica microcapsules, containing 35.8% p-methoxycinnamate (OMC) was prepared An oil in water emulsion containing liquid paraffin (mineral oil) 5.00, decyl oleate 5.00, dimethicone 1.00, cetearyl alc. 1.00, glyceryl stearate 3.00, potassium cetyl phosphate 2.00, water 47.25, xanthan gum 0.15, **propylene glycol** 5.00, 2-bromo-2-nitropropane-1,3-diol & methylparaben & phenoxyethanol & propylbaraben 5.00, 88% lactic acid 0.10, and above silica/OMC (25% OMC in water suspension) 30.00%.

IT **1344-28-1**, Alumina, biological studies **7384-98-7**, **Propylene glycol dicaprylate** **53824-77-4**, **Propylene glycol** dicaprate
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(sunscreen composition containing sol-gel microcapsules)

RN 1344-28-1 HCAPLUS
CN Aluminum oxide (Al2O3) (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7384-98-7 HCAPLUS
CN Octanoic acid, 1-methyl-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



RN 53824-77-4 HCAPLUS
CN Decanoic acid, 1-methyl-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 6 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:107078 HCAPLUS
DOCUMENT NUMBER: 136:166050
TITLE: Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
INVENTOR(S): Bot, Adrian; Dellamary, Luis; Smith, Dan J.; Woods, Catherine M.
PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002009674	A2	20020207	WO 2001-US24038	20010730 <--
WO 2002009674	A3	20030227		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-221544P P 20000728

AB Novel compns. are disclosed which can induce or enhance an immune response against foreign or self antigens (microbial or parasitic) or modulate (suppress) the activity of pathogenic cells in **inflammatory** or autoimmune diseases. Compns. and methods are taught in how to limit the generation of an immune response against formulated peptides and proteins with application in antibody therapy or hormone replacement therapy. Methods of suppressing autoimmunity are also disclosed which use ligands for cellular receptors expressed on cells of the innate immune system and more specifically for down-regulation of autoimmune processes by either deletion or induction of anergy at the level of autoreactive T cells or by triggering active-suppressor T cells that down-regulate the activity of pathogenic cells.

IT **50-70-4**, Sorbitol, biological studies **99-20-7**, Trehalose **9005-65-6**, Tween 80 **106392-12-5**, Poloxamer 188
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel methods and compns. to modulate and control immune responses and immune disorders)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99-20-7 HCAPLUS
CN α-D-Glucopyranoside, α-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

L35 ANSWER 7 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:102246 HCAPLUS
DOCUMENT NUMBER: 136:172497
TITLE: Skin deodorizing and sanitizing compositions comprising antiseptics
INVENTOR(S): Dodd, Michael Thomas; Wei, Karl Shiqing; Trinh, Toan; Sine, Mark Richard; Bartolo, Robert Gregory; Jakubovic, David Andrew
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 197,933, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6344218	B1	20020205	US 1999-321292	19990527 <--
US 2002176879	A1	20021128	US 1999-443420	19991119
US 6656456	B2	20031202		
WO 2000030599	A1	20000602	WO 1999-US27684	19991122 <--
W: AU, BR, CA, CN, CZ, CZ, JP, KR, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000030600	A1	20000602	WO 1999-US27685	19991122 <--
W: CN, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 2000030601	A1	20000602	WO 1999-US27688	19991122 <--
W: AU, BR, CA, CN, CZ, CZ, JP, KR, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1131044	A1	20010912	EP 1999-962825	19991122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1131045	A1	20010912	EP 1999-962826	19991122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1133274	A1	20010919	EP 1999-962827	19991122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002530313	T2	20020917	JP 2000-583484	19991122
JP 2002530314	T2	20020917	JP 2000-583486	19991122
JP 2003526611	T2	20030909	JP 2000-583485	19991122
PRIORITY APPLN. INFO.:			US 1998-197933 B2	19981123
			US 1998-109500P P	19981123
			US 1998-109602P P	19981123
			US 1999-321292 A1	19990527
			WO 1999-US27684 W	19991122
			WO 1999-US27685 W	19991122
			WO 1999-US27688 W	19991122

OTHER SOURCE(S): MARPAT 136:172497

AB The present invention relates to aqueous compns. comprising an odor controlling agent and select sanitizing agents for deodorizing and sanitizing skin surfaces. Articles of manufacture and methods of deodorizing and sanitizing the skin using disclosed compns. are also disclosed. A sanitizing and deodorizing **spray** contained ethanol 40, water 54.8, isopropanol (99%) 3, hydroxypropyl beta-cyclodextrin 1, zinc chloride 1, and benzalkonium chloride 0.2%.

IT **1344-28-1**, Alumina, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(activated; skin deodorizing and sanitizing compns. comprising antiseptics)

RN 1344-28-1 HCAPLUS

CN Aluminum oxide (Al2O3) (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **89-78-1**, Menthol **104-50-7** **111-01-3**, Perhydrosqualene **111-87-5**, Octyl alcohol, biological studies **123-96-6**, 2-Octanol **9002-86-2**, Polyvinyl chloride **11138-66-2**, Xanthan gum **106392-12-5**, Ethylene oxide propylene oxide block copolymer
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(skin deodorizing and sanitizing compns. comprising antiseptics)

RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 104-50-7 HCAPLUS
CN 2(3H)-Furanone, 5-butyldihydro- (8CI, 9CI) (CA INDEX NAME)



RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 111-87-5 HCAPLUS
CN 1-Octanol (9CI) (CA INDEX NAME)



RN 123-96-6 HCAPLUS
CN 2-Octanol (8CI, 9CI) (CA INDEX NAME)



RN 9002-86-2 HCAPLUS
CN Ethene, chloro-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 75-01-4
CMF C2 H3 Cl



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 8 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51280 HCAPLUS
DOCUMENT NUMBER: 136:107539
TITLE: Preparation of high pressure/high shear pharmaceutical/cosmetic dispersions containing waxes and other semi-solids and oils
INVENTOR(S): Ceccoli, Joseph D.; Ross, Michael; Wilmott, James M.; Coleman, Todd; Crawford, Timothy K.
PATENT ASSIGNEE(S): Collaborative Technologies, Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004004	A1	20020117	WO 2001-US21746	20010711 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2004018250 A1 20040129 US 2003-332395 20030805
PRIORITY APPLN. INFO.: US 2000-217617P P 20000711
WO 2001-US21746 W 20010711
OTHER SOURCE(S): MARPAT 136:107539

AB The present invention provides an oil-in-water wax dispersion comprising 1 or more waxes or hydrophobic semi-solids, a dispersion initiator, optionally 1 or more plasticizers or solvents and/or co-solvents, and water. The invention also provides a method for preparing these oil-in-water wax dispersions and their use in topical, oral, anal, ophthalmic, vaginal, otic, cosmetic and nasal formulations. Thus, a dispersion contained water 59.76, Germazide MPB 1.44, Crodacol CS-50 8.10, hydrogenated polyisobutene 18.90, Basis LP20H 1.80, and butylene glycol 10.00.

IT **11138-66-2**, Xanthan gum **25322-69-4**, Polypropylene glycol **68171-38-0**, **Propylene glycol** monoisostearate
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of high pressure/high shear pharmaceutical/cosmetic dispersions containing waxes and other semi-solids and oils)

RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 68171-38-0 HCAPLUS
CN Isooctadecanoic acid, monoester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 30399-84-9
CMF C18 H36 O2
CCI IDS



CM 2

CRN 57-55-6
CMF C3 H8 O2



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 9 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:51237 HCAPLUS
DOCUMENT NUMBER: 136:123631
TITLE: **Aerosol** formulation containing a polar fluorinated compound
INVENTOR(S): Rogueda, Philippe
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003958	A1	20020117	WO 2001-SE1606	20010710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415092	AA	20020117	CA 2001-2415092	20010710 <--
EP 1303258	A1	20030423	EP 2001-952071	20010710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012322	A	20030708	BR 2001-12322	20010710
JP 2004502719	T2	20040129	JP 2002-508413	20010710
NZ 523379	A	20040625	NZ 2001-523379	20010710
ZA 2003000075	A	20040405	ZA 2003-75	20030103
US 2003194378	A1	20031016	US 2003-332568	20030109
NO 2003000133	A	20030224	NO 2003-133	20030110
PRIORITY APPLN. INFO.:			GB 2000-16876 A	20000711
			WO 2001-SE1606 W	20010710

AB The present invention relates to a stable pharmaceutical **aerosol** formulation intended for inhalation. The formulation contains an active substance, an **aerosol** propellant, a polar fluorinated mol. and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture Thus, an **aerosol** formulation contained budesonide 0.125, methoxy-PEG-DSPE 0.320, 1H,1H,2H,2H-perfluorooctan-1-ol 31.7 and HFA-227 to 100%.

IT **50-70-4**, Sorbitol, biological studies **3825-26-1** **9002-92-0**, Brij 30 **9003-11-6** **9004-98-2**, Brij 96 **9004-99-3**, MYRJ 52 **11138-66-2**, Xanthan gum **31566-31-1**, Glyceryl monostearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**aerosol** formulation containing polar fluorinated compds.)
RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 3825-26-1 HCAPLUS
CN Octanoic acid, pentadecafluoro-, ammonium salt (8CI, 9CI) (CA INDEX NAME)



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9003-11-6 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

RN 9004-98-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 10 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:833060 HCAPLUS
DOCUMENT NUMBER: 135:376741
TITLE: Stable metal ion-lipid powdered pharmaceutical compositions
INVENTOR(S): Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E.
PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085137	A2	20011115	WO 2001-US14824	20010508 <--
WO 2001085137	A3	20020418		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6630169	B1	20031007	US 2000-720536	20001222
CA 2408464	AA	20011115	CA 2001-2408464	20010508 <--
EP 1282405	A2	20030212	EP 2001-933194	20010508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533449	T2	20031111	JP 2001-581791	20010508

PRIORITY APPLN. INFO.:			
US 2000-568818	A	20000510	
WO 1999-US6855	W	19990331	
WO 2001-US14824	W	20010508	

AB Microparticle compns. comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compns. and methods of treating certain conditions and disease states by administering the microparticle compns. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compns. of the present invention have superior stability to other microparticle compns. resulting in a microparticle composition with longer shelf life and improved dispersibility. The microparticle compns. of the present invention have a transition temperature (Tm) of at least 20° above the recommended storage temperature (Tst) for drug delivery. An aqueous preparation was prepared by mixing two prepns., A and B, immediately prior to **spray** drying. The preparation A was comprised of a fluorocarbon-in-water emulsion in which 26 g perfluorooctyl bromide was dispersed in 33 g water with the aid of 1.30 g of SPC-3 emulsifier (hydrogenated soy phosphatidylcholine). The preparation B contained 0.162 g CaCl2.2H20 and 0.162 g budesonide dissolved/suspended in 4 g water. The resulting microparticle of the sample had a PL-budesonide-CaCl2.2H20 weight ratio of about 80:10:10. The mean volume aerodynamic particle size of the dry powder was approx. 4.1 μm.

IT **99-20-7**, Trehalose **41017-85-0 106392-12-5**, Poloxamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable metal ion-lipid powdered pharmaceutical compns.)

RN 99-20-7 HCAPLUS
CN α-D-Glucopyranoside, α-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 41017-85-0 HCAPLUS
CN 3,5,9-Trioxa-4-phosphaheptadecan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxooctyl)oxy]-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

L35 ANSWER 11 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:730527 HCAPLUS
DOCUMENT NUMBER: 135:278035
TITLE: Method for administering insulin to the buccal region
INVENTOR(S): Modi, Pankaj

PATENT ASSIGNEE(S): Generex Pharmaceuticals Inc., Can.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072278	A2	20011004	WO 2001-IB564	20010221 <--
WO 2001072278	A3	20020411		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-538829 A 20000330

AB A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compds. The absorption enhancing compds. are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixts. thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 weight/weight of the total formulation, and the total concentration of absorption enhancing compds. are less than 50 weight/weight of the formulation. A micellar solution contained insulin 50 units, sodium lauryl sulfate 4.4, sodium salicylate 4.4, alkali metal edetate 2.2, sodium hyaluronate 1.1%, and Phospholipon-H 10 mg. Mixed micellar liposomal insulin formulation was prepared from the above micellar solution by addition of phospholipin-H and iso-Pr alc. and high speed stirring for 30 min. The mixed micellar solution was administered orally to volunteers. The solution decreased the blood glucose level better than insulin injection.

IT **50-70-4**, Sorbitol, biological studies **89-78-1**, menthol **151-21-3**, sodium lauryl sulfate, biological studies **9002-92-0D**, Polidocanol, alkyl ethers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for administering insulin to buccal region)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)

$HO_3SO-(CH_2)_{11}-Me$

● Na

RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



L35 ANSWER 12 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:566739 HCAPLUS
DOCUMENT NUMBER: 135:157677
TITLE: Pain reliever compositions containing **Capsicum** extract
INVENTOR(S): Barr, Teresa Leigh; Holt, Stephen D.
PATENT ASSIGNEE(S): Medical Merchandising, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. 6,197,823.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001011083	A1	20010802	US 2001-800245	20010306 <--
US 6653352	B2	20031125		
US 6197823	B1	20010306	US 1999-408740	19990929 <--
WO 2002022120	A1	20020321	WO 2001-US26027	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001090552	A5	20020326	AU 2001-90552	20010914
PRIORITY APPLN. INFO.:			US 1999-408740	A2 19990929
			US 2000-662962	A 20000915
			US 2001-800245	A 20010306
			WO 2001-US26027	W 20010914

AB A composition containing **capsicum** extract together with other ingredients to neutralize the discomfort resulting from the application of **Capsicum** extract to the skin enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post-surgical scarring, hemorrhoid pain and itching, and pruritus without the discomfort normally associated with the topical application of the **Capsicum** extract Thus, a night-time formulation contained ibuprofen 200.0, glucosamine 250.0-1500.0, chondroitin 50.0-500.0, boswellin 50.0-250.0, glycyrrhizinate 0.001-2.0, Stevia 1.0-1000.0, melatonin 1.0-10.0, Kava kava 50.0-1000.0, Valerian Root 50.0-400.0, passionflower 50.0-00.0, hops 50.0-400.0, and diphenhydramine-HCl 5.0-50.0 mg.

IT **57-55-6**, **Propylene glycol**, biological studies
1344-28-1, Aluminum oxide, biological studies **3234-85-3**, Myristyl myristate **11138-66-2**, Xanthan gum **31566-31-1**, Glyceryl monostearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pain reliever compns. containing **Capsicum** extract)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 1344-28-1 HCAPLUS
CN Aluminum oxide (Al2O3) (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 3234-85-3 HCAPLUS
CN Tetradecanoic acid, tetradecyl ester (9CI) (CA INDEX NAME)



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



L35 ANSWER 13 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:564821 HCAPLUS
DOCUMENT NUMBER: 135:142248
TITLE: Transdermal anesthetic and vasodilator composition and methods for topical administration
INVENTOR(S): Samuels, Paul J.; Sweeney, Dawn
PATENT ASSIGNEE(S): Children's Hospital Research Foundation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054679	A2	20010802	WO 2001-US2674	20010126 <--
WO 2001054679	A3	20020214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002006435	A1	20020117	US 2001-770344	20010126 <--
PRIORITY APPLN. INFO.:			US 2000-178364P	P 20000127
			US 2001-770344	A 20010126

AB A composition for topical application comprising a therapeutically effective amount of a topical anesthetic, a safe and effective amount of a pharmaceutically acceptable topical vasodilator and a pharmaceutically acceptable carrier and a method of administering the composition to a mammal are disclosed. A topical pharmaceutical contained lidocaine base 2.5, prilocaine hydrochloride 2.5, 1,2,3-propanetriol trinitrate 0.25, carrier and other ingredients 94.75%.

IT **31694-55-0**, Polyoxyethylene glycerol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tallowates; transdermal anesthetic and vasodilator composition and methods for topical administration)

RN 31694-55-0 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-hydroxy- (9CI) (CA INDEX NAME)



IT **9004-99-3**, Polyethylene glycol stearate **9005-02-1**, Polyoxyethylene dilaurate **9005-65-6**, Polysorbate 80 **11099-07-3**, Glyceryl stearate **106392-12-5**, Polyoxyethylene polyoxypropylene block copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal anesthetic and vasodilator composition and methods for topical administration)

RN 9004-99-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9005-02-1 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-[(1-oxododecyl)oxy]- (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS

CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 11099-07-3 HCAPLUS

CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

L35 ANSWER 14 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:472465 HCAPLUS
DOCUMENT NUMBER: 135:66243
TITLE: Process for producing nanometer particles by fluidized-bed **spray**-drying
INVENTOR(S): Kerkhof, Nicholas J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001045677	A1	20010628	WO 2000-US34606		20001219	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2395129	AA	20010628	CA 2000-2395129		20001219	<--
EP 1239844	A1	20020918	EP 2000-986607		20001219	
EP 1239844	B1	20050608				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2003518038	T2	20030603	JP 2001-546416		20001219	
AU 778931	B2	20041223	AU 2001-22814		20001219	
AT 297196	E	20050615	AT 2000-986607		20001219	
ES 2240222	T3	20051016	ES 2000-986607		20001219	
US 2003211162	A1	20031113	US 2002-168520		20021018	
PRIORITY APPLN. INFO.:			US 1999-172573P	P	19991220	
			WO 2000-US34606	W	20001219	

AB Nanometer particles of poorly water-soluble or substantially water-insol. compound are produced by finely-spraying a non-aqueous solution of said compound into a heated and fluidized bed of carrier excipient. The resulting product consists of a free flowing mixture of relatively large particles of carrier excipient and nanometer sized particles (<3 μm) of the compound Approx. 100 g ganaxolone was dissolved in 5 kg ethanol with slight warming to 30°. The solution was sprayed into 1 kg of **spray**-dried lactose NF in a fluidized-bed system equipped with a 6" Wurster column. The **spray** rate was 34-41 mL/min. The static inlet pressure was 2.5-8 bar. The resulting ganaxolone powder mixture was free-flowing and contained 63 mg ganaxolone/g of powder. The ganaxolone particle size in the mixture was determined by a laser diffraction technique by using photocorrelation spectroscopy. The ganaxolone had a volume-weighted mean diameter of 660 nm.

IT **50-70-4**, Sorbitol, biological studies **151-21-3**, SDS, biological studies **31566-31-1**, Glyceryl monostearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for producing nanometer particles by fluidized-bed **spray**-drying)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)

$HO_3SO-(CH_2)_{11}-Me$

● Na

RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 15 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:472463 HCAPLUS
DOCUMENT NUMBER: 135:66241
TITLE: Process for producing nanometer particles by fluid-bed **spray**-drying
INVENTOR(S): Kerkhof, Nicholas J.; Ong, John T. H.
PATENT ASSIGNEE(S): Cocensys, Inc., USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045674	A1	20010628	WO 2000-US34479	20001219 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ES 2240222 T3 20051016 ES 2000-986607 20001219
PRIORITY APPLN. INFO.: US 1999-172573P P 19991220

AB Nanometer particles of poorly water-soluble or substantially water-insol. compound are produced by finely-spraying a non-aqueous solution of said compound into a heated and fluidized bed of carrier excipient. The resulting product consists of a free flowing mixture of relatively large particles of carrier excipient and nanometer sized particles (<1 μm) of compound Approx. 100 g ganaxolone was dissolved in 5 kg ethanol with slight warming to 30°. The solution was sprayed into 1 kg of **spray**-dried lactose NF in a fluidized-bed system equipped with a 6" Wurster column. The **spray** rate was 34-41 mL/min. The static inlet pressure was 2.5-8 bar. The resulting ganaxolone powder mixture was free-flowing and contained 63 mg ganaxolone/g of powder. The ganaxolone particle size in the mixture was determined by a laser diffraction technique by using photocorrelation spectroscopy. The ganaxolone had a volume-weighted mean diameter of 660 nm.

IT **50-70-4**, Sorbitol, biological studies **151-21-3**, SDS, biological studies **9004-99-3**, Polyethylene glycol stearate **31566-31-1**, Glyceryl monostearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for producing nanometer particles by fluidized-bed **spray**-drying)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 16 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:300514 HCAPLUS
DOCUMENT NUMBER: 134:331617
TITLE: Oil-in-water emulsion compositions for polyfunctional active ingredients
INVENTOR(S): Chen, Feng-jing; Patel, Mahesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028555	A1	20010426	WO 2000-US28835	20001018 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002107265 A1 20020808 US 1999-420159 19991018
US 6720001 B2 20040413

PRIORITY APPLN. INFO.: US 1999-420159 A 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

IT **111-87-5**, Octanol, properties
RL: PRP (Properties)
(-water partition; oil-in-water emulsion compns. for polyfunctional active ingredients)

RN 111-87-5 HCAPLUS
CN 1-Octanol (9CI) (CA INDEX NAME)

HO— $(CH_2)_7$ — Me

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, **Propylene glycol**, biological studies **57-55-6D**, **Propylene glycol**, fatty acid esters **57-83-0**, Progesterone, biological studies **404-86-4**, **Capsaicin** **9005-07-6**, PEG 400 dioleate **9005-63-4D**, fatty acid esters **9041-08-1**, Dalteparin sodium **10238-21-8**, Glyburide **11140-04-8**, Imwitor 988 **15663-27-1**, Cisplatin **23288-49-5**, Probucol **25322-69-4**, Polypropylene glycol **37321-62-3**, Lauroglycol FCC **72432-03-2**, **Miglitol** **79902-63-9**, Simvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-in-water emulsion compns. for polyfunctional active ingredients)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 9005-07-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9041-08-1 HCAPLUS
CN Heparin, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 10238-21-8 HCAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 11140-04-8 HCAPLUS
CN Octanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 15663-27-1 HCAPLUS
CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 37321-62-3 HCAPLUS
CN Dodecanoic acid, ester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 143-07-7
CMF C12 H24 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 72432-03-2 HCAPLUS
CN 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 79902-63-9 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 17 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:254826 HCAPLUS
DOCUMENT NUMBER: 134:271275
TITLE: Membrane-forming colloids for the treatment of wound
INVENTOR(S): Kawanishi, Takashi; Takao, Kota; Tsuji, Yuji; Shirokane, Hideki
PATENT ASSIGNEE(S): Kobayashi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001097848	A2	20010410	JP 1999-280707	19990930 <--

PRIORITY APPLN. INFO.: JP 1999-280707 19990930
AB This invention relates to topical compns. in the form of hydrophilic colloids containing water-soluble polymers and liquefied hydrocarbons. The compns. are sprayed on an affected area and quickly form the dry coat,

which can be easily washed out with water. An **aerosol** was formulated containing gelatin 10, tara gum 5, squalane 20, isopropylmethylphenol 4, chitin 1, fructose 20, and liquefied butane gas 40 %.

IT **50-70-4**, Sorbitol, biological studies **89-78-1**, dl-Menthol **110-27-0**, Isopropyl myristate **111-01-3**, Squalane **111-02-4**, Squalene **2444-46-4**, Nonanoic acid vanillylamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane-forming colloids containing polymers and liquefied hydrocarbons and active agents for treatment of wound)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 110-27-0 HCAPLUS
CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 111-02-4 HCAPLUS
CN 2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (2E,6E,10E,14E,18E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 2444-46-4 HCAPLUS
CN Nonanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 18 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:195116 HCAPLUS
DOCUMENT NUMBER: 134:227146
TITLE: Use of a substance P antagonist in a cosmetic for prevention of skin sensitivity
INVENTOR(S): De la Charriere, Olivier; Breton, Lionel
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Fr.
SOURCE: U.S., 9 pp., Cont. of U.S. Ser. No. 358,562, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6203803	B1	20010320	US 1997-881272		19970624	<--
US 6235291	B1	20010522	US 1996-611549		19960311	<--
US 6333042	B1	20011225	US 2000-584724		20000601	<--
US 2001014342	A1	20010816	US 2000-735638		20001214	<--
PRIORITY APPLN. INFO.:			US 1994-358562	B1	19941214	
			FR 1995-5537	A	19950505	
			FR 1994-5537	A	19940505	
			US 1996-611549	A1	19960311	

US 1997-881272 A1 19970624

AB The invention concerns the use of a substance P antagonist in a cosmetic composition used to treat sensitive skin. More specifically, the invention relates to a substance P antagonist used to prevent and/or combat skin irritations, desquamation, erythemas, sensations of dysesthesia/overheating, or pruritus of the skin. A make-up removal face lotion contained Spantide II 5.00, antioxidant 0.05, isopropanol 40.00, preservative 0.30, and water q.s. 100%.

IT **404-86-4, Capsaicin**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(use of substance P antagonist in cosmetic for prevention of skin sensitivity)

RN 404-86-4 HCAPLUS

CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **11099-07-3**, Glycerol stearate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(use of substance P antagonist in cosmetic for prevention of skin sensitivity)

RN 11099-07-3 HCAPLUS

CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 19 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:167782 HCAPLUS
DOCUMENT NUMBER: 134:227361
TITLE: Preparation of mixed micellar pharmaceutical delivery system for proteinic and other drugs
INVENTOR(S): Modi, Pankaj
PATENT ASSIGNEE(S): Generex Pharmaceuticals Inc., Can.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015666	A1	20010308	WO 2000-CA1019	20000825 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6221378	B1	20010424	US 1999-386285	19990831 <--
CA 2382535	AA	20010308	CA 2000-2382535	20000825 <--
EP 1207853	A1	20020529	EP 2000-956008	20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003508421	T2	20030304	JP 2001-519880	20000825
NZ 517313	A	20030530	NZ 2000-517313	20000825
AU 763251	B2	20030717	AU 2000-68143	20000825

PRIORITY APPLN. INFO.:		
US 1999-386285	A	19990831
US 1998-21114	A2	19980210
US 1998-216733	A2	19981221
AU 1999-25053	A3	19990205
WO 2000-CA1019	W	20000825

AB A mixed micellar pharmaceutical formulation and process for making the formulation are described. The formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8-22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compound The absorption enhancing compound is selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixts. thereof. The amount of each absorption enhancing compound is present in a concentration of 1-10% by weight; the total formulation, and the total concentration of absorption enhancing compds. are < 50% by weight of the formulation. Preferably, the formulation is administered, in combination with a propellant, to the buccal cavity, using a metered dose dispenser, which is also described. For example, an oral drops were prepared using 0.5 g sodium lauryl sulfate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. To this solution 40 mg (1000 units) of insulin was added and dissolved completely while stirring, to give about 100

units/mL insulin solution Compared to the injection method, oral insulin gives a faster onset of action and lowers blood glucose levels without creating hypoglycemic condition. Due to the hepatic glucose production, there was a rebound effect. This is believed to be due to the incomplete absorption of insulin.

IT **50-70-4**, Sorbitol, biological studies **151-21-3**, Sodium lauryl sulfate, biological studies **9002-92-0**, Polyoxyethylene lauryl ether **9002-92-0D**, Polydocanol, alkyl ethers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of mixed micelles for oral delivery of proteinic and other drugs)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 20 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:136991 HCAPLUS

DOCUMENT NUMBER: 134:198075
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817 <--
CA 2380642	AA	20010222	CA 2000-2380642	20000710 <--
EP 1210063	A1	20020605	EP 2000-947184	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T2	20030218	JP 2001-516502	20000710
NZ 517659	A	20041224	NZ 2000-517659	20000710
AU 780877	B2	20050421	AU 2000-60838	20000710
US 2001024658	A1	20010927	US 2000-751968	20001229 <--
US 6458383	B2	20021001		

PRIORITY APPLN. INFO.: US 1999-375636 A 19990817
WO 2000-US18807 W 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and **propylene glycol** 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, **Propylene glycol**, biological studies **57-55-6D**, **Propylene glycol**, ethers **110-27-0**, Isopropyl myristate **124-07-2**, **Caprylic** acid, biological studies **142-91-6**, Isopropyl palmitate **151-21-3**, Sodium lauryl sulfate, biological studies **1309-42-8**, Magnesium hydroxide **1330-80-9**, **Propylene glycol** monooleate **1335-30-4**, Aluminum silicate **1338-41-6**, Sorbitan monostearate **9002-92-0**, Brij 35 **9004-81-3** **9004-96-0**, Crodet O40 **9004-98-2**, Polyoxyethylene oleyl

ether **9004-99-3** **9005-02-1**, Kessco PEG 300DL **9005-07-6**, Kessco PEG 1540DO **9005-63-4D**, fatty acid esters **9005-65-6**, Polysorbate 80 **11140-04-8**, Imwitor 988 **15663-27-1**, Cisplatin **21645-51-2**, Aluminum hydroxide, biological studies **26402-26-6**, Glyceryl **monocaprylate 31694-55-0D**, C8-10-esters **36354-80-0**, Glyceryl **dicaprylate 37321-62-3**, Lauroglycol **52581-71-2**, Volpo 3 **60177-36-8**, Sorbitan **monocaprylate 68795-69-7**, **Propylene glycol** monocaprate **98036-77-2**, Hydrotalcite **106392-12-5**, Polyoxyethylene-polyoxypropylene block copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 110-27-0 HCAPLUS
CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 124-07-2 HCAPLUS
CN Octanoic acid (8CI, 9CI) (CA INDEX NAME)



RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)



RN 1309-42-8 HCAPLUS
CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)



RN 1330-80-9 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, monoester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 112-80-1
CMF C18 H34 O2

Double bond geometry as shown.



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 1335-30-4 HCAPLUS
CN Silicic acid, aluminum salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1338-41-6 HCAPLUS
CN Sorbitan, monooctadecanoate (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 50-70-4
CMF C6 H14 O6

Absolute stereochemistry.



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-81-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-96-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-98-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9005-02-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-[(1-oxododecyl)oxy]- (9CI) (CA INDEX NAME)



RN 9005-07-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 11140-04-8 HCAPLUS
CN Octanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 15663-27-1 HCAPLUS
CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



RN 26402-26-6 HCAPLUS
CN Octanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 31694-55-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-propanetriyltris[ω-hydroxy- (9CI) (CA INDEX NAME)



RN 36354-80-0 HCAPLUS
CN Octanoic acid, diester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 37321-62-3 HCAPLUS
CN Dodecanoic acid, ester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 143-07-7
CMF C12 H24 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 52581-71-2 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 60177-36-8 HCAPLUS
CN Sorbitan, monooctanoate (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 50-70-4
CMF C6 H14 O6

Absolute stereochemistry.



RN 68795-69-7 HCAPLUS
CN Decanoic acid, monoester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 334-48-5
CMF C10 H20 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 98036-77-2 HCAPLUS
CN Aluminate (Al(OH)63-), (OC-6-11)-, magnesium carbonate hydroxide (4:9:2:2) (9CI) (CA INDEX NAME)

CM 1

CRN 18893-33-9
CMF Al H6 O6
CCI CCS



CM 2

CRN 3812-32-6
CMF C O3



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 21 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:75273 HCAPLUS
DOCUMENT NUMBER: 134:136752
TITLE: Hybrid coating for medical devices
INVENTOR(S): Zhong, Sheng-ping
PATENT ASSIGNEE(S): Boston Scientific Corporation, USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. 5,869,127.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6179817	B1	20010130	US 1999-238707	19990128 <--
US 5702754	A	19971230	US 1995-392141	19950222 <--
US 5869127	A	19990209	US 1997-877825	19970618 <--
PRIORITY APPLN. INFO.:			US 1995-392141	A2 19950222
			US 1997-877825	A2 19970618

AB Disclosed are hybrid coatings for implantable medical devices. Such coatings include a first layer of an aqueous dispersion or emulsion of an organic acid functional group containing polymer, a crosslinker and a therapeutic agent dispersed therein. The coating also includes a second layer of an aqueous solution or dispersion of an organic acid functional group-containing bio-active agent. The hybrid coatings are especially suited for preventing restenosis of endoprostheses by the combined action of the therapeutic agent and the bio-active agent. Methods of making and using devices coated with such compns. are also provided. A first coating composition containing polyester-based aliphatic water-borne polyurethane containing carboxylic acid groups (NeoRez R981) 250, 0.5 % fluorad FC-129 stock solution 10, 34% NH4OH 4, Neocryl CX 100 crosslinker agent 20, and 20 % Paclitaxel stock solution 20 mL, and a second coating composition containing 1.2 % aqueous solution of sodium heparin 300 mL were applied on the surface of stent by **spray** coating sep., dried, and then put into a 50° vacuum oven for 3 h. The resulted coating has controlled-releasable Paclitaxel and covalently bond heparin on the

surface.
IT **9002-86-2**, Polyvinyl chloride **9041-08-1**, Sodium heparin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biocompatible/bioactive hybrid coating for medical devices)
RN 9002-86-2 HCAPLUS
CN Ethene, chloro-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 75-01-4
CMF C2 H3 Cl



RN 9041-08-1 HCAPLUS
CN Heparin, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:50443 HCAPLUS
DOCUMENT NUMBER: 134:105653
TITLE: Sunscreens containing UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing the natural skin barrier
INVENTOR(S): Muller, Rainer Helmut; Wissing, Sylvia; Mader, Karsten
PATENT ASSIGNEE(S): Pharmasol G.m.b.H., Germany
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001003652	A2	20010118	WO 2000-EP6534	20000710 <--
WO 2001003652	A3	20010712		
WO 2001003652	C2	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10016155	A1	20010118	DE 2000-10016155	20000331 <--
CA 2375556	AA	20010118	CA 2000-2375556	20000710 <--
BR 2000012445	A	20020402	BR 2000-12445	20000710
EP 1194111	A2	20020410	EP 2000-951366	20000710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003504318	T2	20030204	JP 2001-508936	20000710
ZA 2002000256	A	20020711	ZA 2002-256	20020111

US 6814959 B1 20041109 US 2002-30425 20020408
PRIORITY APPLN. INFO.: DE 1999-19932156 A 19990713
DE 2000-10016155 A 20000331
WO 2000-EP6534 W 20000710

AB The invention concerns sunscreens, i.e. UV radiation reflecting or absorbing agents, designed to be applied on the skin, the mucous membranes, the scalp and the hair for protection against harmful UV radiation and to reinforce the natural skin barrier. The inventive agents comprise polymorphous, crystalline or semicryst. solid polymeric or lipidic particles. Tthus, a UV blocking lipid emulsion was produced by high-pressure homogenization of 10 weight/weight% cetyl palmitate and Tego Care 450.

IT **57-55-6**, **Propylene glycol**, biological studies
89-78-1, Menthol **94-96-2** **110-27-0**,
Isopropylmyristate **538-24-9**, Glyceroltrilaurate **540-10-3**
, Cetylpalmitate **1077-28-7**, α- **Liponic** acid
1309-48-4, Magnesiumoxide, biological studies **9005-65-6**,
Tween 80 **31566-31-1**, Glycerolmonostearate **42922-74-7**,
α-D-Glucopyranoside, β-D-fructofuranosyl, monooctanoate
77466-09-2, **Miglyol** 840 **106392-12-5**, Poloxamer
188
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing natural skin barrier as sunscreens)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 94-96-2 HCAPLUS
CN 1,3-Hexanediol, 2-ethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 110-27-0 HCAPLUS

CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 538-24-9 HCAPLUS
CN Dodecanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



RN 540-10-3 HCAPLUS
CN Hexadecanoic acid, hexadecyl ester (9CI) (CA INDEX NAME)



RN 1077-28-7 HCAPLUS
CN 1,2-Dithiolane-3-pentanoic acid (9CI) (CA INDEX NAME)



RN 1309-48-4 HCAPLUS
CN Magnesium oxide (MgO) (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 42922-74-7 HCAPLUS
CN α-D-Glucopyranoside, β-D-fructofuranosyl, monooctanoate (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2

$HO_2C-(CH_2)_6-Me$

CM 2

CRN 57-50-1
CMF C12 H22 O11

Absolute stereochemistry.



RN 77466-09-2 HCAPLUS
CN Miglyol 840 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9

CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

L35 ANSWER 23 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:10080 HCAPLUS
DOCUMENT NUMBER: 134:76373
TITLE: Pulmonary administration of soluble complement receptor-1 (sCR1) and its derivatives
INVENTOR(S): Levin, James L.; Regal, Jean F.; Toth, Carol A.
PATENT ASSIGNEE(S): Avant Immunotherapeutics, Inc., USA; Regents of the University of Minnesota
SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 16,918, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6169068	B1	20010102	US 1995-602761	19950811 <--
WO 9417822	A1	19940818	WO 1994-US1405	19940208 <--

W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1993-16918 B2 19930212
WO 1994-US1405 W 19940208

AB A method is disclosed for treating diseases or disorders involving complement (e.g. bronchoconstriction or anaphylaxis) by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement-related disorders by administering complement-inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by **aerosolization** of a complement-inhibitory protein and subsequent inhalation.

IT **50-70-4**, Sorbitol, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bulking agent; pulmonary administration of soluble complement receptor-1 (sCR1) and its derivs.)

RN 50-70-4 HCAPLUS

CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **9005-63-4D**, fatty acid esters **9005-65-6**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pulmonary administration of soluble complement receptor-1 (sCR1) and its derivs.)
RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:880938 HCAPLUS
DOCUMENT NUMBER: 134:46784
TITLE: Oil-core compositions for the sustained release of hydrophobic drugs
INVENTOR(S): Sankaram, Mantripragada B.; Thrift, Richard N.; Bethune, Claudette R.
PATENT ASSIGNEE(S): Skyepharma, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074653	A1	20001214	WO 2000-US15401	20000602 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2375371	AA	20001214	CA 2000-2375371	20000602 <--
EP 1189597	A1	20020327	EP 2000-946777	20000602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2003501376	T2	20030114	JP 2001-501190	20000602
AU 763945	B2	20030807	AU 2000-60480	20000602
NZ 515644	A	20041224	NZ 2000-515644	20000602
US 2003211140	A1	20031113	US 2002-212030	20020805
US 2004213837	A1	20041028	US 2004-846083	20040514

PRIORITY APPLN. INFO.: US 1999-137669P A1 19990604
WO 2000-US15401 W 20000602
US 2002-212030 B1 20020805

AB Physiol. active oil-core particles, and physiol. active oil-core particles that include a hydrophobic core material, a hydrophobic drug dissolved or suspended in the core material, and a layer of amphipathic lipids surrounding the hydrophobic core are prepared An optional continuous phase can be an oil-immiscible solution In one aspect, the method involves the use of a volatile solvent that is removed after the formation of the suspension. The suspension can be used substantially as created, or the particles formulated as a solid dosage form. In another aspect, the particles are formed substantially simultaneously with the volatilization of a propellant, for example, by spraying through an atomizing actuator. The resulting particles have superior particle size distribution and yield properties. The method is appropriate for use with physiol. agents that would be sensitive to heating during the encapsulating process, and also allows aseptic processing by filtration without heating the solns. used in processing. An example composition comprises bupivacaine, **tricaprylin**, dioleoylphosphatidylcholine, dipalitoylphosphatidylglycerol, chloroform, cholesterol and lysine.

IT **50-70-4**, Sorbitol, biological studies **538-23-8**, **Tricaprylin**
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oil-core compns. for the sustained release of hydrophobic drugs)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 25 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:738879 HCAPLUS
DOCUMENT NUMBER: 133:301197
TITLE: Oxalic acid or oxalate compositions and methods for bacterial, viral, and other diseases or conditions
INVENTOR(S): Hart, Francis J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 50 pp., Cont.-in-part of U. S. Ser. No. 629,538.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6133318	A	20001017	US 1998-14943		19980128	<--
US 6133317	A	20001017	US 1996-629538		19960409	<--
US 6407141	B1	20020618	US 2000-535572		20000327	
PRIORITY APPLN. INFO.:			US 1995-6785P	P	19951115	
			US 1996-629538	A2	19960409	
			US 1997-36983P	P	19970129	
			US 1998-14943	A2	19980128	

AB A single medicine oxalic acid or oxalate or "magic bullet" and method for treatment or prevention of infectious or pathogenic microbial, bacterial, viral and other diseases in warm-blooded animals, including humans and pets, is provided. A composition includes at least one therapeutically effective form of oxalic acid or oxalate selected from ester, lactone or salt form including sodium oxalate, oxalic acid dihydrate, anhydrous oxalic acid, oxamide, and oxalate salts, natural or processed foods including molds, plants or vegetables containing oxalic acid or oxalate, beverages, liqs. or juices containing oxalic acid or oxalate, additives containing oxalic acid or oxalate, and combinations thereof. The composition may also contain a pharmaceutically acceptable carrier or diluent for the therapeutically effective form of oxalic acid or oxalate. Methods are provided including the steps of periodically administering, by topical, oral, or parenteral application, a therapeutically effective dosage of a composition including at least one therapeutically effective form of oxalic acid or oxalate and improving chemotherapy reducing the intake of oxalic acid or oxalate blockers such as citric acid, ascorbic acid (vitamin C), pyridoxine hydrochloride (vitamin B6), calcium, alc., resins, clays, foods containing calcium, beverages containing alc., citric acid, or ascorbic acid, red meat or white meat of fowl containing pyridoxine hydrochloride, or other foods nutritional supplements or beverages containing oxalic acid or oxalate blockers.

IT **67-48-1**, Choline chloride **7757-93-9**, Dicalcium phosphate
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
RN 67-48-1 HCAPLUS
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)

$Me_3{}^+N-CH_2-CH_2-OH$

● Cl^-

RN 7757-93-9 HCAPLUS
CN Phosphoric acid, calcium salt (1:1) (8CI, 9CI) (CA INDEX NAME)



● Ca

IT **57-55-6**, 1,2-Propanediol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 26 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725436 HCAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	AA	20001012	CA 2000-2366702	20000316 <--

EP 1165048 A1 20020102 EP 2000-916547 20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, **propylene glycol** 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

IT **53824-77-4**, **Propylene glycol** dicaprate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Captex 100; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 53824-77-4 HCAPLUS
CN Decanoic acid, 1-methyl-1,2-ethanediyl ester (9CI) (CA INDEX NAME)



IT **9004-96-0**, Polyethylene glycol monooleate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Crodel O 40, Kessco PEG 1000MO; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 9004-96-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-hydroxy- (9CI) (CA INDEX NAME)



IT **9004-81-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Kessco PEG 1000ML, Mapeg 200ML; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 9004-81-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



IT **9005-02-1**, Polyethylene glycol dilaurate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Kessco PEG 1540DL; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)
RN 9005-02-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-[(1-oxododecyl)oxy]- (9CI) (CA INDEX NAME)



IT **9005-07-6**, Polyethylene glycol dioleate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Kessco PEG 1540DO; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)
RN 9005-07-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **54-31-9** **68-35-9**, Sulfadiazine **110-27-0**, Isopropyl myristate **142-91-6**, Isopropyl palmitate **151-21-3**, Sodium dodecyl sulfate, biological studies **404-86-4**, **Capsaicin** **745-65-3**, Alprostadil **848-75-9**, Lormetazepam **1309-42-8**, Magnesium hydroxide **1330-80-9**, **Propylene glycol** oleate **1335-30-4**, Aluminum silicate **1338-41-6**, Sorbitan monostearate **9002-92-0**, Polyoxyethylene lauryl ether **9004-98-2**, Polyoxyethylene oleyl ether **9004-99-3**, Myrj 51 **9005-65-6**, Polysorbate 80 **9016-45-9** **10238-21-8** **11140-04-8**, Imwitor 988 **21645-51-2**, Aluminum hydroxide, biological studies **23288-49-5**, Probucol

26402-26-6, Glyceryl **monocaprylate 36354-80-0**,
Glyceryl **dicaprylate 37321-62-3**, Lauroglycol FCC
52581-71-2, Volpo 3 **57307-93-4**, Pentaerythritol
caprylate 68993-42-0D, Polyethylene glycol
caprylate, glycerides **72432-03-2**, **Miglitol**
79665-94-4 106392-12-5, Polyoxyethylene-polyoxypropylene
block copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 54-31-9 HCAPLUS
CN Benzoic acid, 5-(aminosulfonyl)-4-chloro-2-[(2-furanylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 68-35-9 HCAPLUS
CN Benzenesulfonamide, 4-amino-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 110-27-0 HCAPLUS
CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)

$HO_3SO-(CH_2)_{11}-Me$

● Na

RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 745-65-3 HCAPLUS
CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 848-75-9 HCAPLUS
CN 2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl- (9CI) (CA INDEX NAME)



RN 1309-42-8 HCAPLUS
CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)



RN 1330-80-9 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, monoester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 112-80-1
CMF C18 H34 O2

Double bond geometry as shown.



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 1335-30-4 HCAPLUS
CN Silicic acid, aluminum salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 1338-41-6 HCAPLUS
CN Sorbitan, monooctadecanoate (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 50-70-4
CMF C6 H14 O6

Absolute stereochemistry.



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-98-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



D1— $(CH_2)_8$ —Me

RN 10238-21-8 HCAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 11140-04-8 HCAPLUS
CN Octanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2

HO_2C— $(CH_2)_6$ —Me

CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 26402-26-6 HCAPLUS
CN Octanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 36354-80-0 HCAPLUS
CN Octanoic acid, diester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5

CMF C3 H8 O3



RN 37321-62-3 HCAPLUS
CN Dodecanoic acid, ester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 143-07-7
CMF C12 H24 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 52581-71-2 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 57307-93-4 HCAPLUS
CN Octanoic acid, ester with 2,2-bis(hydroxymethyl)-1,3-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 115-77-5
CMF C5 H12 O4



RN 68993-42-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy-, octanoate (9CI) (CA INDEX NAME)

CM 1

CRN 25322-68-3
CMF (C2 H4 O)n H2 O
CCI PMS



CM 2

CRN 124-07-2
CMF C8 H16 O2



RN 72432-03-2 HCAPLUS
CN 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 79665-94-4 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, diester with triglycerol (9CI) (CA INDEX NAME)

CM 1

CRN 56090-54-1
CMF C9 H20 O7

CCI IDS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 112-80-1
CMF C18 H34 O2

Double bond geometry as shown.



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, 1,2-Propanediol, biological studies **106-32-1**, Ethyl **caprylate 623-84-7**, **Propylene glycol** diacetate **1331-12-0**, **Propylene glycol** monoacetate **25322-69-4**, Polypropylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilizer; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)
RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 106-32-1 HCAPLUS
CN Octanoic acid, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 623-84-7 HCAPLUS
CN 1,2-Propanediol, diacetate (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1331-12-0 HCAPLUS
CN 1,2-Propanediol, monoacetate (7CI, 8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 64-19-7
CMF C2 H4 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 27 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:608551 HCAPLUS
DOCUMENT NUMBER: 133:213151
TITLE: Pharmaceutical compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Manesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050007	A1	20000831	WO 2000-US165	20000105 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6294192	B1	20010925	US 1999-258654	19990226 <--
CA 2365536	AA	20000831	CA 2000-2365536	20000105 <--
AU 2000022242	A5	20000914	AU 2000-22242	20000105 <--
AU 771659	B2	20040401		
EP 1158959	A1	20011205	EP 2000-901394	20000105 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537317	T2	20021105	JP 2000-600619	20000105
NZ 513810	A	20040227	NZ 2000-513810	20000105

PRIORITY APPLN. INFO.: US 1999-258654 A 19990226
WO 2000-US165 W 20000105

AB The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms

a clear, aqueous dispersion of the surfactants containing the therapeutic agent.

The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical composition contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacel186 0.29, sodium taurocholate 0.26, and **propylene glycol** 0.46 mg.

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, 1,2-Propanediol, biological studies **57-55-6D**, **Propylene glycol**, ethers **57-83-0**, Progesterone, biological studies **106-32-1**, Ethyl **caprylate 110-27-0**, Isopropyl myristate **124-07-2**, Octanoic acid, biological studies **142-91-6**, Isopropyl palmitate **404-86-4**, **Capsaicin 623-84-7**, **Propylene glycol** diacetate **1331-12-0**, **Propylene glycol** monoacetate **1335-71-3**, **Propylene glycol** oleate **9002-92-0**, Brij 30 **9004-81-3**, Polyoxyethylene laurate **9004-96-0**, PEG-32 oleate **9004-98-2**, Polyoxyethylene oleyl ether **9004-99-3**, Polyoxyethylene stearate **9005-02-1**, Polyoxyethylene dilaurate **9005-07-6**, Polyoxyethylene dioleate **9005-37-2**, **Propylene glycol** alginate **9005-63-4D**, Polyoxyethylene sorbitan, derivs. **9005-65-6**, Polysorbate 80 **9016-45-9** **10238-21-8**, Glyburide **11140-04-8**, Imwitor 988 **23288-49-5**, Probucol **25322-69-4**, Polypropylene glycol **26402-26-6**, Glyceryl **monocaprylate 36354-80-0**, Glyceryl **dicaprylate 37321-62-3**, Lauroglycol **52581-71-2**, Volpo 3 **72432-03-2**, **Miglitol** **79902-63-9**, Simvastatin **106392-12-5**, Ethylene oxide propylene oxide block copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)

RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 106-32-1 HCAPLUS
CN Octanoic acid, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



.

RN 110-27-0 HCAPLUS
CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 124-07-2 HCAPLUS
CN Octanoic acid (8CI, 9CI) (CA INDEX NAME)



RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 623-84-7 HCAPLUS
CN 1,2-Propanediol, diacetate (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1331-12-0 HCAPLUS
CN 1,2-Propanediol, monoacetate (7CI, 8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 64-19-7
CMF C2 H4 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 1335-71-3 HCAPLUS
CN 9-Octadecenoic acid (9Z)-, ester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 112-80-1
CMF C18 H34 O2

Double bond geometry as shown.



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-81-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-96-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-98-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9005-02-1 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxododecyl)-ω-[(1-oxododecyl)oxy]- (9CI) (CA INDEX NAME)



RN 9005-07-6 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(9Z)-1-oxo-9-octadecenyl]-ω-[[(9Z)-1-oxo-9-octadecenyl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 9005-37-2 HCAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



D1— $(CH_2)_8$ —Me

RN 10238-21-8 HCAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 11140-04-8 HCAPLUS
CN Octanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2

HO_2C— $(CH_2)_6$ —Me

CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 23288-49-5 HCAPLUS
CN Phenol, 4,4'-[(1-methylethylidene)bis(thio)]bis[2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 26402-26-6 HCAPLUS
CN Octanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 36354-80-0 HCAPLUS
CN Octanoic acid, diester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 124-07-2
CMF C8 H16 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 37321-62-3 HCAPLUS
CN Dodecanoic acid, ester with 1,2-propanediol (9CI) (CA INDEX NAME)

CM 1

CRN 143-07-7
CMF C12 H24 O2



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 52581-71-2 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 72432-03-2 HCAPLUS

CN 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R,3R,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 79902-63-9 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 28 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:383598 HCAPLUS
DOCUMENT NUMBER: 133:22173
TITLE: Cosmetic or dermatological composition comprising at least one alkynyl carbamate and at least one polyol
INVENTOR(S): Saint-Leger, Didier
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1005851	A1	20000607	EP 1999-403002	19991202 <--
EP 1005851	B1	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2786689	A1	20000609	FR 1998-15304	19981203 <--
KR 2000047834	A	20000725	KR 1999-54229	19991201 <--
JP 2000169362	A2	20000620	JP 1999-342720	19991202 <--
BR 9905791	A	20001128	BR 1999-5791	19991202 <--
US 2001051169	A1	20011213	US 1999-449924	19991202 <--
US 6759051	B2	20040706		
RU 2177308	C2	20011227	RU 1999-125330	19991202 <--
AT 219919	E	20020715	AT 1999-403002	19991202
ES 2175913	T3	20021116	ES 1999-403002	19991202
PT 1005851	T	20021129	PT 1999-403002	19991202
CN 1262922	A	20000816	CN 1999-125543	19991203 <--

PRIORITY APPLN. INFO.: FR 1998-15304 A 19981203
OTHER SOURCE(S): MARPAT 133:22173

AB Cosmetic or dermatol. composition comprising at least one alkynyl carbamate AC.tplbond.CCH2OC(O)NHR (A = halogen, R = H, alkyl hydroxyalkyl) and at least one polyol chosen from non-etherified polyols or polyol (poly)alkyl or (poly)alkenyl ether, the polyols have 4-28 carbon atoms and 2-6 hydroxyl function. An antidandruff lotion contained 3-iodo-2-propynyl butylcarbamate 0.1, 3-(ethyl-2-hexyloxy)-1,2-propanediol 0.2, 95% ethanol 30, and water q.s. 100 g.

IT **50-70-4**, Sorbitol, biological studies **94-96-2**, 2-Ethyl-1,3-hexanediol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cosmetic or dermatol. composition comprising at least one alkynyl carbamate and at least one polyol)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 94-96-2 HCAPLUS
CN 1,3-Hexanediol, 2-ethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **1320-67-8**, **Propylene glycol** monomethyl ether
7778-85-0, **Propylene glycol** dimethyl ether
10221-57-5, **Propylene glycol** diethyl ether
25265-71-8, DiPropylene glycol **52125-53-8**,
Propylene glycol monoethyl ether
RL: NUU (Other use, unclassified); USES (Uses)
(cosmetic or dermatol. composition comprising at least one alkynyl carbamate and at least one polyol)
RN 1320-67-8 HCAPLUS
CN Propanol, 1(or 2)-methoxy- (9CI) (CA INDEX NAME)

CM 1

CRN 67-56-1
CMF C H4 O



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 7778-85-0 HCAPLUS
CN Propane, 1,2-dimethoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 10221-57-5 HCAPLUS

CN Propane, 1,2-diethoxy- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 25265-71-8 HCAPLUS
CN Propanol, oxybis- (9CI) (CA INDEX NAME)



2 (D1—Me)

RN 52125-53-8 HCAPLUS
CN Propanol, 1(or 2)-ethoxy- (9CI) (CA INDEX NAME)

CM 1

CRN 64-17-5
CMF C2 H6 O



CM 2

CRN 57-55-6
CMF C3 H8 O2



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 29 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:218395 HCAPLUS
DOCUMENT NUMBER: 132:255772
TITLE: Solid anhydrous cosmetic products comprising liposome encapsulated active agents
INVENTOR(S): Vollhardt, Jurgen; Manzo, Robert P.; Malkan, Nisha
PATENT ASSIGNEE(S): Dragoco Gerberding & Co. A.-G., Germany
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. 5,783,211.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6045823	A	20000404	US 1998-120269	19980722 <--
US 5783211	A	19980721	US 1997-962906	19971103 <--
US 6083529	A	20000704	US 1998-59320	19980413 <--
EP 974332	A1	20000126	EP 1999-114338	19990721 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6387398	B1	20020514	US 1999-365033	19990802

PRIORITY APPLN. INFO.:

US 1996-715962	B1	19960919
US 1997-962906	A2	19971103
US 1996-715598	B1	19960918
US 1998-120269	A	19980722

AB Anhydrous cosmetic stick formulations such as lip balms, lipsticks, and underarm deodorant or antiperspirant sticks, comprising an organic matrix having particles homogeneously dispersed therein, which particles are preferably prepared by a process comprising **spray**-drying a mixture of liposome encapsulated active agent, modified starch, and optionally a hydrocolloid gum such as maltodextrin. A lipstick contained cetyl acetate candy acetylated lanolin alc. 5.00, PEG-2 lanolin alc. ether (Solulan PB 2) 5.00, iso-Pr palmitate (**Lexol** IPP) 23.00, silica (Cab-O-Sil) 1.00, pigments 10.00, beeswax 6.00, candelilla wax 7.00, ozokerite 5.00, carnauba wax 3.00, myristyl lactate (Ceraphyl 50) 5.00, castor oil 27.80, methylparaben 0.10, Pr paraben (Cosept P) 0.10 and starchosomes 2.00%.

IT **142-91-6**, Isopropyl palmitate **11138-66-2**, Xanthan gum
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solid anhydrous cosmetic products comprising liposome encapsulated active agents)

RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 30 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:717837 HCAPLUS
DOCUMENT NUMBER: 131:314241
TITLE: Stabilized protein crystals, formulations containing them and methods of making them
INVENTOR(S): Margolin, Alexey L.; Khalaf, Nazer K.; St. Clair, Nancy L.; Rakestraw, Scott L.; Shenoy, Bhami C.
PATENT ASSIGNEE(S): Altus Biologics Inc., USA
SOURCE: PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955310	A1	19991104	WO 1999-US9099	19990427 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2330476	AA	19991104	CA 1999-2330476	19990427 <--
AU 9937646	A1	19991116	AU 1999-37646	19990427 <--
AU 757991	B2	20030313		
EP 1073421	A1	20010207	EP 1999-920064	19990427 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512949	T2	20020508	JP 2000-545510	19990427
US 2002045582	A1	20020418	US 1999-374132	19990810
US 6541606	B2	20030401		
ZA 2000006023	A	20011113	ZA 2000-6023	20001026 <--
US 2003175239	A1	20030918	US 2003-383266	20030305

PRIORITY APPLN. INFO.:		
US 1998-83148P	P	19980427
US 1998-224475	A2	19981231
US 1997-70274P	P	19971231
WO 1999-US9099	W	19990427
US 1999-374132	A1	19990810

AB Methods are provided for the stabilization, storage, and delivery of biol. active macromols., such as proteins, peptides and nucleic acids. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations in pharmaceutical and veterinary formulations, diagnostics, cosmetics, food, and agricultural feeds. The crystals are stabilized by addition of excipients such as carbohydrates or by encapsulating them in a polymeric carrier. Methods are presented for encapsulating proteins, glycoproteins, enzymes, antibodies, hormones, and peptide crystals or crystal formulations into compns. for biol. delivery to humans and animals. Thus, lipase from Candida rugosa was dissolved in distilled water, treated with celite, adjusted to pH 4.8 with AcOH, filtered, ultrafiltered to remove proteins of <30 kDa mol. weight, and crystallization was initiated by addition of 2-methyl-2,4-pentanediol. Sucrose was added to the mother liquor to a concentration of 10%, and the crystals were separated by centrifugation, suspended in EtOH, and air dried at room temperature Alternatively, the lipase crystals were crosslinked and encapsulated in lactic acid/glycolic acid copolymer; the microspheres formed were 90 μm in diameter

IT **9001-62-1P**, Lipase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); FFD (Food or feed use); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stabilized protein crystals, formulations containing them and methods of making them)

RN 9001-62-1 HCAPLUS

CN Lipase, triacylglycerol (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **106392-12-5**, Pluronic

RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized protein crystals, formulations containing them and methods of making them)
RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

IT **99-20-7**, Trehalose
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilizer; stabilized protein crystals, formulations containing them and methods of making them)
RN 99-20-7 HCAPLUS
CN α-D-Glucopyranoside, α-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 31 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:355574 HCAPLUS
DOCUMENT NUMBER: 130:356944
TITLE: Highly flavored dental floss
INVENTOR(S): Ochs, Harold D.; Duden, Carol A.; Saindon, Mark D.;

Dave, Vipul
PATENT ASSIGNEE(S): McNeil-PPC, Inc., USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 919208	A2	19990602	EP 1998-309302	19981113 <--
EP 919208	A3	20010411		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9804740	A	20000328	BR 1998-4740	19981116 <--

PRIORITY APPLN. INFO.: US 1997-970716 A 19971114

AB The invention provides a highly flavored dental article for cleaning the interproximal surfaces of the teeth such as dental floss comprising one filament having a water-insol. coating. Flavorant and a flavor enhancer are provided on the outer surface of the coating and within the depth of the coating. The filament substrate is made from a polymer such as a polyamide, fluorinated polymer, rayon, polyester, acetate polymer, polyolefin, block copolymer, cotton, wool, silk, and mixts. thereof. A most preferred coating composition contained beeswax 65, **spray**-dried flavor (natural and artificial flavor in modified starch encapsulate) 29, EC-25 5, and Na saccharin 1 %.

IT **50-70-4**, Sorbitol, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(as bulk sweetener; polymeric monofilaments coated with waxes and flavors for dental articles)
RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **89-78-1D**, Menthol, derivs.
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polymeric monofilaments coated with waxes and flavors for dental articles)
RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **1338-41-6**, Sorbitan monostearate **31566-31-1**, Glyceryl monostearate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilizer; polymeric monofilaments coated with waxes and flavors for dental articles)

RN 1338-41-6 HCAPLUS
CN Sorbitan, monooctadecanoate (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 50-70-4
CMF C6 H14 O6

Absolute stereochemistry.



RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



L35 ANSWER 32 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:175580 HCAPLUS
DOCUMENT NUMBER: 130:213475
TITLE: Cosmetic compositions for reducing body odor comprising uncomplexed cyclodextrin
INVENTOR(S): Lucas, Juliet Marie; Bartolo, Robert Gregory; Dodd, Michael Thomas; Trinh, Toan; Buckner, Robin Yager; Kajs, Theresa Marie
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 736,471, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5879666	A	19990309	US 1997-947075	19971008 <--
CA 2269808	AA	19980430	CA 1997-2269808	19971023 <--
CA 2269808	C	20031216		
WO 9817240	A1	19980430	WO 1997-US18954	19971023 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749108	A1	19980515	AU 1997-49108	19971023 <--
AU 721891	B2	20000713		
BR 9713276	A	20000321	BR 1997-13276	19971023 <--
EP 1006993	A1	20000614	EP 1997-911821	19971023 <--
EP 1006993	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1303266	A	20010711	CN 1997-180174	19971023 <--
CZ 289379	B6	20020116	CZ 1999-1450	19971023 <--
JP 2002505661	T2	20020219	JP 1998-519562	19971023 <--
IL 129569	A1	20040601	IL 1997-129569	19971023
AT 279173	E	20041015	AT 1997-911821	19971023
NO 9901897	A	19990622	NO 1999-1897	19990421 <--
KR 2000052768	A	20000825	KR 1999-703576	19990423 <--

PRIORITY APPLN. INFO.:	US 1996-736471	B2	19961024
	US 1996-736470	A	19961024
	US 1997-947075	A	19971008
	US 1997-951184	A	19971015
	WO 1997-US18954	W	19971023

AB The present invention relates to an odor absorbing composition, which is safe

for use on human skin comprising from about 0.1% to about 5%, by weight of the composition, of solubilized, water-soluble, uncomplexed cyclodextrin; from about 0.1% to about 36%, by weight of the composition, of an oil phase selected from the group consisting of emollients, moisturizers, and skin protectants; an emulsifier; and an aqueous carrier. The odor absorbing compns. of the present invention may also contain an effective amount of hydrophobic antimicrobials. The present invention also relates to methods of using the compns. of the present invention to reduce body odor and/or vaginal odor. The composition can be applied directly as a **spray**, poured from a bottle and applied by hand, or applied via a wipe. A composition contained Dow Corning 365 11.42 (35% dimethicone emulsion) **propylene glycol** 1 citric acid 0.03, disodium phosphate 0.02, Suttocide A 0.50, hydroxypropyl β-cyclodextrin 1, zinc phenolsulfonate 1.01, and water q.s. 100%.

IT **7440-44-0**, Carbon, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(activated; cosmetic compns. for reducing body odor comprising uncomplexed cyclodextrin)
RN 7440-44-0 HCAPLUS
CN Carbon (7CI, 8CI, 9CI) (CA INDEX NAME)

C

IT **89-78-1**, Menthol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cosmetic compns. for reducing body odor comprising uncomplexed cyclodextrin)
RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 33 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:126762 HCAPLUS
DOCUMENT NUMBER: 130:200771
TITLE: Compositions for controlling environmental odors on the body comprising cyclodextrin
INVENTOR(S): Lucas, Juliet Marie; Dodd, Michael Thomas; Bartolo, Robert Gregory; Trinh, Toan; Buckner, Robin Yager; Kajs, Theresa Marie
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 736,470, abandoned.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5874067	A	19990223	US 1997-951184	19971015 <--
CA 2269808	AA	19980430	CA 1997-2269808	19971023 <--
CA 2269808	C	20031216		
WO 9817240	A1	19980430	WO 1997-US18954	19971023 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9749108	A1	19980515	AU 1997-49108	19971023 <--
AU 721891	B2	20000713		
BR 9713276	A	20000321	BR 1997-13276	19971023 <--
EP 1006993	A1	20000614	EP 1997-911821	19971023 <--
EP 1006993	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1303266	A	20010711	CN 1997-180174	19971023 <--
CZ 289379	B6	20020116	CZ 1999-1450	19971023 <--
JP 2002505661	T2	20020219	JP 1998-519562	19971023 <--
IL 129569	A1	20040601	IL 1997-129569	19971023
AT 279173	E	20041015	AT 1997-911821	19971023
NO 9901897	A	19990622	NO 1999-1897	19990421 <--
KR 2000052768	A	20000825	KR 1999-703576	19990423 <--

PRIORITY APPLN. INFO.:

US 1996-736470	B2	19961024
US 1996-736471	A	19961024
US 1997-947075	A	19971008
US 1997-951184	A	19971015
WO 1997-US18954	W	19971023

AB The present invention encompasses a method of controlling malodors on human skin comprising the application to the human skin of a composition comprising from about 0.1% to about 5%, by weight of the composition, of solubilized, water-soluble, uncomplexed cyclodextrin; from about 0.1% to about 36%, by weight of the composition, of an oil phase selected from the group consisting of emollients, moisturizers, and skin protectants; an emulsifier; and an aqueous carrier. The compns. may also optionally comprise one or more of the following; hydrophobic antimicrobials; water-soluble antimicrobial preservatives; low mol. weight polyols; zinc salts; water-soluble polymers; soluble carbonate and/or bicarbonate salts; chelating agents; zeolites; activated carbon; and mixts. thereof. The compns. can be applied directly as a **spray**, poured from a bottle and applied by hand, or applied via a wipe. A composition contained Dow Corning-365 (35% dimethicone emulsion) 11.42, **propylene glycol** 1, citric acid 0.03, disodium phosphate 0.02, Glydant Plus 0.3, tetrasodium EDTA 0.1, hydroxy Pr beta cyclodextrin 1, zinc phenolsulfonate 1.01, and distilled water q.s. 100%.

IT **7440-44-0**, Carbon, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(activated; compns. for controlling environmental odors on body

comprising cyclodextrin)
RN 7440-44-0 HCAPLUS
CN Carbon (7CI, 8CI, 9CI) (CA INDEX NAME)

C

IT **89-78-1**, Menthol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. for controlling environmental odors on body comprising cyclodextrin)
RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 34 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:771289 HCAPLUS
DOCUMENT NUMBER: 130:17258
TITLE: Topical compositions containing eutectic mixture of drugs
INVENTOR(S): Passmore, Clare; Gilligan, Claire
PATENT ASSIGNEE(S): Galen (Chemicals) Limited, UK
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851283	A1	19981119	WO 1998-IE36	19980514 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2289966	AA	19981119	CA 1998-2289966	19980514 <--
AU 9875456	A1	19981208	AU 1998-75456	19980514 <--
AU 734429	B2	20010614		
EP 981330	A1	20000301	EP 1998-923030	19980514 <--

EP 981330		B1	20020807			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
NZ 501235		A	20010629	NZ 1998-501235		19980514 <--
JP 2001525820		T2	20011211	JP 1998-548991		19980514 <--
AT 221770		E	20020815	AT 1998-923030		19980514
PT 981330		T	20021231	PT 1998-923030		19980514
ES 2182309		T3	20030301	ES 1998-923030		19980514
IL 132682		A1	20040620	IL 1998-132682		19980514
NO 9905573		A	20000114	NO 1999-5573		19991112 <--
US 6841161		B1	20050111	US 2000-423715		20000112
PRIORITY APPLN. INFO.:				IE 1997-346	A	19970514
				WO 1998-IE36	W	19980514

AB The invention concerns a topical composition comprising an emulsion of at least one discontinuous phase in a continuous phase, where the discontinuous phase includes a eutectic mixture of first and second pharmacol. active agents and the continuous phase is provided by a pharmaceutically acceptable carrier. The eutectic mixture has a m.p. below 40°. The topical composition may addnl. comprise, in the eutectic mixture, a third or fourth pharmaceutically acceptable component. An emulsified gel suitable for treating musculoskeletal disorders, contained ibuprofen 5, Me nicotinate 5, hydroxyethyl cellulose 3, Nipastat Na 0.2, citric acid·H2O 1.03, Na2HPO4·12 H2O 3.65, Tween-80 0.5, and water 81.62 g.

IT **89-78-1**, Menthol **404-86-4**, **Capsaicin** **9005-65-6**, Tween 80 **11138-66-2**, Xanthan gum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. containing eutectic mixture of drugs)

RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 35 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:668083 HCAPLUS
DOCUMENT NUMBER: 129:293874
TITLE: Pharmaceutical compositions containing flavonoids for the control and treatment of anorectal and colonic diseases
INVENTOR(S): Singh, Amarjit; Jain, Rajesh; Singla, Anil Kumar
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India; University Institute of Pharmaceutical Sciences
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 868914	A1	19981007	EP 1997-302242	19970401 <--
EP 868914	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ES 2189923	T3	20030716	ES 1997-302242	19970401
PRIORITY APPLN. INFO.:			EP 1997-302242 A	19970401

AB A pharmaceutical composition, and process for the manufacture thereof, comprising one or more flavonoids obtained from the plant Euphorbia prostata useful in the control and treatment of anorectal and colonic diseases. Standardized extract of E. prostrata, when administered orally showed an inhibition of both carrageenan-induce edema with ED50 value of 5.98 mg/kg and histamine-induced edema with ED50 value of 16.37 mg/kg. A capsule contained above extract 15, lactose 250, colloidal silicone dioxide 10, and talc 25 mg.

IT **89-78-1**, Menthol **21645-51-2**, Aluminum hydroxide, biological studies **25322-69-4**, Polypropylene glycol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing flavonoids for control and treatment of anorectal and colonic diseases)

RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 36 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:490404 HCAPLUS
DOCUMENT NUMBER: 129:113559
TITLE: Method for reducing lung afflictions by inhalation of cytokine solutions.
INVENTOR(S): Huland, Edith; Huland, Hartwig
PATENT ASSIGNEE(S): Germany
SOURCE: U.S., 10 pp., Cont.-in-part of U.S. 5,399,341.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780012	A	19980714	US 1994-242542	19940513 <--
EP 462305	A1	19911227	EP 1990-111717	19900621 <--
EP 462305	B1	19941102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
US 5399341	A	19950321	US 1991-717824	19910619 <--

PRIORITY APPLN. INFO.: EP 1990-111717 A 19900621
US 1991-717824 A2 19910619

AB A method for administering to a patient having at least one affliction of infections, immunodeficiency syndromes, **inflammatory** diseases, autoimmune diseases, foreign body transplants, or requiring immuno-regulation of tumor diseases, which is present in the lungs. The method administers a non-systemic inhalation of an **aerosol**

composition to the lungs effective to reduce the affliction. The **aerosol** composition is a solution of a cytokine and a pharmaceutically acceptable aqueous carrier solution The **aerosol** composition is uniformly administered to the patient over a course of treatment of several months. An example solution contained interleukin-2 3.6 X 106 IU, mannitol 10, Na dodecyl sulfate 0.036, NaH2PO4 0.034, Na2HPO4 0.178mg and dextrose 5% to 1.0mL.

IT **50-70-4**, D-Glucitol, biological studies **9005-65-6**, Polyoxyethylene sorbitan monooleate **9016-45-9**, Polyoxyethylene nonylphenyl ether
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reducing lung afflictions by inhalation of cytokine solns.)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



D1— $(CH_2)_8$ —Me

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 37 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:221018 HCAPLUS
DOCUMENT NUMBER: 128:286372
TITLE: Topical medicament containing diclofenac
INVENTOR(S): Mueller, Gerhard
PATENT ASSIGNEE(S): Kade Pharmazeutische Fabrik G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 7 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 834312	A1	19980408	EP 1997-117282	19971006 <--
EP 834312	B1	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19641259	A1	19980416	DE 1996-19641259	19961007 <--
AT 230594	E	20030115	AT 1997-117282	19971006
PT 834312	T	20030430	PT 1997-117282	19971006
ES 2189910	T3	20030716	ES 1997-117282	19971006
PRIORITY APPLN. INFO.:			DE 1996-19641259 A	19961007

AB A topical anti-**inflammatory** and analgesic composition contains diclofenac or a salt thereof, an aqueous solvent, and ≥1 phospholipid as solubilizer. The composition is stable and well tolerated, and allows rapid penetration of diclofenac through the skin. Thus, a **spray** contained diclofenac Na 50.0, DL-α-tocopherol 0.3, phenoxyethanol 1.0, lecithin 30.0, **propylene glycol** 80.0, NaH2PO4 buffer (pH 6.3) 100.0, diethylene glycol monoethyl ether 300.0, and water 438.7 mg.

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, **Propylene glycol**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical medicament containing diclofenac)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 38 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:146650 HCAPLUS
DOCUMENT NUMBER: 128:196691
TITLE: Analgesic lotion for hemorrhoids and method of making such lotion
INVENTOR(S): Ivy, Jeffery Wade; Payne, Curtis Emery; Burda,

Christopher Dominic
PATENT ASSIGNEE(S): Au Pharmaceuticals, Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5720962	A	19980224	US 1995-539063	19951004 <--
WO 9834628	A1	19980813	WO 1997-GB338	19970205 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9716122	A1	19980826	AU 1997-16122	19970205 <--

PRIORITY APPLN. INFO.: US 1995-539063 A 19951004
WO 1997-GB338 A 19970205

AB This invention relates to an externally applied lotion that causes irritation or mild **inflammation** of the skin or mucous membranes for the purpose of relieving pain in hemorrhoids and the method of making such lotion. The formulation of the present invention contains ingredients to perform the five functions of vasoconstrictor, astringent, analgesic, antipruritic, and anesthetic. An alternate embodiment of the invention provides a formulation of the invention having a suitable viscosity to enable the lotion to be applied by a **spray** applicator directly to the site of application. A lotion comprises 9.0000-11.0000 parts hamamelis water; 0.0045-0.0055 parts epinephrine·HCl; 0.0900-0.1100 parts menthol crystals; 4.0653-4.9687 parts aloe powder; 64.2907-78.5775 parts purified water; 0.3499-0.4277 parts carbomer; 4.0000-4.8888 parts **propylene glycol**; 0.1000-0.1222 parts methylparaben; 0.1000-0.1222 parts propylparaben; 0.1000-0.1222 parts tetrasodium EDTA; 0.7000-0.8555 parts DEA cetyl phosphate; 1.0000-1.2222 parts stearic acid; 0.2500-0.3055 parts glyceryl stearate; 0.2500-0.3055 parts PEG 100 stearate; 5.0000-6.1111 parts C12-15-alkyl benzoate; 0.1000-0.1222 parts jojoba oil; 0.2000-0.2444 parts ginseng; 0.2000-0.2444 parts imidazolidinyl urea; and 0.2000-0.2444 parts triethanolamine.

IT **57-55-6**, **Propylene glycol**, biological studies
9004-99-3, PEG stearate **11099-07-3**, Glyceryl stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic lotions for hemorrhoids)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 39 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:617947 HCAPLUS
DOCUMENT NUMBER: 127:218020
TITLE: Smokable filler material for smoking articles
INVENTOR(S): McAdam, Kevin Gerard
PATENT ASSIGNEE(S): British-American Tobacco Co., Ltd., UK; McAdam, Kevin Gerard
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732490	A1	19970912	WO 1997-GB587	19970304 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2247935	AA	19970912	CA 1997-2247935	19970304 <--
CA 2247935	C	20030923		
AU 9722248	A1	19970922	AU 1997-22248	19970304 <--
AU 720501	B2	20000601		
EP 884957	A1	19981223	EP 1997-906818	19970304 <--
EP 884957	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1218372	A	19990602	CN 1997-194463	19970304 <--
BR 9707944	A	19990727	BR 1997-7944	19970304 <--
JP 2000506015	T2	20000523	JP 1997-531558	19970304 <--
NZ 331581	A	20000526	NZ 1997-331581	19970304 <--
AT 265811	E	20040515	AT 1997-906818	19970304
ZA 9701950	A	19970910	ZA 1997-1950	19970306 <--
US 6408856	B1	20020625	US 1998-142096	19980901
HK 1014838	A1	20040917	HK 1999-100175	19990114

PRIORITY APPLN. INFO.: GB 1996-5554 A 19960307
WO 1997-GB587 W 19970304

AB A smokable filler material which attempts to mimic tobacco leaf in its simplest components to provide a simpler smoke to the smoker comprises **aerosol** generating materials, a substantially non-combustible inorg. filler, a binder and an extract from a flavorful fuel source material. It may also comprise a biopolymer (polysaccharides) from groups such as starches, celluloses, pectins, lignins, or related compds. Filler materials containing tobacco extract, starch, glycerol, cellulose, pectin, **propylene glycol** alginate, and chalk were prepared The filler material was inserted into a substantially noncombustible, pre-extruded wrapper, attached to a filter element of fibrous cellulose acetate tow, and machine smoked. Smoke data shows that the wet tar (particulate matter water and nicotine free) was considerably reduced.

IT **57-55-6**, 1,2-Propanediol, uses **1309-48-4**, Magnesium oxide, uses **7440-44-0**, Carbon, uses **9005-37-2**, **Propylene glycol** alginate **9005-53-2**, Lignin, uses
RL: MOA (Modifier or additive use); USES (Uses)
(smokable filler material for smoking articles)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 1309-48-4 HCAPLUS
CN Magnesium oxide (MgO) (9CI) (CA INDEX NAME)



RN 7440-44-0 HCAPLUS
CN Carbon (7CI, 8CI, 9CI) (CA INDEX NAME)

C

RN 9005-37-2 HCAPLUS

CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-53-2 HCAPLUS
CN Lignin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L35 ANSWER 40 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:347295 HCAPLUS
DOCUMENT NUMBER: 126:321093
TITLE: Preparation of drug nanoparticles by **spray** drying
INVENTOR(S): Selvaraj, Ulagaraj; Messing, Gary L.
PATENT ASSIGNEE(S): Penn State Research Foundation, USA; Selvaraj, Ulagaraj; Messing, Gary L.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9713503	A1	19970417	WO 1996-US16417	19961011 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 862420	A1	19980909	EP 1996-939455	19961011 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1995-5194P P 19951013
WO 1996-US16417 W 19961011

AB The present invention relates to a method for manufacturing nanoparticles comprising combining an agent and a matrix to form a composite mixture and **spray** drying the composite mixture, wherein the nanoparticles are less than about 5000 nm. Suitable agents that can be formulated into nanoparticle include therapeutic and diagnostic agents, cosmetics, dyes, photog. agent, foods, pesticides, among others. Et 3,5-diacetamido-2,4,6-triiodobenzoate 5 g was dissolved in 100 mL DMSO and to this solution, 10 g sucrose dissolved in 10 mL water was added. The solution was sonicated and then atomized. The atomized droplets were transported through the glass

tubing at 60-250° to obtain fine particulates.

IT **1309-48-4**, Magnesia, biological studies **21645-51-2**, Aluminum hydroxide, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gels; matrix material for preparation of drug nanoparticles by **spray** drying)

RN 1309-48-4 HCAPLUS
CN Magnesium oxide (MgO) (9CI) (CA INDEX NAME)



RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



IT **50-70-4**, D-Glucitol, biological studies **9003-11-6**, Ethylene oxide-propylene oxide copolymer **11099-07-3**, Glycerol stearate **11138-66-2**, Xanthan gum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix material for preparation of drug nanoparticles by **spray** drying)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9003-11-6 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L35 ANSWER 41 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:217824 HCAPLUS
DOCUMENT NUMBER: 126:203757
TITLE: Nonsteroidal antiinflammatory analgesic compositions containing surfactants and thickening agents for **aerosol** products
INVENTOR(S): Oowada, Ryoichi; Wakabayashi, Satoru
PATENT ASSIGNEE(S): Osaka Shipbuilding, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09025244	A2	19970128	JP 1995-178558	19950714 <--
PRIORITY APPLN. INFO.:			JP 1995-178558	19950714

AB The compns. contain 10-50 weight% undiluted liquid (A) containing nonsteroidal **inflammation** inhibitors 0.1-10, H2O 75-99.5, surfactants 0.1-10, and thickening agents 0.01-10 weight% and 50-90 weight% spraying agents (B). The liquid (A) may addnl. contain monohydric alcs. and/or polyhydric alcs. The compns. show low irritation to nasal mucosa and are uniformly spread over the skin upon spraying. A preparation containing an undild. liquid containing

indomethacin 0.75, H2O 90.65, polyoxyethylene-polyoxypropylene cetyl ether 1, xanthan gum 0.3, and EtOH 5 weight% and LPG at 3:7 showed average particle size of the **aerosol** 110 μm and had no irritation to nasal mucosa, while a control containing no surfactant showed average particle size 30 μm and had irritating action.

IT **9004-99-3**, Polyethylene glycol monostearate **9016-45-9**, Polyoxyethylene nonylphenyl ether **9087-53-0**, Polyoxyethylene-polyoxypropylene cetyl ether **11138-66-2**, Xanthan gum
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory analgesic compns. containing surfactants and thickening agents for **aerosol** products)

RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9087-53-0 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, hexadecyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 36653-82-4
CMF C16 H34 O



CM 2

CRN 9003-11-6
CMF (C3 H6 O . C2 H4 O)x
CCI PMS

CM 3

CRN 75-56-9
CMF C3 H6 O



CM 4

CRN 75-21-8
CMF C2 H4 O

RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L35 ANSWER 42 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:177237 HCAPLUS
DOCUMENT NUMBER: 126:196164
TITLE: Chemical and elemental comparison of two formulations of **oleoresin capsicum**
AUTHOR(S): Haas, Js; Whipple, Re; Grant, Pm; Andresen, Bd; Volpe, Am; Pelkey, Ge
CORPORATE SOURCE: Forensic Science Center, Lawrence Livermore National Laboratory, Livermore, CA, 94550, USA
SOURCE: Science & Justice (**1997**), 37(1), 15-24
CODEN: SJUSFE; ISSN: 1355-0306
PUBLISHER: Forensic Science Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In-custody deaths following the application of **pepper spray** weaponry by law enforcement personnel have increased in California over the last few years. **Oleoresin capsicum** (OC), an oily extract of hot **peppers**, is the active ingredient in the **spray**, but little detailed information on product mixts. is available. Since OC exts. contain a multitude of natural compds. at irregular concns., there could be considerable variation in overall chemical composition among the different formulations of both "natural" and "synthetic" OC prepns. This was confirmed by organic and inorg. analyses performed on OC **sprays** produced by two manufacturers licensed for distribution within the state of California. The results indicated that the differences could lead to considerable inconsistency in weapon effectiveness, and suggested that more comprehensive studies are warranted.
IT **111-01-3**, 2,6,10,15,19,23-Hexamethyltetracosane **111-82-0**

, Methyl dodecanoate **142-91-6**, 1-Methylethyl hexadecanoate **404-86-4**, **Capsaicin 19408-84-5**, Dihydrocapsaicin **20279-06-5**, Homodihydrocapsaicin **28789-35-7**, Nordihydrocapsaicin **58493-48-4**, **Homocapsaicin**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**pepper spray** chemical and elemental composition)

RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 111-82-0 HCAPLUS
CN Dodecanoic acid, methyl ester (9CI) (CA INDEX NAME)



RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 19408-84-5 HCAPLUS
CN Nonanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 20279-06-5 HCAPLUS
CN Decanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-9-methyl- (9CI) (CA INDEX NAME)



RN 28789-35-7 HCAPLUS
CN Octanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-7-methyl- (9CI) (CA INDEX NAME)



RN 58493-48-4 HCAPLUS
CN 7-Decenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-9-methyl-, (7E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L35 ANSWER 43 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:90517 HCAPLUS
DOCUMENT NUMBER: 126:108685
TITLE: Oral care Ultramulsion based products
INVENTOR(S): Hill, Ira D.; Walters, Peter P.; Brown, Dale G.
PATENT ASSIGNEE(S): Whitehill Oral Technologies, Inc., USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9639116	A1	19961212	WO 1996-US8714	19960604 <--
W: AU, BR, CA, CN, JP, MX, SG				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5645841	A	19970708	US 1995-462930	19950605 <--
US 5651959	A	19970729	US 1995-462203	19950605 <--
US 5665374	A	19970909	US 1995-462599	19950605 <--
US 5711936	A	19980127	US 1995-464403	19950605 <--
US 5733529	A	19980331	US 1995-461698	19950605 <--
CA 2222407	AA	19961212	CA 1996-2222407	19960604 <--
AU 9659787	A1	19961224	AU 1996-59787	19960604 <--
AU 712266	B2	19991104		
EP 831762	A1	19980401	EP 1996-917114	19960604 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1190342	A	19980812	CN 1996-195388	19960604 <--
BR 9608343	A	19990105	BR 1996-8343	19960604 <--
JP 11506769	T2	19990615	JP 1996-501219	19960604 <--

PRIORITY APPLN. INFO.:		
US 1995-461698	A1	19950605
US 1995-462203	A1	19950605
US 1995-462599	A1	19950605
US 1995-462930	A1	19950605
US 1995-464403	A1	19950605
WO 1996-US8714	W	19960604

AB Oral care Ultramulsion based oral care products are disclosed, such as toothpastes, treated flosses and dental stimulators, interdental coating substances, oral rinses, mouth/throat conditioning internal treatment products, and anti-gingivitis products. All of these products are improved when an Ultramulsion dispersion containing silicone and a surfactant is used. The Ultramulsion dispersions of the present invention combine certain characteristics of emulsions with certain features of microemulsions. Like conventional emulsions, they are two phase systems comprising a silicone dispersed in a continuous, surfactant phase, wherein the silicone is insol. in the surfactant. Unlike conventional emulsions, but like microemulsions, these dispersions are stable. Unlike microemulsions, but like conventional emulsions, these Ultramulsion dispersions are not formed spontaneously. Like conventional emulsions, the Ultramulsion dispersions do not contain a cosolvent commonly found in microemulsions. An Ultramulsion contained dimethicone (viscosity 2,500,000 cSt) 10.0, thymol 0.063, menthol 0.055, eucalyptol 0.091, Me salicylate 0.055, and Poloxamer 338 89.76 %. An alc.-free oral rinse contained water 83.02, 70% sorbitol solution 10.0, glycerin 3.0, sodium saccharin 0.06, sodium butyrate 0.44, EDTA 0.05, xanthan gum 0.03, and above Ultaramulsion 3.0%.

IT **89-78-1**, Menthol **106392-12-5**, Poloxamer 338
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oral care Ultramulsion based products)
RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

IT **21645-51-2**, Aluminum hydroxide, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral care Ultramulsion based products)
RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



L35 ANSWER 44 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:618763 HCAPLUS
DOCUMENT NUMBER: 125:257224
TITLE: Redispersible nanoparticulate film matrixes with protective polymeric overcoats
INVENTOR(S): Desieno, Mark A.; Stetsko, Gregg

PATENT ASSIGNEE(S): Nanosystems L.L.C., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625150	A1	19960822	WO 1996-US1845	19960209 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5573783	A	19961112	US 1995-387651	19950213 <--
CA 2212803	AA	19960822	CA 1996-2212803	19960209 <--
CA 2212803	C	20031007		
AU 9648669	A1	19960904	AU 1996-48669	19960209 <--
EP 812187	A1	19971217	EP 1996-904612	19960209 <--
EP 812187	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11500127	T2	19990106	JP 1996-525046	19960209 <--
AT 238770	E	20030515	AT 1996-904612	19960209

PRIORITY APPLN. INFO.: US 1995-387651 A 19950213
WO 1996-US1845 W 19960209

AB A pharmaceutical film matrix, comprising nanoparticles of a low solubility drug associated with a steric stabilizer and a film dispersing agent, is overcoated with a protective polymer layer. Pharmaceutical compns. comprising the film matrix-coated carrier exhibit excellent bioavailability, are useful for treating mammals and are extremely stable in that they are capable of being redispersed without extensive agglomeration into larger particles after being stored. Two danazol dispersions were prepared by dissolving the PVP in water, dispersing the drug, and milling to a particle size of 150-250 nm. The pharmaceutical compns. were prepared by **spray** coating onto 5 solid carriers (sugar beads, granular sugar, maltodextrin, Avicel PH200, and Avicel CL 611) at varying levels of film dispersing agent (additive) and danizol content.

IT **7757-93-9**, Dicalcium phosphate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carrier particles; redispersible pharmaceutical nanoparticulate film matrixes with protective polymeric overcoats)

RN 7757-93-9 HCAPLUS
CN Phosphoric acid, calcium salt (1:1) (8CI, 9CI) (CA INDEX NAME)



● Ca

IT **151-21-3**, Sodium lauryl sulfate, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersing agent; redispersible pharmaceutical nanoparticulate film matrixes with protective polymeric overcoats)
RN 151-21-3 HCAPLUS
CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)



IT **9004-99-3**, Polyoxyethylene stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steric stabilizer; redispersible pharmaceutical nanoparticulate film matrixes with protective polymeric overcoats)
RN 9004-99-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(1-oxooctadecyl)-ω-hydroxy- (9CI)
(CA INDEX NAME)



L35 ANSWER 45 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:425383 HCAPLUS
DOCUMENT NUMBER: 125:67166
TITLE: Cosmetic and pharmaceutical compositions containing enduring perfumes
INVENTOR(S): Bacon, Dennis Ray; Trinh, Toan; Trandai, Angie
PATENT ASSIGNEE(S): Procter and Gamble Company, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612468	A1	19960502	WO 1995-US11897	19950918 <--
W: AU, BR, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5540853	A	19960730	US 1994-326457	19941020 <--
CA 2210971	AA	19960502	CA 1995-2210971	19950918 <--
CA 2210971	C	20020101		
AU 9536357	A1	19960515	AU 1995-36357	19950918 <--
AU 723030	B2	20000817		
EP 790820	A1	19970827	EP 1995-933858	19950918 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1994-326457 A 19941020
WO 1995-US11897 W 19950918

AB Cosmetic and pharmaceutical compns. comprise from about 0.001% to about 10%, preferably from about 0.005% to about 6%, enduring perfumes and from about 0.01% to about 95% surfactant system. The enduring perfumes provides a lasting olfactory sensation thus minimizing the need to use a large amts. A perfume composition contained benzyl salicylate 20, ethylene brassylate 20, 50% galaxolide 20, hexyl cinnamic aldehyde 20, and tetrahydrolinalool 20%. Formulation of cosmetic and topical pharmaceutical compns. containing above perfume are disclosed.

IT **108-32-7**, Propylene carbonate **25322-69-4**, Polypropylene glycol **29656-68-6**, Ethyl hexanediol
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cosmetic and pharmaceutical compns. containing enduring perfumes)

RN 108-32-7 HCAPLUS
CN 1,3-Dioxolan-2-one, 4-methyl- (9CI) (CA INDEX NAME)



RN 25322-69-4 HCAPLUS
CN Poly[oxy(methyl-1,2-ethanediyl)], α-hydro-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 29656-68-6 HCAPLUS
CN Hexanediol, ethyl- (9CI) (CA INDEX NAME)





L35 ANSWER 46 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	1996:336393 HCAPLUS
DOCUMENT NUMBER:	125:19009
TITLE:	Solid delivery systems for controlled release of molecules incorporated therein
INVENTOR(S):	Roser, Bruce Joseph; Colaco, Camilo; Jerrow, Mohamed Abdel Zahra; Blair, Julian Alexander; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair
PATENT ASSIGNEE(S):	Quadrant Holdings Cambridge Limited, UK
SOURCE:	PCT Int. Appl., 99 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603978	A1	19960215	WO 1995-GB1861	19950804 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6290991	B1	20010918	US 1994-349029	19941202 <--
CA 2197982	AA	19960215	CA 1995-2197982	19950804 <--
AU 9531851	A1	19960304	AU 1995-31851	19950804 <--
AU 688557	B2	19980312		
EP 773781	A1	19970521	EP 1995-927856	19950804 <--
EP 773781	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10503769	T2	19980407	JP 1995-506345	19950804 <--
HU 77777	A2	19980828	HU 1998-694	19950804 <--
CN 1204959	A	19990113	CN 1995-195496	19950804 <--
EP 1138319	A2	20011004	EP 2001-116637	19950804 <--
EP 1138319	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
EP 1138337	A2	20011004	EP 2001-116638	19950804 <--
EP 1138337	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
RU 2177785	C2	20020110	RU 1997-103529	19950804 <--
EE 3593	B1	20020215	EE 1997-62	19950804 <--
PL 184068	B1	20020830	PL 1995-318898	19950804
SK 283026	B6	20030204	SK 1997-277	19950804
AT 252373	E	20031115	AT 1995-927856	19950804
PT 773781	T	20040331	PT 1995-927856	19950804
ES 2208687	T3	20040616	ES 1995-927856	19950804
EP 1516615	A2	20050323	EP 2004-29125	19950804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
FI 9700867	A	19970408	FI 1997-867	19970228 <--
NO 9701688	A	19970411	NO 1997-1688	19970411 <--
AU 9871864	A1	19980820	AU 1998-71864	19980612 <--
AU 707605	B2	19990715		
US 6331310	B1	20011218	US 2000-628380	20000801 <--
US 2001038858	A1	20011108	US 2001-755737	20010105 <--
US 6586006	B2	20030701		
US 2002012687	A1	20020131	US 2001-945180	20010831 <--
US 6565871	B2	20030520		
US 2003054040	A1	20030320	US 2002-280468	20021025
US 6811792	B2	20041102		
US 2003147961	A1	20030807	US 2003-376136	20030227
US 6893657	B2	20050517		
US 2004052825	A1	20040318	US 2003-652212	20030829
US 2004219206	A1	20041104	US 2004-857100	20040528
US 2005276845	A1	20051215	US 2005-134573	20050520
US 2005276846	A1	20051215	US 2005-134700	20050520
US 2005276759	A1	20051215	US 2005-134701	20050520
JP 2006056898	A2	20060302	JP 2005-284596	20050929

PRIORITY APPLN. INFO.:

GB	1994-15810	A 19940804
US	1994-349029	A 19941202
EP	1995-927856	A3 19950804
JP	1996-506345	A3 19950804
WO	1995-GB1861	W 19950804
US	1997-500877	B1 19970818
US	2000-628380	A1 20000801
EP	2001-116638	A3 20010713
US	2001-945180	A1 20010831
US	2003-376136	A1 20030227
US	2003-652212	A1 20030829

AB Solid dosage delivery systems suitable for delivery of bioactive materials s.c., intradermal, i.m., and i.v. are disclosed. The delivery systems comprise a vitreous vehicle, e.g. polyol, loaded with the guest substance and capable of releasing the guest substance in situ at various controlled rates. Microparticles were prepared by **spray** drying a solution of 0.39 M trehalose, 0.14 M calcium lactate and 0.5% MB9. This particles were coated by addition of a saturated solution of zinc palmitate in toluene and cooling at 60-30°. The particles were then filtered under vacuum to remove excess zinc palmitate, washed with acetone, and air-dried. The resulting powder remained unwetted in water for ≥ 3 days and released MB9 slowly into the water.

IT **57-83-0**, Progesterone, biological studies **99-20-7**, Trehalose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release solid delivery systems comprising polyols)

RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99-20-7 HCAPLUS
CN α-D-Glucopyranoside, α-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L35 ANSWER 47 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:194804 HCAPLUS
DOCUMENT NUMBER: 124:241818
TITLE: Mouthwashes or other oral liquid compositions containing gellan gum and nonionic surfactants to improve stability
INVENTOR(S): Okumura, Kenji; Saito, Tooru; Ootsuki, Hidehiko
PATENT ASSIGNEE(S): Sunstar Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08003074	A2	19960109	JP 1994-138609	19940621 <--
JP 3429065	B2	20030722		

PRIORITY APPLN. INFO.: JP 1994-138609 19940621

AB Mouthwashes or other oral liquid compns. contain gellan gum and nonionic surfactants in addition to other ingredients to improve gellan gum stability and to prolong active ingredient retention time. A mouthwash contained tocopherol nicotinate 0.05, gellan gum 0.2, ethoxylated castor oil 0.5, ethanol 5.0, sodium dihydrogen phosphate 0.01, sodium monohydrogen phosphate 0.01, glycerin 13, sodium saccharin 0.01, perfumes 0.3, and water to 100 parts.

IT **120-40-1**, Lauric acid diethanolamide **9003-11-6D**, Ethylene oxide-propylene oxide copolymer, phytosterol and phytostanol ethers **9005-63-4D**, Polyoxyethylene sorbitan, fatty acid esters **9016-45-9**, Polyoxyethylene nonylphenyl ether **31694-55-0D**, Polyoxyethylene glycerol, fatty acid esters
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(mouthwashes or other oral liquid compns. containing gellan gum and nonionic surfactants to improve stability)

RN 120-40-1 HCAPLUS
CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 9003-11-6 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI)
(CA INDEX NAME)



D1— $(CH_2)_8$ —Me

RN 31694-55-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α,α',α''-1,2,3-
propanetriyltris[ω-hydroxy- (9CI) (CA INDEX NAME)



L35 ANSWER 48 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:687000 HCAPLUS
DOCUMENT NUMBER: 123:77153
TITLE: Carboxamides as crystallization inhibitors for azole fungicide **sprays**.

INVENTOR(S): Wirth, Wolfgang; Wangermann, Klaus; Botta, Artur; Rosenfeld, Frank
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 33 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4341986	A1	19950614	DE 1993-4341986	19931209 <--
WO 9515685	A1	19950615	WO 1994-EP3926	19941128 <--
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, NO, NZ, PL, RO, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9510678	A1	19950627	AU 1995-10678	19941128 <--

PRIORITY APPLN. INFO.: DE 1993-4341986 A 19931209
WO 1994-EP3926 W 19941128

OTHER SOURCE(S): CASREACT 123:77153; MARPAT 123:77153

AB The title carboxamides, prepared by known methods, are RCONR1R2 [R = H, (cyclo)alkyl, (cyclo)alkenyl, aryl, XCONR3R4, etc.; R1, R2 = H, (cyclo)alkyl, hydroxyalkyl, Ph, benzyl, etc.; X = alkylene, alkenylene; R3R4 = H, (cyclo)alkyl, alkenyl, Ph, benzyl, phenethyl; R1R2 and R3R4 = CH2CH2OCH2CH2, CH2CH2NR5CH2CH2; R5 = Me, Et]. Thus, ω-undecenic acid pyrrolidide stabilized a 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol **spray.**

IT **996-97-4P 5831-86-7P 7472-55-1P**
128666-07-9P
RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(preparation as crystallization inhibitor for azole fungicide **sprays**)

RN 996-97-4 HCAPLUS
CN Octanamide, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5831-86-7 HCAPLUS
CN Hexanamide, N,N-dibutyl-2-ethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 7472-55-1 HCAPLUS
CN Hexanamide, N-butyl-2-ethyl- (8CI, 9CI) (CA INDEX NAME)



RN 128666-07-9 HCAPLUS
CN Hexanamide, 2-ethyl-N-propyl- (9CI) (CA INDEX NAME)



L35 ANSWER 49 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:492147 HCAPLUS
DOCUMENT NUMBER: 122:222967
TITLE: Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
INVENTOR(S): Biegajski, James E.; Venkatraman, Subbu S.; Scott, Ann M.
PATENT ASSIGNEE(S): Cygnus Therapeutic Systems, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9505416	A2	19950223	WO 1994-US9305	19940819 <--
WO 9505416	A3	19950323		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2169729	AA	19950223	CA 1994-2169729	19940819 <--
CA 2169729	C	20010403		
AU 9475683	A1	19950314	AU 1994-75683	19940819 <--
EP 717761	A1	19960626	EP 1994-925925	19940819 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1134163	A	19961023	CN 1994-193819	19940819 <--
JP 09504810	T2	19970513	JP 1994-507171	19940819 <--
US 5700478	A	19971223	US 1995-505185	19950803 <--
PRIORITY APPLN. INFO.:			US 1993-109125 A	19930819
			US 1993-109273 A	19930819
			WO 1994-US9305 W	19940819

AB Water-soluble pressure-sensitive adhesives include a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer miscible

with the polymer. Suitable polymers are solid at room temperature; and have a hydrophilicity as measured by water uptake greater than about 25%; they have a b.p. >80°. The adhesives may be provided in dry film form. Adhesives adhere both to mucosal surfaces and to variety of materials that may constitute a part of a device or prosthesis to be held in a body cavity that has a mucosal lining. Also, a laminated device for the controlled release of a substance within a mucosa-lined body cavity includes the substance dissolved or dispersed in either or both of the water-soluble pressure-sensitive adhesive layer and optionally one or more water-soluble polymer layers. Also, devices for administering a substance over an extended time for relief of sore throat or cough, or for administering a breath freshening agent, particularly a **mist** odorant, include a water soluble polymer film layer containing the active ingredient, and a water soluble pressure sensitive mucoadhesive layer. A laminated composite device for antimicrobial controlled release containing PVP 47.0, glycerol 37.0, hydroxypropyl cellulose (Klucel HPC GF) 16.0%, resp., was formulated.

IT **50-70-4**, Sorbitol, biological studies **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plasticizer; pressure-sensitive mucoadhesive compns. as biomaterials and drug sustained-release matrixes)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **89-78-1**, Menthol **1338-41-6**, Sorbitan monostearate **11138-66-2**, Xanthan gum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pressure-sensitive mucoadhesive compns. as biomaterials and drug sustained-release matrixes)

RN 89-78-1 HCAPLUS
CN Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 1338-41-6 HCAPLUS
CN Sorbitan, monooctadecanoate (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 50-70-4
CMF C6 H14 O6

Absolute stereochemistry.



RN 11138-66-2 HCAPLUS
CN Xanthan gum (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L35 ANSWER 50 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:389797 HCAPLUS
DOCUMENT NUMBER: 122:154184
TITLE: **Aerosol** compositions containing pesticides
INVENTOR(S): Kawamoto, Shoichi; Sugano, Hiromoto
PATENT ASSIGNEE(S): Earth Chemical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06321703	A2	19941122	JP 1994-30096	19940228 <--
JP 3476238	B2	20031210		

PRIORITY APPLN. INFO.: JP 1994-30096 A 19940228
JP 1993-78591 19930315

AB A safe **aerosol** with little oily solvent is prepared, even though it contains an **inflammable** hydrocarbon instead of freons; it consists of water, an oily solvent, a propellant, and ≥ 1 dispersant selected from the group comprising sorbitan sesquioleate, polyoxyethylene lauryl ether, diglyceryl monooleate, and hexaglycerin polyricinoleate.

IT **9002-92-0**, Polyoxyethylene lauryl ether **114355-43-0**
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)

(dispersant; **aerosol** compns. containing pesticides and)
RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 114355-43-0 HCAPLUS
CN 9-Octadecenoic acid, 12-hydroxy-, (9Z,12R)-, ester with hexaglycerol (9CI) (CA INDEX NAME)

CM 1

CRN 36675-34-0
CMF C18 H38 O13
CCI IDS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 141-22-0
CMF C18 H34 O3

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L35 ANSWER 51 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:686617 HCAPLUS
DOCUMENT NUMBER: 121:286617
TITLE: Permeation enhancement of topical pharmaceuticals by inducing phase separation of epithelial lipid bilayers
INVENTOR(S): Elias, Peter M.; Thornfeldt, Carl R.; Feingold, Kenneth R.; Holleran, Walter M.
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421271	A1	19940929	WO 1994-US3085	19940321 <--

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

IL 109036	A1	19981227	IL 1994-109036		19940318 <--
AU 9464136	A1	19941011	AU 1994-64136		19940321 <--
EP 693932	A1	19960131	EP 1994-911673		19940321 <--
R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE					
US 6190894	B1	20010220	US 1998-58401		19980409 <--
US 6562606	B1	20030513	US 2000-608568		20000630
PRIORITY APPLN. INFO.:			US 1993-33811	A	19930319
			WO 1994-US3085	W	19940321
			US 1994-260559	B2	19940616
			US 1996-733712	B1	19961023
			US 1998-58401	A1	19980409

AB Topical compns. containing ≥1 intercellular phase-separating agent, such as epicholesterol (I), are used for inducing phase separation of the epithelial multilayered lipid bilayers within the intercellular spaces of the stratum corneum in a host in need of the topical administration of a physiol. active substance. Combination of I with transvaccenic acid in **propylene glycol**/EtOH delivered LHRH at 4.7 times the amount delivered by the vehicle. A lotion contained estradiol valerate 1-10, cetyl alc. 200, **propylene glycol** 100, Na lauryl sulfate 15, I 10 g, and water 400mL.

IT **57-55-6**, **Propylene glycol**, biological studies
111-02-4, Squalene **404-86-4**, **Capsaicin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(permeation enhancement of topical pharmaceuticals by inducing phase separation of epithelial lipid bilayers)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 111-02-4 HCAPLUS
CN 2,6,10,14,18,22-Tetracosahexaene, 2,6,10,15,19,23-hexamethyl-, (2E,6E,10E,14E,18E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 404-86-4 HCAPLUS
CN 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)- (9CI)

(CA INDEX NAME)

Double bond geometry as shown.



L35 ANSWER 52 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:662443 HCAPLUS
DOCUMENT NUMBER: 121:262443
TITLE: French limiting values for occupational exposure to chemicals
AUTHOR(S): Anon.
CORPORATE SOURCE: Fr.
SOURCE: Cahiers de Notes Documentaires (**1993**), 153, 557-74
CODEN: CNDIBJ; ISSN: 0007-9952
DOCUMENT TYPE: Journal
LANGUAGE: French

AB Limit values (suggested limiting values and maximum permissible values) for occupational exposure to chems., including carcinogens, which have been published by the French Labor Ministry are presented in one table. This table is preceded by information on the following points: monitoring of workplace atmospheres (sampling and anal.; **aerosols**); permitted values (definitions and aims; additivity convention; elements and compds.; limiting occupational exposure values; carcinogens); mandatory values; and values recommended by the French National Health Insurance Fund (CNAM).

IT **107-98-2**, 1-Methoxy-2-propanol **532-27-4**, α-**Chloroacetophenone** **1309-48-4**, Magnesium oxide, biological studies **1344-28-1**, Aluminum oxide (Al2O3), biological studies **2698-41-1**, o-Chlorobenzylidene malononitrile **6423-43-4** **7440-02-0**, Nickel, biological studies
RL: ADV (Adverse effect, including toxicity); POL (Pollutant); BIOL (Biological study); OCCU (Occurrence)
(occupational exposure; occupational exposure and stds. for limiting workplace concns. of chems. in France)

RN 107-98-2 HCAPLUS
CN 2-Propanol, 1-methoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 532-27-4 HCAPLUS
CN Ethanone, 2-chloro-1-phenyl- (9CI) (CA INDEX NAME)



RN 1309-48-4 HCAPLUS
CN Magnesium oxide (MgO) (9CI) (CA INDEX NAME)



RN 1344-28-1 HCAPLUS
CN Aluminum oxide (Al2O3) (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 2698-41-1 HCAPLUS
CN Propanedinitrile, [(2-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 6423-43-4 HCAPLUS
CN 1,2-Propanediol, dinitrate (8CI, 9CI) (CA INDEX NAME)



RN 7440-02-0 HCAPLUS
CN Nickel (8CI, 9CI) (CA INDEX NAME)

Ni

L35 ANSWER 53 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:135528 HCAPLUS
DOCUMENT NUMBER: 116:135528
TITLE: Performance-oriented packaging standards; changes to classification, hazard communication, packaging and handling requirements based on UN standards and agency initiative
CORPORATE SOURCE: United States Dept. of Transportation, Washington, DC, 20590-0001, USA
SOURCE: Federal Register (**1990**), 55(246), 52402-729, **21 Dec 1990**
CODEN: FEREAC; ISSN: 0097-6326
DOCUMENT TYPE: Journal

LANGUAGE: English

AB The hazardous materials regulations under the Federal Hazardous Materials Transportation Act are revised based on the United Nations recommendations on the transport of dangerous goods. The regulations cover the classification of materials, packaging requirements, and package marking, labeling, and shipping documentation, as well as transportation modes and handling, and incident reporting. Performance-oriented stds. are adopted for packaging for bulk and nonbulk transportation, and SI units of measurement generally replace US customary units. Hazardous material descriptions and proper shipping names are tabulated together with hazard class, identification nos., packing group, label required, special provisions, packaging authorizations, quantity limitations, and vessel stowage requirements.

IT **96-24-2**, Glycerol α-monochlorohydrin **104-75-6**, 2-Ethylhexylamine **124-13-0**, Octyl aldehyde **532-27-4**, Chloracetophenone **762-16-3** **1120-21-4**, Undecane **1341-24-8**, **Chloroacetophenone** **6423-43-4** **7440-44-0**, Carbon, miscellaneous **27176-87-0**, Dodecylbenzenesulfonic acid
RL: ADV (Adverse effect, including toxicity); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process)
(packaging and transport of, stds. for)

RN 96-24-2 HCAPLUS
CN 1,2-Propanediol, 3-chloro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 104-75-6 HCAPLUS
CN 1-Hexanamine, 2-ethyl- (9CI) (CA INDEX NAME)



RN 124-13-0 HCAPLUS
CN Octanal (8CI, 9CI) (CA INDEX NAME)



RN 532-27-4 HCAPLUS
CN Ethanone, 2-chloro-1-phenyl- (9CI) (CA INDEX NAME)



RN 762-16-3 HCAPLUS
CN Peroxide, bis(1-oxooctyl) (9CI) (CA INDEX NAME)



RN 1120-21-4 HCAPLUS
CN Undecane (8CI, 9CI) (CA INDEX NAME)



RN 1341-24-8 HCAPLUS
CN Ethanone, 1-phenyl-, monochloro deriv. (9CI) (CA INDEX NAME)





RN 6423-43-4 HCAPLUS
CN 1,2-Propanediol, dinitrate (8CI, 9CI) (CA INDEX NAME)



RN 7440-44-0 HCAPLUS
CN Carbon (7CI, 8CI, 9CI) (CA INDEX NAME)

C

RN 27176-87-0 HCAPLUS
CN Benzenesulfonic acid, dodecyl- (8CI, 9CI) (CA INDEX NAME)





L35 ANSWER 54 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:578274 HCAPLUS
DOCUMENT NUMBER: 113:178274
TITLE: **Aerosol** compositions for pharmaceuticals and cosmetics
INVENTOR(S): Akita, Shigeki; Oguri, Kunio
PATENT ASSIGNEE(S): Osaka Aerosol Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02032190	A2	19900201	JP 1988-181754	19880722 <--
JP 2729244	B2	19980318		

PRIORITY APPLN. INFO.: JP 1988-181754 19880722

AB An **aerosol** useful in pharmaceutical and cosmetic prepns. contain water 30-60, EtOH and/or isoPrOH 20-60, Me2O 11-40, a physiol. active agent 0.1-12, and an inhibitor of volatility with high ignition temperature 0.1-10% by weight The discharge amount from the **aerosol** is 0.1-0.5 g/s at 25°. The **spray** is not flammable and not wasted by scattering. An anti-**inflammatory**, analgesic **aerosol** composition was prepared consisting of camphor 3.0, methanol 3.0, Me salicylate 2.5, glycol salicylate 1.5, **propylene glycol** 5.0 g, a 99% undenatured alc. 20.0, isoPrOH 5.0, water 30.0, Me2O 27.0, and liquefied petroleum gas 3.0 mL.

IT **57-55-6**, **Propylene glycol**, biological studies
111-01-3, Squalane
RL: BIOL (Biological study)
(pharmaceutical and cosmetic **aerosol** composition containing)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



L35 ANSWER 55 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:218230 HCAPLUS
DOCUMENT NUMBER: 110:218230
TITLE: Air contaminants
CORPORATE SOURCE: United States Occupational Safety and Health Administration, Washington, DC, 20210, USA

SOURCE: Federal Register (**1989**), 54(12, Bk. 2), 2332-983, **19 Jan 1989**
CODEN: FEREAC; ISSN: 0097-6326
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Under the Federal Occupational Safety and Health act, OSHA is amending existing air containment stds. and setting new permissible exposure limits for toxic substances commonly used in the workplace.

IT **532-27-4 1309-48-4**, Magnesium oxide, biological studies **1320-67-8**, **Propylene glycol** monomethyl ether **1344-28-1**, α-Alumina, biological studies **2698-41-1**, o-Chlorobenzylidene malononitrile **6423-43-4**, **Propylene glycol** dinitrate **7440-02-0**, Nickel, biological studies **7440-02-0D**, Nickel, compds. **34590-94-8**
RL: ADV (Adverse effect, including toxicity); POL (Pollutant); BIOL (Biological study); OCCU (Occurrence)
(air pollution by, occupational exposure to, stds. for, in USA)

RN 532-27-4 HCAPLUS
CN Ethanone, 2-chloro-1-phenyl- (9CI) (CA INDEX NAME)



RN 1309-48-4 HCAPLUS
CN Magnesium oxide (MgO) (9CI) (CA INDEX NAME)



RN 1320-67-8 HCAPLUS
CN Propanol, 1(or 2)-methoxy- (9CI) (CA INDEX NAME)

CM 1

CRN 67-56-1
CMF C H4 O



CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 1344-28-1 HCAPLUS
CN Aluminum oxide (Al2O3) (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 2698-41-1 HCAPLUS
CN Propanedinitrile, [(2-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 6423-43-4 HCAPLUS
CN 1,2-Propanediol, dinitrate (8CI, 9CI) (CA INDEX NAME)



RN 7440-02-0 HCAPLUS
CN Nickel (8CI, 9CI) (CA INDEX NAME)

Ni

RN 7440-02-0 HCAPLUS
CN Nickel (8CI, 9CI) (CA INDEX NAME)

Ni

RN 34590-94-8 HCAPLUS
CN Propanol, 1(or 2)-(2-methoxymethylethoxy)- (9CI) (CA INDEX NAME)



2 (D1—Me)

L35 ANSWER 56 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:637046 HCAPLUS
DOCUMENT NUMBER: 109:237046
TITLE: Foam-producing analgesic and anti-**inflammatory aerosols**
INVENTOR(S): Nakagawa, Akira; Saiki, Toshihiko; Miyata, Satoru; Masuda, Kenji; Oguri, Kunio; Mekata, Satoshi; Teramoto, Keiichiro
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan; Osaka Aerosol Industry Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63119420	A2	19880524	JP 1986-266428	19861108 <--
JP 07078019	B4	19950823		

PRIORITY APPLN. INFO.: JP 1986-266428 19861108

AB **Aerosols** producing analgesic and anti-**inflammatory** foams contain **inflammation** inhibitors 0.3-15.0, surfactants 0.1-5.0, H2O 3.0-20.0, powders 0.1-5.0, and propellants 60.0-90.0% by weight An **aerosol** was prepared consisting of l-menthol 3.7, dl-camphor 0.3, Me salicylate 1.6, glycol salicylate 0.7, eucalyptus oil 0.4, squalane 0.3, 1,3-butylene glycol 0.5, polyoxyethylene polyoxypropylene cetyl ether 1.0, EtOH 2.0, H2O 8.5, talc 1.0, and freon-114 80% by weight l-Menthol, dl-camphor, Me salicylate, glycol salicylate, eucalyptus oil, squalane, and 1,3-butylene glycol were mixed and heated to 50° to give a uniform solution To this solution were added polyoxyethylene polyoxypropylene cetyl ether, EtOH, water, and talc, and the mixture was emulsified. The whole emulsion was packed in an **aerosol** container, and Freon-114 was added under pressure to give a foam-producing **aerosol.**

IT **111-01-3**, Squalane **9016-45-9**, Polyoxyethylene nonylphenyl ether **9087-53-0**, Polyoxyethylene polyoxypropylene cetyl ether
RL: BIOL (Biological study)
(analgesic and anti-**inflammatory aerosols** containing)

RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 9016-45-9 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(nonylphenyl)-ω-hydroxy- (9CI) (CA INDEX NAME)



D1—$(CH_2)_8$—Me

RN 9087-53-0 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, hexadecyl ether (9CI) (CA INDEX

NAME)

CM 1

CRN 36653-82-4
CMF C16 H34 O



CM 2

CRN 9003-11-6
CMF (C3 H6 O . C2 H4 O)x
CCI PMS

CM 3

CRN 75-56-9
CMF C3 H6 O



CM 4

CRN 75-21-8
CMF C2 H4 O

L35 ANSWER 57 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:44065 HCAPLUS
DOCUMENT NUMBER: 108:44065
TITLE: Aqueous, nonstinging, antiinflammatory steroid formulations for nasal administration
INVENTOR(S): Benjamin, Eric Joel; Anik, Shabbir Tyabji; Lin, Ya Yun Tracy
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 246652	A2	19871125	EP 1987-107416	19870521 <--
EP 246652	A3	19880203		

EP 246652	B1	19910717			
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE					
US 4782047	A	19881101	US 1986-866171	19860522	<--
DK 8702586	A	19871123	DK 1987-2586	19870521	<--
DK 175238	B1	20040719			
FI 8702231	A	19871123	FI 1987-2231	19870521	<--
FI 88459	B	19930215			
FI 88459	C	19930525			
NO 8702127	A	19871123	NO 1987-2127	19870521	<--
NO 173365	B	19930830			
NO 173365	C	19931208			
AU 8773273	A1	19871126	AU 1987-73273	19870521	<--
AU 609718	B2	19910509			
JP 62283927	A2	19871209	JP 1987-126846	19870521	<--
JP 2521291	B2	19960807			
ZA 8703663	A	19881228	ZA 1987-3663	19870521	<--
AT 65183	E	19910815	AT 1987-107416	19870521	<--
CA 1288048	A1	19910827	CA 1987-537690	19870521	<--
IL 82615	A1	19911121	IL 1987-82615	19870521	<--
ES 2031467	T3	19921216	ES 1987-107416	19870521	<--
US 4983595	A	19910108	US 1988-247008	19880920	<--
PRIORITY APPLN. INFO.:			US 1986-866171 A	19860522	
			EP 1987-107416 A	19870521	

AB Aqueous antiinflammatory steroid formulations, which are useful for treatment of **inflammation** of the nasal mucosa without stinging, contain 0.01-0.05% antiinflammatory steroid, 2-10% **propylene glycol**, 10-25% PEG 400, and 1-4% Polysorbate 20. A nasal **spray** contained flunisolide hemihydrate 0.025, **propylene glycol** 5.0, PEG 400 20.0, Polysorbate 20 2.50, benzalkonium chloride 0.035, Na2EDTA 0.01, BHT 0.01, citric acid 0.005, Na citrate dihydrate 0.00765, sorbitol 2.00, and water to 100%; the pH was adjusted to 5.2. In a one month intranasal toxicity study in rabbits, no adverse reactions were seen using this formulation.

IT **50-70-4**, Sorbitol, biological studies **57-55-6**, **Propylene glycol**, biological studies
RL: BIOL (Biological study)
(nasal **spray** containing antiinflammatory steroid and, nonstinging)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



L35 ANSWER 58 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:512526 HCAPLUS
DOCUMENT NUMBER: 101:112526
TITLE: Thermoplastic resin coating dispersions
PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59074170	A2	19840426	JP 1982-182900	19821020 <--

PRIORITY APPLN. INFO.: JP 1982-182900 19821020

AB Compns. used for **spray** coating the inner surface of cylindrical objects comprise (a) a thermoplastic resin powder, (b) a liquid medium capable of dispersing a, and (c) an inorg. powder dispersible in b. Such compns. do not deposit the resin when passing through the **spray** tubes. Thus, Epiclon 7050 **[63055-40-3]** 6.7, EtOCH2CH2OAc (I) 10, iso-BuOH 10, and Al silicate 10 parts were mixed, further mixed with Plyophen TD 447 [61585-09-9] (phenolic resin) 4.8, I 30, iso-BuOH 10, and xylene 20.1 parts, and dissolved completely to prepare a paint composition by adding 8 parts Daiamid X-1891 (nylon 12 [24937-16-4] powder, particle size 60 μ). The compns. showed excellent characteristics in **spray** coating.

IT **1335-30-4**
RL: USES (Uses)
(nylon powdered dispersions in epoxy resins containing, sprayable coatings, for can seams)
RN 1335-30-4 HCAPLUS
CN Silicic acid, aluminum salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **25068-38-6**
RL: USES (Uses)
(nylon powder dispersions in, sprayable coatings, for can seams)
RN 25068-38-6 HCAPLUS
CN Phenol, 4,4'-(1-methylethylidene)bis-, polymer with (chloromethyl)oxirane (9CI) (CA INDEX NAME)

CM 1

CRN 106-89-8
CMF C3 H5 Cl O



CM 2

CRN 80-05-7
CMF C15 H16 O2



IT **25035-04-5 25587-80-8**
RL: USES (Uses)
(powdered, dispersion in epoxy resins, sprayable coatings, for can seams)
RN 25035-04-5 HCAPLUS
CN Poly[imino(1-oxo-1,11-undecanediyl)] (9CI) (CA INDEX NAME)



RN 25587-80-8 HCAPLUS
CN Undecanoic acid, 11-amino-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 2432-99-7
CMF C11 H23 N O2



=> d his l37

(FILE 'HCAPLUS' ENTERED AT 15:47:41 ON 14 APR 2006)
L37 39 S L3(L)L33(L)L11

=> d ibib abs hitstr l37 1-39

L37 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:74567 HCAPLUS
DOCUMENT NUMBER: 144:156706
TITLE: Composition and method for treating acne including anti-inflammatory Hepes oleate
INVENTOR(S): Watson, Dana M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006019935	A1	20060126	US 2004-894047	20040720
PRIORITY APPLN. INFO.:			US 2004-894047	20040720

AB The present invention is directed toward a topical composition for the treatment of acne comprising water, an anti-acne agent such as benzoyl peroxide, thickening agent, emulsifiers, stabilizers, and a natural esterified anti-inflammatory (Hepes Oleate). This combined therapy is more effective than either active ingredient alone and is particularly effective for those who do not respond well to benzoyl peroxide alone.

IT **11099-07-3**, Glyceryl stearate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for treating acne including anti-**inflammatory** Hepes oleate)

RN 11099-07-3 HCAPLUS

CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



L37 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1221008 HCAPLUS
DOCUMENT NUMBER: 143:466234
TITLE: Sprayable formulations for the treatment of acute inflammatory skin conditions
INVENTOR(S): Hirsh, Mark; Hirsh, Jane; Skolnik, Ira; Trumbore, Mark
PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005255048	A1	20051117	US 2005-128947	20050513
WO 2005115336	A2	20051208	WO 2005-US16812	20050513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-571178P P 20040515
US 2005-655306P P 20050223

AB A topical spray or foam, methods of making the formulation, and methods of use thereof, are developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, anti-pruritic agents to minimize itching, and skin protective compds. may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein at least one of the drugs is bound to an ion exchange resin. The use of binding resins, such as ion exchange resins, allows drugs with incompatible solvent requirements to be prepared in a single-phase formulation. For example, a spray foam containing two antibacterial agents and one antifungal agent was prepared A concentrate containing clindamycin 1.0, muciprocin 2.0, metronidazole 0.75, water 30.95, propylene glycol 2.5, glycerin 1.25, polyglyceryl-3 methylglucose distrearate 1.5, ethylhexyl stearate 3.0, ethylhexyl palmitate 2.5, mineral oil 2.75, glyceryl stearate 0.9, stearyl alc. 0.4, cetyl dimethicone 0.5, preservative as needed, and propellant HFC134a 50.0%, resp., was placed in an aerosol spray can, and the can was loaded with HFC134a propellant so that the composition was approx. 70% concentrate and 30% HFC, i.e., 3 g of propellant were added per 7 g of concentrate

IT **11099-07-3**, Glyceryl stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical formulations containing antimicrobial and antifungal drugs for treatment of acute **inflammatory** skin conditions)

RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



L37 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:516278 HCAPLUS
DOCUMENT NUMBER: 143:31912
TITLE: Combination of licochalcone A or an extract of radix Glycyrrhiza inflata, comprising licochalcone A, phenoxyethanol and optionally glycerin
INVENTOR(S): Kruse, Inge; Raschke, Thomas; Vietzke, Jens-Peter; Eckert, Julia
PATENT ASSIGNEE(S): Beiersdorf AG, Germany
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1541164	A1	20050615	EP 2004-27339	20041117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
DE 10356164	A1	20050804	DE 2003-10356164	20031202
US 2005136139	A1	20050623	US 2004-1224	20041202

PRIORITY APPLN. INFO.: DE 2003-10356164 A 20031202
AB The invention concerns cosmetic and dermatol. compns. that contain licochalcone A or an extract of radix Glycyrrhiza inflata, comprising licochalcone A, phenoxyethanol and optionally **glycerin** for the treatment of skin **inflammation** and dry skin. Thus an O/W night cream contained (weight/weight%): glyceryl stearate 2; she abutter 2; stearyl alc. 2; cetyl alc. 2; hydrogenated coco glycerides 2; **caprylic** /capric triglyceride 2; ethylhexyl coco fatty acid **ester** 2; cyclomethicone 3; **dicaprylyl** ether 2; tocopheryl acetate 1; sodium ascorbyl phosphate 0.1; licochalcone A 0.01; retinyl palmitate 0.1; phenoxyethanol 0.6; paraben 0.6; ethylhexyl **glycerin** 0.5; carbomer 0.1; EDTA 0.2; **glycerin** 10; dyes 0.05; fillers 0.2; perfume q.s.; water to 100.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:485344 HCAPLUS
DOCUMENT NUMBER: 143:13010
TITLE: Cosmetic compositions containing licochalcone A or an extract of Glycyrrhiza inflata and an organic thickener
INVENTOR(S): Raschke, Thomas; Wolber, Rainer; Kolbe, Ludger; Eckert, Julia
PATENT ASSIGNEE(S): Beiersdorf Ag, Germany
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 1537855	A1	20050608	EP 2004-27340		20041117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU					
DE 10357452	A1	20050630	DE 2003-10357452		20031203
US 2005191266	A1	20050901	US 2004-1081		20041202
PRIORITY APPLN. INFO.:			DE 2003-10357452	A	20031203

AB The invention concerns cosmetic and dermatol. compns. containing licochalcone A or an extract of Glycyrrhiza inflata and an organic thickener selected from the group of Carbopols, synthetic copolymers and crosspolymers, gums and cellulose derivs. The formulations are used to prevent and treat dry and **inflamed** skin. Thus an O/W night cream contained (weight/weight%): glyceryl stearate citrate 2; shea butter 2; stearyl alc. 2; cetyl alc. 2; hydrogenated coco glycerides 2; **caprylic**/capric triglyceride 2; ethylhexyl coco fatty acid **ester** 2; cyclomethicone 3; **dicaprylyl** ether 2; tocopheryl acetate 1; Ubiquinone Q10 0.1; sodium ascorbyl phosphate 0.1; licochalcone A 0.01; retinyl palmitate 0.1; paraben 0.6; ethylhexyl **glycerin** 0.5; Aristoflex AVC 0.3; EDTA 0.2; **glycerin** 10; dyes 0.05; fillers and additives (silica and BHT) 0.2; perfume q.s.; water to 100.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:96064 HCAPLUS
DOCUMENT NUMBER: 142:183435
TITLE: Wax sticks containing essential oils and anti-inflammatory agents for application to under the nose
INVENTOR(S): Tsuchiya, Kazuyuki; Hibi, Hirohisa
PATENT ASSIGNEE(S): Pigeon Corp., Japan; Nippon Shikizai Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005029512	A2	20050203	JP 2003-271150	20030704
PRIORITY APPLN. INFO.:			JP 2003-271150	20030704

AB Title sticks, especially useful for children with common cold, comprise anti-inflammatory agents and eucalyptus oil- and/or peppermint oil-containing essential oils dispersed in oily bases with m.p. ≥60°. The essential oils are inhaled to alleviate stuffed nose, and the anti-inflammatory agents prevent the skin from frequently blowing the nose. Thus, a wax stick was formulated containing eucalyptus oil, peppermint oil, and stearyl glycyrrhetinate.

IT **538-23-8**, **Trioctanoin**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wax sticks containing essential oils and anti-**inflammatory** agents for treatment of common cold in children)

RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:610072 HCAPLUS
DOCUMENT NUMBER: 141:135583
TITLE: Non-lethal temporary incapacitation formulation and novel solvent system
INVENTOR(S): Loghman-Adham, Kamran
PATENT ASSIGNEE(S): Zarc International, Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062641	A1	20040729	WO 2003-US611	20030110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-US611 20030110
AB A nonlethal temporarily **incapacitating** formulation having a new solvent system that has reduced blow back longer hang time when used as an aerosol spray. The solvent and formulation are nontoxic, nonhazardous, nonflammable, highly stable, environmentally safe and able to withstand extreme operating temps. The solvent system is a mixture of propylene **glycerol dicaprylate**/caprate and **glycerol** tris (2-**ethylhexanoate**) and is suitable for use for a wide range of automotive, household and industrial applications.

L37 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:931214 HCAPLUS
DOCUMENT NUMBER: 139:399814
TITLE: Topical composition containing a cortisone derivative for the treatment of inflammatory conditions of the skin
INVENTOR(S): Mckenzie, Leslie Peter
PATENT ASSIGNEE(S): Engelbrecht, Edna, S. Afr.; Jackson, Berdine
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097100	A1	20031127	WO 2003-ZA64	20030514
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003252187	A1	20031202	AU 2003-252187	20030514
ZA 2004010074	A	20050927	ZA 2004-10074	20041214
PRIORITY APPLN. INFO.:			ZA 2002-3853 A	20020515
			WO 2003-ZA64 W	20030514

AB The invention provides a topical composition which includes at least a cortisone component, an antihistamine component and an EO liposome component. The invention also provides a method of healing or preventing inflammatory conditions of the skin of a person. A composition contained an oil phase comprising glyceryl stearate, ceteareths, Butyrospermum parrii, Emulgate CL Spez, Pr p-hydroxybenzoate and a water phase comprising propylene glycol Me p-hydroxybenzoate, hydrocortisone acetate, diphenhydramine, EO liposome complex, and distilled water.

IT **11099-07-3**, Glyceryl stearate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical composition containing a cortisone derivative for the treatment of **inflammatory** conditions of the skin)

RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:868469 HCAPLUS
DOCUMENT NUMBER: 139:354554
TITLE: Method for the manufacture of textiles bonded with functional oily substances
INVENTOR(S): Segawa, Tsunehiro; Tanaka, Hiroaki
PATENT ASSIGNEE(S): TS CHemical Y. K., Japan; Taiyo Sangyo K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003313772	A2	20031106	JP 2002-158311	20020423
PRIORITY APPLN. INFO.:			JP 2002-158311	20020423

AB An emulsion comprising oily substances, polyglycerin higher fatty acid **esters**, sucrose fatty acid **esters**, higher or lower alcs., and water and an aqueous solution comprising hydrophilic synthetic resins, are used for adhering the oily substances to textiles. The invention textiles provide durable functionality. For example, an emulsion comprising **capsaicin**-containing **oleoresin**, polyglycerin **monocaprylate**, polyglycerin monomyristate, **glycerin**, ethanol, sucrose monostearate, and water; and an aqueous solution containing an acrylic emulsion, antistatic agents, aminosilicones, and sericins, were prepared A T/C fabric was treated with the above mixture and dried for the immobilization of the **capsaicin.**

L37 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:532117 HCAPLUS
DOCUMENT NUMBER: 139:80652
TITLE: Non-lethal temporary incapacitation formulation and novel solvent system
INVENTOR(S): Loghman-Adham, Kamran
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003129138	A1	20030710	US 2002-36546	20020107
PRIORITY APPLN. INFO.:			US 2002-36546	20020107

AB A nonlethal temporarily **incapacitating** formulation having a new solvent system that has reduced blow back longer hang time when used as an aerosol spray. The solvent and formulation are nontoxic, non-hazardous, nonflammable, highly stable, environmentally safe and able to withstand extreme operating temps. The solvent system is a mixture of propylene **glycerol dicaprylate**/caprate and **glycerol** tris(2-**ethylhexanoate**) and is suitable for use for a wide range of automotive, household and industrial applications.

L37 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:238141 HCAPLUS

DOCUMENT NUMBER: 138:242893
TITLE: Cosmetic and dermatological preparations containing ascorbates and α-liponic acid
INVENTOR(S): Mummert, Christopher; Schimpf, Ralph; Sauermann, Kirsten; Filbry, Alexander; Jaspers, Soeren; Schreiner, Volker; Raschke, Thomas; Staeb, Franz
PATENT ASSIGNEE(S): Beiersdorf AG, Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10144262	A1	20030327	DE 2001-10144262	20010908
PRIORITY APPLN. INFO.:			DE 2001-10144262	20010908

AB The invention concerns cosmetic and dermacol. prepns. that contain ascorbates and α- **liponic** acid for use in prevention and treatment of skin **inflammation**, dry skin, skin pigmentation; to protect from uv radiation and skin aging. Thus an O/W emulsion contained (weight/weight%): glyceryl stearate citrate 2; myristyl myristate 1; stearyl alc. 2; cetyl alc. 1; hydrogenated coco fatty glycerides 2; butylene glycol **dicaprylate**/dicaprate 1; ethylhexyl coco fatty acid **ester** 3; vaseline 4; **dicapryl** ether 1; bis-ethylhexyloxyphenol methoxyphenyltriazine 1; α- **liponic** acid 0.15; ascorbic acid 2; iminodisuccinate 0.1; phenoxyethanol 0.3; paraben 0.5; diazolidinyl urea 0.25; Xanthan gum 0.1; polyacrylic acid 0.2; **glycerin** 8; dyes 0.05; perfume q.s.; water to 100.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:42822 HCAPLUS
DOCUMENT NUMBER: 138:95626
TITLE: Allantoin emulsions for treatment of inflammatory diseases
INVENTOR(S): Farber, Elliott
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U. S. 6,281,236.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003012784	A1	20030116	US 2000-570120	20000512
US 6531500	B2	20030311		
US 6281236	B1	20010828	US 1999-360095	19990723
US 2001003753	A1	20010614	US 2001-758696	20010111
US 6673826	B2	20040106		
CA 2408689	AA	20011122	CA 2001-2408689	20010509
WO 2001087232	A2	20011122	WO 2001-US14899	20010509
WO 2001087232	A3	20020307		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001061290	A5	20011126	AU 2001-61290		20010509
EP 1284601	A2	20030226	EP 2001-935174		20010509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001010773	A	20040309	BR 2001-10773		20010509
JP 2004513068	T2	20040430	JP 2001-583701		20010509
US 2002055531	A1	20020509	US 2001-991283		20011113
US 2003162821	A1	20030828	US 2002-322782		20021219
US 2004082634	A1	20040429	US 2003-728838		20031208
PRIORITY APPLN. INFO.:			US 1999-360095	A2	19990723
			US 2000-570120	A2	20000512
			US 2001-758696	A2	20010111
			US 2001-758781	A	20010111
			WO 2001-US14899	W	20010509

AB An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester with C8-22. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier or the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone, cetyl alc. and stearic acid, sodium stearoyl lactylate and sodium isostearoyl lactylate, polyethylene glycol ether of cetearyl alc. or a polyethylene glycol ester of stearic acid and glyceryl stearate.. The composition can include other ingredients. Among the diseases that can be treated is epidermolysis bullosa.

IT **11099-07-3**, Glyceryl stearate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allantoin emulsions for treatment of **inflammatory** diseases)

RN 11099-07-3 HCAPLUS

CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5

CMF C3 H8 O3



L37 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:927200 HCAPLUS
DOCUMENT NUMBER: 138:8342
TITLE: Dermatological compositions containing anesthetics and/or anti-inflammatory agents and/or hydroxycarboxylate salts
INVENTOR(S): Rood, Gloria A.; Evenstad, Kenneth L.; O'Neill, Victoria A.; Gorham, Thomas R.
PATENT ASSIGNEE(S): Upsher-Smith Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096374	A2	20021205	WO 2002-US17074	20020531
WO 2002096374	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003017181	A1	20030123	US 2002-159562	20020531
US 2005059644	A1	20050317	US 2004-977374	20041029
PRIORITY APPLN. INFO.:			US 2001-295105P P	20010531
			US 2002-159562 A3	20020531

OTHER SOURCE(S): MARPAT 138:8342
AB Dermatol. compns. (methods of making and using) that include 1 or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an α-hydroxy acid. Thus, a cream contained water 52.45, methylparaben 0.15, glycerin 4.0, propylene glycol 5.0, light mineral oil 10.0, stearic acid 5.0, Polawax (self-emulsifying wax) 7.0, 70% ammonium lactate 5.2, 60% sodium lactate 5.6, and potassium lactate 5.6%.
IT **11099-07-3**, Glyceryl stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonionic surfactant; dermatol. compns. containing anesthetics and/or anti-**inflammatory** agents and/or hydroxycarboxylate salts)
RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



L37 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:354080 HCAPLUS
DOCUMENT NUMBER: 136:359655
TITLE: Topical allantoin compositions for treatment of skin inflammatory diseases
INVENTOR(S): Farber, Elliott
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 758,696.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002055531	A1	20020509	US 2001-991283	20011113
US 6281236	B1	20010828	US 1999-360095	19990723
US 2003012784	A1	20030116	US 2000-570120	20000512
US 6531500	B2	20030311		
US 2001003753	A1	20010614	US 2001-758696	20010111
US 6673826	B2	20040106		
WO 2003041688	A1	20030522	WO 2002-US36438	20021113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1999-360095 A2 19990723
US 2000-570120 A2 20000512
US 2001-758696 A2 20010111
US 2001-991283 A 20011113

AB A method of treating a skin condition or disease characterized by ulceration, inflammation, or blistering comprises applying to the skin of

a patient an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is an oil-in-water emulsion based on an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include an acidic wax such as beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone. In still another alternative, the emulsifier system can include cetyl alc. and stearic acid, sodium stearoyl lactylate and sodium isostearoyl lactylate, at least one polyethylene glycol ether of cetearyl alc., or a polyethylene glycol ester of stearic acid and glyceryl stearate. The composition can include other ingredients. The pH of the composition used in a method according to the present invention is about 3.0-6.0; preferably, a narrower pH range is used, varying with each embodiment of the composition Among the diseases that can be treated is epidermolysis bullosa. For example, a female patient with epidermolysis bullosa was treated with the allantoin-containing skin cream comprising 68.68% water, 1.90% 30% sodium lauryl sulfate solution, 0.15% tetrasodium EDTA, 0.12% citric acid, 10.60% lanolin oil, 4.20% cetyl alc., 2.00% stearyl alc., 1.90% beeswax, 2.00% cod liver oil, 0.50% butylated hydroxytoluene, 0.10% St. John's wort extract, 0.10% chamomile extract, 0.10% witch hazel extract, 0.10% arnica extract, 0.30% methylparaben, 0.20% propylparaben, 1.50% allantoin, and 0.20% fragrance. The cream cut the healing time for an open wound in half and actually kept blisters from spreading over larger areas.

IT **11099-07-3**, Glyceryl stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical allantoin compns. for treatment of skin **inflammatory** diseases)

RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



L37 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:718044 HCAPLUS
DOCUMENT NUMBER: 135:278021
TITLE: Cooling sheets containing water for horses
INVENTOR(S): Kusuniki, Akihiko; Goto, Motoaki; Sugisaki, Yoshiki
PATENT ASSIGNEE(S): Saitama Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001270823	A2	20011002	JP 2000-126645	20000324
PRIORITY APPLN. INFO.:			JP 2000-126645	20000324

AB The sheets, which are attached to the legs of racehorses for prevention and treatment of **inflammation**, contain polyacrylic acids, polyols, polyvalent metals, ≥60 weight% H2O, and oils. A composition containing H2O, Aerosil 200 (SiO2), liquid paraffin, Nikkol HCO 60 (polyoxyethylene hydrogenated castor oil), Nikkol SP 10 (sorbitan fatty acid **ester**), Sunrose F 30HC (Na-CMC), **glycerin**, **propylene glycol**, Al(OH)3 gel, Aronvis M (Na polyacrylate), Aronvis AH 105 [partially neutralized poly(acrylic acid)], Sanwet IM 1000 (superabsorbent polymer), N-methyl-2-pyrrolidone, Me p-hydroxybenzoate, Pr p-hydroxybenzoate, and tartaric acid was applied on a polyester nonwoven fabric and covered with a polypropylene film to give a cooling sheet, which showed good initial tack and could be easily peeled off from horse legs 6 h after attachment.

L37 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:664510 HCAPLUS
DOCUMENT NUMBER: 135:231696
TITLE: Storage-stable topical anti-inflammatory preparations containing steroid esters
INVENTOR(S): Baba, Takaaki; Nakaya, Yoshimasa; Okada, Takeshi
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001247463	A2	20010911	JP 2000-61601	20000307
PRIORITY APPLN. INFO.:			JP 2000-61601	20000307

AB Title prepns. contain steroid esters, glycerin, polar oils, and optionally diphenhydramine (salts). Thus, a cream containing prednisolone acetate valerate (I), diphenhydramine hydrochloride, crotamiton, and glycerin was stored at 50° for 1 mo to show 95.9% residual I and no odor of organic acids.

IT **110-27-0**, Isopropyl myristate **142-91-6**, Isopropyl palmitate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(storage-stable topical anti-**inflammatory** prepns. containing steroid **esters**, **glycerin**, and polar oils)

RN 110-27-0 HCAPLUS

CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 142-91-6 HCAPLUS
CN Hexadecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:552802 HCAPLUS
DOCUMENT NUMBER: 135:127225
TITLE: Topical compositions containing bearberry extracts and NSAIDs
INVENTOR(S): Ota, Yoichi; Okada, Takeshi; Nakajima, Yuya; Hagiwara, Hiroshi
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001206852	A2	20010731	JP 2000-21779	20000126
PRIORITY APPLN. INFO.:			JP 2000-21779	20000126

AB This invention relates to transdermal prepns. comprising bearberry leaves exts. (or arbutin) and nonsteroidal anti-**inflammatories**, such as Bu flufenamate and bufexamac. The compns. are effective for the treatment of eczema and dermatitis. A skin lotion contained bearberry exts. (dry solid component) 3, Bu flufenamate 3, ZnO 2, cetanol 3, **glycerin ester** 0.1, decaglyceryl monooleate 3, paraffin oils 2, squalane 5, iso-Pr myristate 3, **propylene glycol** 6.5, **glycerin** 7, methylparaben 0.1, and distilled water balance to 100 %.

L37 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:435486 HCAPLUS
DOCUMENT NUMBER: 135:37205
TITLE: Allantoin compositions for treatment of skin inflammatory diseases
INVENTOR(S): Farber, Elliott
PATENT ASSIGNEE(S): Alwyn Co., Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 570,120.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001003753	A1	20010614	US 2001-758696	20010111
US 6673826	B2	20040106		
US 6281236	B1	20010828	US 1999-360095	19990723
US 2003012784	A1	20030116	US 2000-570120	20000512
US 6531500	B2	20030311		
CA 2408163	AA	20011122	CA 2001-2408163	20010509
WO 2001087301	A1	20011122	WO 2001-US15102	20010509
WO 2001087301	C2	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001063035	A5	20011126	AU 2001-63035	20010509
EP 1337248	A1	20030827	EP 2001-937283	20010509
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533481	T2	20031111	JP 2001-583769	20010509
BR 2001010775	A	20040720	BR 2001-10775	20010509
US 2002055531	A1	20020509	US 2001-991283	20011113
US 2004082634	A1	20040429	US 2003-728838	20031208

PRIORITY APPLN. INFO.:		
US 1999-360095	A2	19990723
US 2000-570120	A2	20000512
US 2000-570266	A	20000512
US 2001-758696	A	20010111
WO 2001-US15102	W	20010509

AB An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least 1 emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. Thus, a skin cream contained 1.50% allantoin and PEG stearate 2.60% in addition to other adjuvants. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone. In still another alternative, the emulsifier system can include cetyl alc. and stearic acid. In yet another alternative, the emulsifier system can include sodium stearoyl lactylate and sodium isostearoyl lactylate. In another alternative, the emulsifier system can include at least 1 polyethylene glycol ether of cetearyl alc. In still another alternative, the emulsifier system can include a polyethylene glycol ester of stearic acid and glyceryl stearate. The composition can include other ingredients. The pH of the composition used in a method according to the present invention is from about 3.0 to about 6.0; preferably, a narrower pH range is used, varying with each embodiment of the composition Among the diseases that can be treated is epidermolysis

bullosa.
IT **11099-07-3**, Glyceryl stearate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allantoin compns. for treatment of skin **inflammatory** diseases)
RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:434847 HCAPLUS
DOCUMENT NUMBER: 135:66217
TITLE: Anti-itch patch containing analgesics, anesthetics, or corticosteroids
INVENTOR(S): Rolf, David; Buseman, Teri
PATENT ASSIGNEE(S): Lectec Corporation, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041746	A1	20010614	WO 2000-US33498	20001211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001041745	A1	20010614	WO 2000-US12970	20000512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6469227	B1	20021022	US 2000-569783		20000512
PRIORITY APPLN. INFO.:			US 1999-170041P	P	19991210
			US 2000-569783	A	20000512
			WO 2000-US12970	W	20000512

AB An adhesive anti-itch patch comprising a flexible backing having a front side and a back side and a therapeutic formulation positioned on the entire surface or on a portion of the front side of the backing is described. The therapeutic formulation includes a medicament, i.e., an antipruritic agent, such as an analgesic, an anesthetic, or a corticosteroid, useful for treating a condition associated with an insect bite, a rash, a skin irritation, poison ivy, poison oak, an **inflammatory** skin condition, or poison sumac; and a pressure sensitive adhesive. A method for treating a skin condition associated with itching includes applying to the skin surface an adhesive patch of the present invention. For example, therapeutic formulation contained (by weight) lidocaine 2.5%, camphor 3.0%, **propylene glycol** 8.4%, polyethylene glycol 0.7%, fragrance 0.5%, **glycerin** 42.4%, Aloe vera 1.0%, algin 22.5%, water 4.0%, and acrylic **ester** copolymer adhesive 15.0%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:376982 HCAPLUS
DOCUMENT NUMBER: 133:6217
TITLE: Fireproof glycol-based cleaning solvents
INVENTOR(S): Suzuki, Masayasu; Kaneko, Akiyasu
PATENT ASSIGNEE(S): Hitachi Techno Engineering K. K., Japan; Kaneko Kagaku K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2000154399	A2	20000606	JP 1999-257097		19990910
US 6204237	B1	20010320	US 1999-399204		19990917
PRIORITY APPLN. INFO.:			JP 1998-265077	A	19980918
			JP 1999-257097	A	19990910

AB Title solvents comprise 100 parts propylene glycols with flash point (FP) of ≥28° and 10-70 parts PrBr and/or iso-PrBr. A mixture of 100 propylene glycol n-Bu ether (with FP 62°) and 10 parts PrBr showed no inflammability, no penetration to various plastics or rubbers, no corrosion to Al, and high degreasing ability (oil-coated steel substrates).

IT **9002-86-2**, PVC
RL: MSC (Miscellaneous)
(substrates; PrBr- and/or iso-PrBr-containing **propylene glycol** derivs. as cleaning solvents with **inflammability**

and penetration prevention)
RN 9002-86-2 HCAPLUS
CN Ethene, chloro-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 75-01-4
CMF C2 H3 Cl



L37 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:227949 HCAPLUS
DOCUMENT NUMBER: 132:255788
TITLE: Use of surface-active citrate esters for stabilization of flavones, flavanones and/or flavonoids, synergistic mixtures of flavones, flavanones and/or flavonoids and citrate esters, and cosmetic and dermatological preparations containing such mixtures
INVENTOR(S): Max, Heiner; Schoenrock, Uwe; Staeb, Franz; Untiedt, Sven
PATENT ASSIGNEE(S): Beiersdorf A.-G., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19845305	A1	20000406	DE 1998-19845305	19981001
EP 1000603	A1	20000517	EP 1999-117912	19990913
EP 1000603	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 288733	E	20050215	AT 1999-117912	19990913
ES 2237004	T3	20050716	ES 1999-117912	19990913

PRIORITY APPLN. INFO.: DE 1998-19845305 A 19981001
AB Surface-active citrate **esters** protect flavones, flavanones, and/or flavonoids in cosmetic and dermatol. prepns. from photochem. and oxidative degradation and act synergistically with these compds. to protect the skin from photochem. and oxidative damage which could otherwise lead to skin aging and **inflammatory** processes. Thus, an oil-in-water cream contained glyceryl stearate citrate 3.60, sorbitan monostearate 1.20, cetostearyl alc. 1.20, octyldodecanol 3.00, **caprylic** /capric triglyceride 3.00, **dicaprylyl** ether 3.00, α-glucosylrutin 0.20, tri-Na EDTA 0.20, xanthan gum 0.10, **glycerin** 3.00, perfume, preservative, dyes, antioxidants, and H2O to 100.00 weight%.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:622178 HCAPLUS
DOCUMENT NUMBER: 131:248251
TITLE: Dermatological healing kit, components therefor, and

process for making
INVENTOR(S): Zaveri, Chanda
PATENT ASSIGNEE(S): Geneda Corporation, USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 870,919, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5958437	A	19990928	US 1998-22808	19980212
WO 9855082	A1	19981210	WO 1998-US11655	19980604
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9878202	A1	19981221	AU 1998-78202	19980604
CA 2239699	AA	19981206	CA 1998-2239699	19980605

PRIORITY APPLN. INFO.:		
US 1997-870919	B2	19970606
US 1998-22808	A	19980212
WO 1998-US11655	W	19980604

AB The invention is a dermatol. healing kit having a pigment stabilizer component and an anti-inflammatory emollient component, wherein the pigment stabilizer contains a mixture of glycerin, butylene glycol, bearberry extract, and Mitracarpe extract;Mg ascorbyl phosphate; and Tricholoma matsutake singer; and the anti-inflammatory emollient component contains Zanthoxylum bungeanum; decarboxy camosine chlorhydrate; Polygonum multiflorum thumb; Rubus thunbergii; and an aqueous mixture of Siegerbeckia orientalis extract The kits are effective for treating damage to and discolorations of laser-treated, ablated skin surfaces, and thus for the faster elimination of erythema from surface inflammation, for the moisturizing the skin, and for preventing and/or counteracting the darkening of skin faster than was heretofore possible.

IT **11099-07-3**, Glyceryl stearate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(dermatol. healing kits containing pigment stabilizers and anti-**inflammatory** emollients for laser-treated skin)

RN 11099-07-3 HCAPLUS
CN Octadecanoic acid, ester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2

$HO_2C-(CH_2)_{16}-Me$

CM 2

CRN 56-81-5
CMF C3 H8 O3



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:624007 HCAPLUS
DOCUMENT NUMBER: 129:235439
TITLE: Body cleansing agent
INVENTOR(S): Foerster, Thomas; Hollenbrock, Martina; Scholz, Wolfhard; Pittermann, Wolfgang; Schmitt, Michael
PATENT ASSIGNEE(S): Henkel Kommanditgesellschaft auf Aktien, Germany
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9840044	A1	19980917	WO 1998-EP1174		19980303
W: CA, CN, CZ, HU, NO, PL, SK, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
DE 19710149	A1	19980917	DE 1997-19710149		19970312
CA 2283917	AA	19980917	CA 1998-2283917		19980303
EP 967958	A1	20000105	EP 1998-913622		19980303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
NO 9904385	A	19990910	NO 1999-4385		19990910
US 6303109	B1	20011016	US 1999-380881		19991012
PRIORITY APPLN. INFO.:			DE 1997-19710149	A	19970312
			WO 1998-EP1174	W	19980303

AB Lipid-soluble, water-insol. cosmetic or dermatol. active substances (e.g. local anesthetics, anti-**inflammatory**, anti-aging, or antimicrobial agents, conditioners, sun blockers) which can be included in body cleansing agents are provided in the form of an aqueous preparation with ≥5 weight% water-soluble ionic or nonionic surfactant content. The active substances are solubilized with a polar lipid in lipid-surfactant mixed micelles or liquid crystals or by microemulsification with a nonpolar lipid, wherein the emulsion particles have a diameter <500 nm. These compns. show enhanced skin penetration by the active substances. Thus, an active substance concentrate was prepared by combining vitamin E acetate 1.8, linoleic acid 3.6, **glycerin** monooleate 23.0, and C8-16-alkyl glucoside 28.1 parts at 60° and adding 1,2-**propylene glycol** 9.5 and H2O 34.0; the turbid concentrate appears lamellar under the polarizing microscope. This concentrate 7.5 was mixed with 92.5 parts of a shower bath preparation containing SDS 10.0, coco fatty acid/protein condensate 1.0, coco amidopropylbetaine 1.0, C10-16-alkyl glucoside 4.0, ethoxylated glycerides 1.0, ethoxylated C12-14 fatty alcs. 0.5, NaOBz 0.4, p-hydroxybenzoate **esters** 0.3, Na lactate 0.2, lactic acid 0.6, d-panthenol 0.2, NaCl 0.5, and H2O to 100 weight%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:705784 HCAPLUS
DOCUMENT NUMBER: 125:339072
TITLE: Compositions and process for treating uremic pruritus
INVENTOR(S): Clemente, Emmet; Mendes, Robert W.; Anaebonam, Aloysius O.; Ahmed, Mumtaz
PATENT ASSIGNEE(S): Ascent Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9631205	A1	19961010	WO 1996-US4004	19960325
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5576346	A	19961119	US 1995-415718	19950403
AU 9652590	A1	19961023	AU 1996-52590	19960325
ZA 9602634	A	19961007	ZA 1996-2634	19960402
PRIORITY APPLN. INFO.:			US 1995-415718 A	19950403
			WO 1996-US4004 W	19960325

OTHER SOURCE(S): MARPAT 125:339072
AB A process and pharmaceutical composition for treatment of uremic pruritus in humans is disclosed. The pharmaceutical composition comprises of a chromone compound, such as 1,3-bis-(2-carboxychromon-5-yloxy)-2-hydroxypropane or a pharmacol. acceptable salt, **ester** or amide thereof dissolved or dispersed in a pharmacol. acceptable carrier. In accordance with the process, a therapeutically effective amount of the composition is topically administered to a pruritic lesion of a human patient. Topical treatment with cromolyn reduces the **inflammation** of the underlying vessels, causing the lesion to regress thereby eliminating the discoloration of the skin caused by the uremic pruritus. A cream contained cromolyn sodium 4, emulsifying wax 9, PPG-2 myristyl ether propionate 2.5, polyoxy-10-oleyl ether 1, squalene 4, white wax 2, dimethicone 1, cetyl alc. 3, propylparaben 0.1, purified water 68.8, **glycerin** 2.5, di-Na edetate dihydrate 0.1, **propylene glycol** 1.5, methylparaben 0.2, imidurea 0.3 %, and phosphoric acid q.s.to pH 5.5.

L37 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:679355 HCAPLUS
DOCUMENT NUMBER: 121:279355
TITLE: Changes in volatile components and capsaicin of oleoresin red pepper during cooking
AUTHOR(S): Choi, Ok-Soo; Ha, Bong-Seuk
CORPORATE SOURCE: Dept. Food and Nutrition, Gyeongsang National University, Jinju, 660 - 701, S. Korea
SOURCE: Han'guk Yongyang Siklyong Hakhoechi (1994), 23(2), 232-7
CODEN: HYSHDL; ISSN: 0253-3154
DOCUMENT TYPE: Journal
LANGUAGE: Korean

AB Changes of volatile components in modified oleoresin red pepper during cooking at high temperature were investigated. Dried red pepper was milled to 100 mesh particle size and oily compds. were extracted by reduced pressure steam distillation The reidue was reextd. and concentrated The exts. were combined.

The same volume of water and 4% of polyglycerol condensed ricinoleate (PGDR) were added to the combined extract, and emulsified to make oleoresin red pepper. 119 Volatile compds. were separated from the dried red pepper and oleoresin and 35 components were identified in both samples. The major flavor compds. were identified to be 2-methoxy-phenol, 2,6-bis (1,1-dimethylethyl)-4-methyl-phenol, 1,4-dimethylbenzene, 1,2-benzenedicarboxylic acid, 2-methoxy-4-methylphenol, 4-ethyl-2-methoxy-phenol, and 5-methyl-2-furancarboxaldehyde, and their transferral from raw red pepper to oleoresin was low. Ninety-three volatile compds. were isolated after 3 h cooking at 100°C and 82 volatile compds. were separated after that at 150°C. Degeneration of volatile compds. was proportional to the temperature of cooking. Capsaicin was relatively stable during cooking, and that remaining after cooking at 100 and 150°C was 84.7 and 73.3%, resp. Oleoresin from red pepper had some antioxidn. effect at 100°C cooking, but an antioxidn. effect at 150°C cooking was not shown due to degradation of capsaicin.

IT **538-23-8**, Octanoic acid 1,2,3-propanetriyl ester
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(changes in volatile components and **capsaicin** of **oleoresin** red **pepper** during cooking)

RN 538-23-8 HCAPLUS

CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:307507 HCAPLUS
DOCUMENT NUMBER: 120:307507
TITLE: Pharmaceutical compositions containing serine protease inhibitors as antiviral agents
INVENTOR(S): Lezdey, John; Wachter, Allan
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407525	A1	19940414	WO 1993-US9371	19930929

W: AU, BR, CA, GB, HU, JP, KR, NO, RU
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5376633	A	19941227	US 1993-122204		19930915
EP 626858	A1	19941207	EP 1993-923757		19930929
EP 626858	B1	20011212			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
AU 677367	B2	19970424	AU 1994-53507		19930929
AU 9453507	A1	19940426			
AT 210459	E	20011215	AT 1993-923757		19930929
CA 2129132	C	20040330	CA 1993-2129132		19930929
PRIORITY APPLN. INFO.:			US 1992-953234	A	19920930
			US 1993-122204	A	19930915
			WO 1993-US9371	W	19930929

AB Pharmaceutical compns. containing serine protease inhibitors are used as antiviral agents for treatment of viral infections. A cream contained α-1-antitrypsin (I) 9.0, olive oil 1.0, cetanol 2.0, stearic acid 1.0, **glycerin** aliphatic acid **ester** 12.0, Tween 60 0.5, **propylene glycol** 0.5, Me paraben 0.1, Pr paraben 0.02, and water to 100mg. Skin rash in 5 patients suffering from herpes simplex I were treated daily with a 15% solution of I followed by a cream containing 10% I. After 2 days, in all 5 patients the **inflammation** and rash were significantly reduced and after 4 days the rash had disappeared.

L37 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:567731 HCAPLUS
DOCUMENT NUMBER: 119:167731
TITLE: Solubilizing agent compositions for slightly soluble pharmaceuticals
INVENTOR(S): Takahashi, Kazuhiko; Uji, Kingo; Niwa, Akiko; Matsumoto, Koichi; Takahashi, Koichi
PATENT ASSIGNEE(S): Nihon Surfactant Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05178763	A2	19930720	JP 1991-45423	19910219
PRIORITY APPLN. INFO.:			JP 1991-45423	19910219

AB The title compns., useful for antipyretics, anti-inflammatory agents, analgesics, etc., contain (i) polyalc. middle-chain fatty acid esters or (ii) polar oily substances chosen from lactic acid alkyl esters, dibasic acid alkyl esters, polyalc. alkyl ethers, acylated amino acids, aliphatic alcs., and fatty acids. Diclofenac Na 10.0, propylene glycol monocaprylate 30.0, and H2O 60.0% were mixed to give a transparent liquid preparation
IT **538-23-8**, Glycerin trioctanoate
RL: BIOL (Biological study)
(antipyretic and anti-**inflammatory** agents containing, as solubilizer)
RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:415263 HCAPLUS
DOCUMENT NUMBER: 119:15263
TITLE: Enhancement effect of an ethanol/Panasate 800 binary vehicle on anti-inflammatory drug permeation across excised hairless mouse skins
AUTHOR(S): Uchida, Takahiro; Lee, Cheon Koo; Sekiya, Noboru; Toto, Shigeru
CORPORATE SOURCE: Fac. Pharm. Sci., Kyushu Univ., Fukuoka, 812, Japan
SOURCE: Biological & Pharmaceutical Bulletin (1993), 16(2), 168-71
CODEN: BPBLEO; ISSN: 0918-6158
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel binary vehicle system consisting of EtOH and Panasate 800 (tricaprylin) was used with 5 nonsteroidal anti-inflammatory drugs, and its enhancing effect on drug permeation across the hairless mouse skin in vitro was assessed. The permeability of all 5 drugs was markedly increased by treatment of the skin with EtOH/Panasate 800 binary systems compared with either EtOH or Panasate 800 alone, and the effect reached a maximum in the EtOH/Panasate 800 (40/60) system. With this binary system, the skin permeation of the drugs was increased in the following order: salicyluric acid > salicylic acid > alclofenac > ketoprofen > ibuprofen. A 1-layer skin model was used to study the skin permeation profiles of the 5 drugs. The diffusion parameter (D'), partition parameter (K'), and permeation constant (Kp = D' + K') were calculated by using the Laplace-transformed equations. The reduction of lag time and the increase of flux caused by EtOH/Panasate 800 binary vehicle systems was due to an increase of the D' value by Panasate 800 and of the K' value by EtOH. Especially, the EtOH/Panasate 800 (40/60) binary vehicle system produced the largest Kp value for each drug. For all the EtOH/Panasate 800 binary vehicle systems tested, the logarithms of the calculated Kp were in inverse proportion to the logarithms of the n-octanol/water partition coefficient of the drug.

IT **538-23-8, Tricaprylin**
RL: BIOL (Biological study)
(nonsteroidal **inflammation** inhibitors skin permeation enhancement by vehicle containing)
RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:658231 HCAPLUS
DOCUMENT NUMBER: 117:258231
TITLE: pharmaceutical compositions containing substituted α1-antitrypsin for treatment of inflammation
INVENTOR(S): Lezdey, John; Wachter, Allen
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 4 pp. Cont.-in-part of U.S. Ser. No. 598,241.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5134119	A	19920728	US 1991-643910	19910118
PRIORITY APPLN. INFO.:			US 1990-598241 A2	19901016

AB Pharmaceutical compns. containing amino acid 358-substituted α1-antitrypsin (I) are used for treatment of mast cell implicated skin **inflammations.** A cream contained leucine analog of I (II) 1.0, olive oil 5.5, cetanol 2.0, stearic acid 5.0, **glycerin** aliphatic acid **ester** 12.0, Tween 60 0.5, **propylene glycol** 0.5, methylparben 0.1, propylparaben 0.02, and water to 100g. A patient suffering from atopic dermatitis with swelling and open lesions of the hand was treated by immersing the hand in a solution of II.

L37 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:69061 HCAPLUS
DOCUMENT NUMBER: 114:69061
TITLE: Topical compositions containing diclofenac
INVENTOR(S): Donati-Pedemonti, Elisabetta; Lualdi, Paolo
PATENT ASSIGNEE(S): Altergon S. A., Switz.
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 372527	A1	19900613	EP 1989-122486	19891206
EP 372527	B1	19930512		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 89163	E	19930515	AT 1989-122486	19891206
PRIORITY APPLN. INFO.:			IT 1988-22902 A	19881209
			EP 1989-122486 A	19891206

AB An anti-**inflammatory** composition comprising diclofenac

hydroxyethylpyrrolidine (I), lipid substances with amphipathic characters, surfactants, and additives, is incorporated in a viscous hydrophilic gel for topical use. The lipid substances include cetyl and stearyl esters of **ethylhexanoic** acid, ethoxylated C8-18 mono-, di-, or triglycerides, phospholipids of vegetable origin, and lanolin esters. The viscous hydrophilic gel is a neutralized acrylic acid polymer. The compns. show improvement in cutaneous absorption and are easy to apply locally. A typical topical composition contained I 0.5-2, cetyl stearyl 2-**ethylhexanoate** 1-4, polyethylene glycol stearate 1-2, PEG 300 (or **propylene glycol**) 5-10, polymerized acrylic acid 0.5-3, triethanolamine 1-4, isopropanol 6-10, a perfume 0.1-0.2, and water to 100%. A topical composition containing I 1.32% and other ingredients as above was tested in rats according to Randall-Selitto method; an anti-**inflammatory** activity of I from the composition was significantly greater than that of I from the comparative composition containing I 1.32, neutralized arylic acid polymer 2.00, isopropanol 10.00, and water to 100.00%.

L37 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:465280 HCAPLUS
DOCUMENT NUMBER: 113:65280
TITLE: Liquid oral pharmaceutical compositions of nonsteroidal anti-inflammatory drugs
INVENTOR(S): Park, Moo K.; Caldwell, Henry C.
PATENT ASSIGNEE(S): Formulations Development Laboratories, Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4918103	A	19900417	US 1988-223420	19880725
US 5011852	A	19910430	US 1990-488955	19900306
US 5059626	A	19911022	US 1991-648513	19910130
PRIORITY APPLN. INFO.:			US 1988-223420	A3 19880725
			US 1990-488955	A3 19900306

AB A single-phase, nonaq. liquid for oral administration comprises (1) a nonsteroidal anti-inflammatory agent selected from the group consisting of a phenylacetic acid derivative, indeneacetic acid derivative, and a naphthaleneacetic acid derivative and (2) an edible oil comprising an ester of glycerol or propylene glycol with C6-12 fatty acids. The composition does not contain any substantial quantity of EtOH to prevent the ester formation. An anti-inflammatory liquid contained ibuprofen 1, saccharin 0.02, methanol 0.2 g, eucalyptus oil 0.1 mL, polysorbate-85 2 g, and Miglyol-810 to 100 mL.

IT **538-23-8**
RL: BIOL (Biological study)
(anti-**inflammatory** liquid containing)

RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 31 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:540530 HCAPLUS
DOCUMENT NUMBER: 111:140530
TITLE: Bioavailability-improved ketoprofen creams
INVENTOR(S): Tsuchiya, Yorisuke; Miyamoto, Misao; Takagi, Tomohiro; Tsunematsu, Takao
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01025719	A2	19890127	JP 1987-180253	19870720
JP 09110685	A2	19970428	JP 1996-255887	19870720

PRIORITY APPLN. INFO.: JP 1987-180253 A3 19870720

AB Anti-**inflammatory** and analgesic creams contain ketoprofen (I), **glycerin** mono- and/or difatty acid **esters**, polyalcs., carboxyvinyl polymers, H2O-soluble bases, emulsifying agents, and H2O. Carbopol-940 (carboxyvinyl polymer) 1, iso-Pr myristate 3, diisopropyl adipate 3, **glycerin** distearate (II) 4, poly(oxyethylene) sorbitan monostearate 1.5, poly(oxyethylene) stearyl ether phosphate 1, Na poly(oxyethylene) oleyl ether phosphate 2.5, I 3, and Pr p-hydroxybenzoate 0.2 part were mixed with 5 parts **propylene glycol** at 80°, emulsified with 73.3 parts H2O, and adjusted to pH 6.0 with 2.5 parts triethanolamine at 40° to give a cream. The cream was applied to the skin from rats, resulting in 10 and 58 μ/cm2 permeation of I 2 h and 6 h after the application, resp., vs. 1 and 4 μg/cm2, for a control cream prepared similarly but without II, resp.

L37 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:484109 HCAPLUS
DOCUMENT NUMBER: 111:84109
TITLE: Oral superoxide dismutase pharmaceuticals
INVENTOR(S): Maeda, Hiroshi; Suzuki, Fujio; Oda, Tatsuya; Hamamoto, Takayoshi; Oka, Kiichiro
PATENT ASSIGNEE(S): Kuraray Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 63267729 A2 19881104 JP 1987-102429 19870425
PRIORITY APPLN. INFO.: JP 1987-102429 19870425
AB Oral pharmaceutical compns. comprising a styrene-maleic anhydride copolymer residue-containing superoxide dismutase and a glyceride of medium to high fatty acids are prepared as inflammation inhibitors. A composition containing 1
mg 14C glycine-labeled Bu-esterified styrene- maleic anhydride copolymer-containing superoxide dismutase (preparation given), 0.95 mL panacete 810, and 0.05 mL Unigly GO-206 at 0.2 mL was orally administered to mice and concentration of the drug after 3h in blood plasma, liver, kidney, and muscle
was 2253, 7073, 1970, 3169, and 665 dpm, resp.
IT **538-23-8**, Panacete 800
RL: BIOL (Biological study)
(anti-**inflammatory** composition containing superoxide dismutase derivs. and)
RN 538-23-8 HCAPLUS
CN Octanoic acid, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L37 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:436898 HCAPLUS
DOCUMENT NUMBER: 109:36898
TITLE: Stable emulsions for foods and beverages
INVENTOR(S): Chino, Yoshiaki; Nakamura, Tetsuya; Yokoyama, Mitsuhide; Hosokawa, Makoto
PATENT ASSIGNEE(S): Hasegawa, T., Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63074457	A2	19880404	JP 1986-219693	19860919
JP 06097955	B4	19941207		

PRIORITY APPLN. INFO.: JP 1986-219693 19860919
AB Title emulsions contain edible oil materials, arabic acid alkali metal salts, and ≥1 surfactant selected from fatty **esters** of **glycerin**, sorbitan, or **propylene glycol.**
Thus, aqueous gum arabic was passed through a cation-exchange resin; then 500 g of the solution was adjusted to pH 4.0 with aqueous NaOH to give aqueous Na arabate, which was prehomogenized with a mixture of orange oil 10.0, **paprika** colorant 2.0, sucrose diacetate hexaisobutyrate 47.5, refined coconut oil 40.0, and **glycerin** fatty **ester** 0.5 g and then homogenized with 400 g **glycerin** at 300 kg/cm2 to give an emulsion. Granule size and absorbancy of the emulsion were 0.5 μm and 0.153 initially and 0.5 μm and 0.157 after shaking 150 times/min

for 5 h, vs. 0.5-1 μm and 0.198 initially and 1-1.2 μm and 0.255 after shaking for the emulsion without **glycerin** fatty **ester.**

L37 ANSWER 34 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:191165 HCAPLUS
DOCUMENT NUMBER: 102:191165
TITLE: Soft gelatin capsules having improved stability by incorporation of embrittlement inhibiting substances
INVENTOR(S): Brox, Werner
PATENT ASSIGNEE(S): R. P. Scherer Corp., USA
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 8403416	A1	19840913	WO 1984-US321		19840229
W: AU, JP, US					
EP 121321	A2	19841010	EP 1984-301238		19840227
EP 121321	A3	19860129			
EP 121321	B1	19910710			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
AT 65023	E	19910715	AT 1984-301238		19840227
DK 8401467	A	19840903	DK 1984-1467		19840229
DK 162875	B	19911223			
DK 162875	C	19920518			
AU 8426981	A1	19840928	AU 1984-26981		19840229
AU 566832	B1	19871029			
JP 60500867	T2	19850606	JP 1984-501367		19840229
JP 06000695	B4	19940105			
FI 8400832	A	19840903	FI 1984-832		19840301
FI 79244	B	19890831			
FI 79244	C	19891211			
CA 1211049	A1	19860909	CA 1984-448594		19840301
NO 8400793	A	19840903	NO 1984-793		19840302
ES 530270	A1	19850316	ES 1984-530270		19840302
US 4780316	A	19881025	US 1986-914122		19861001
PRIORITY APPLN. INFO.:			GB 1983-5693	A	19830302
			EP 1984-301238	A	19840227
			WO 1984-US321	A	19840229
			US 1984-670739	A1	19841031

AB Pharmaceutical unit dosage forms comprise ≥1 active materials dissolved or suspended in a liquid polyethylene glycol [25322-68-3] and encapsulated in a soft gelatin capsule shell. The capsule shell, in addition, contains a plasticizer such as glycerin [56-81-5], sorbitol [**50-70-4**] or **propylene glycol** [**57-55-6**], and an embrittlement-inhibiting composition (a mixture of sorbitol and ≥1 sorbitans, e.g., Anidrisorb 35/70 [96081-19-5]). Some benzodiazepines such as temazepam [846-50-4] and lormetazepam [**848-75-9**] have improved bioavailability when administered as polyethylene glycol solns. in soft capsules. Thus, a fill composition per capsule contained temazepam 10, polyethylene glycol 400 230, and glycerin 13 mg and a dry shell composition included gelatin 52, glycerin 32, Anidrisorb 35/70 12 and water 5 weight%. These capsules had generally lower hardness and longer effective storage life compared to the conventional capsules.

L37 ANSWER 35 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:154810 HCAPLUS
DOCUMENT NUMBER: 102:154810
TITLE: Betamethasone dipropionate cream
INVENTOR(S): Florance, Richard K.; Sequeira, Joel A.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4489071	A	19841218	US 1983-559671	19831209
ZA 8409231	A	19850731	ZA 1984-9231	19841126
IL 73626	A1	19871231	IL 1984-73626	19841126
AU 8435980	A1	19850613	AU 1984-35980	19841128
AU 565947	B2	19871001		
EP 146065	A2	19850626	EP 1984-114635	19841201
EP 146065	A3	19850807		
EP 146065	B1	19890712		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 44462	E	19890715	AT 1984-114635	19841201
DK 8405822	A	19850610	DK 1984-5822	19841206
DK 164022	B	19920504		
DK 164022	C	19920928		
CA 1238276	A1	19880621	CA 1984-469648	19841207

PRIORITY APPLN. INFO.: US 1983-559671 A 19831209
EP 1984-114635 A 19841201

GI



I

AB A topical cream containing betamethasone dipropionate (I) [5593-20-4] for treatment of **inflammation** is prepared A cream was prepared containing I 0.64, white petrolatum 250, white wax flakes 100, cyclomethicone 70, glyceryl oleate [25496-72-4] 30, ceteth 20 [9004-95-9] 0.5, 70% sorbitol [**50-70-4**] solution 150, 4-chloro-m-cresol [59-50-7] 1, **propylene glycol** [**57-55-6**] 50, NaH2PO4.H2O 2.65, H3PO4 0.01 mg and H2O to 1 g of emulsion.

L37 ANSWER 36 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:567373 HCAPLUS
DOCUMENT NUMBER: 95:167373
TITLE: Fluidized oleoresin compositions
INVENTOR(S): Stanton, Norman K.

PATENT ASSIGNEE(S): Dart and Kraft, Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4284657	A	19810818	US 1980-110787	19800109
CA 1131069	A1	19820907	CA 1981-368090	19810108

PRIORITY APPLN. INFO.: US 1980-110787 A 19800109

AB An aqueous based, fluidized condiment is prepared by mixing black **pepper**, clove, or ginger **oleoresins** 10-20; surfactant, such as sorbitol monooleate polyoxyethylene ether [**9005-65-6**] 10-20; a thickening agent, such as xanthan [**11138-66-2**], guar [9000-30-0], or arabic gum [9000-01-5] 0.25-2; acidifying agent, such as phosphoric acid 0.025-1, and water .apprx.60% (by weight). Thus, 10 lb of com. clove **oleoresin**, 225 g of sorbitol monooleate polyoxyethylene ether, having .apprx.20 oxyethylene groups/mol., and 9.75 g of xanthan gum are blended at 165°F for 5-10 min. The blend is combined with a separately prepared acidic (pH 2.4) aqueous mixture containing 1037 g of water, 2.25 g of 80% phosphoric acid, and 1.2 g of K sorbate to give a condiment composition, which is substantially stable against separation upon shelf storage at ambient temperature for ≥9 mo. The fluidized aqueous **oleoresin** compns. may be conveniently utilized to season food products.

L37 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:107368 HCAPLUS
DOCUMENT NUMBER: 86:107368
TITLE: Compositions based on poly(vinyl chloride) for linoleum
AUTHOR(S): Askarov, M. A.; Shakirova, E. N.; Matatova, D.; Kamalov, Kh.; Nigmatov, K. N.; Katanaev, V. G.
CORPORATE SOURCE: USSR
SOURCE: Deposited Doc. (1974), VINITI 2781-74, 8 pp. Avail.: BLLD
DOCUMENT TYPE: Report
LANGUAGE: Russian

AB The PVC [**9002-86-2**] floor coverings with optimum physicomech. properties are prepared from compns. containing 1-3% epoxy resin ED 5 [**25068-38-6**] as stabilizers and 5.7% lignin (I) [**9005-53-2**] substituted for PVC. Stabilization with epoxy resins in combination with various dyes and light stabilizers had a synergistic effect on tensile strength and elongation of PVC linoleum. The tensile strength of PVC samples increased from 0.74 to 1.35 kg/cm2 on addition of ED 5 in combination with benzotriazole [95-14-7] or I, and to 1.22 in combination with p-aminosalicyclic acid [65-49-6]. The rigidity of PVC on aging decreased in the presence of stabilizers and decrease depended on the amount and structure of the stabilizer.

L37 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:441678 HCAPLUS
DOCUMENT NUMBER: 85:41678
TITLE: Damage on crops by gases emitted from the plastic materials for covering

AUTHOR(S): Inden, Tokutaro; Tachibana, Shoji
CORPORATE SOURCE: Fac. Agric., Mie Univ., Tsu, Japan
SOURCE: Gakujutsu Hokoku - Mie Daigaku Nogakubu (1975), 50, 1-10
CODEN: MDNGAY; ISSN: 0462-4408
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB The toxicity of gases emitted from the plastic covering materials was tested in cucumber, tomato, egg plant, **pepper**, strawberry and Chinese cabbage. Of 25 plasticizers tested, diisobutyl phthalate (I) [84-69-5] was the most toxic, followed by bis(2-ethylhexyl) adipate [103-23-1], diisodecyl adipate [**27178-16-1**], Bu oleate [142-77-8] and dibutyl phthalate [84-74-2] as evidenced by chlorotic symptoms. Of 29 stabilizers examined, triphenyl phosphite [101-02-0], monolauryl diphenyl phosphite [32582-20-0] and organic compound complex stabilizers were the most toxic. Crops were also markedly injured by the gases emitted from the plastic sheets containing these compds. The sensitivity of crops to I increased in the order: egg plant < strawberry < **pepper** < tomato < cucumber.

L37 ANSWER 39 OF 39 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:26785 HCAPLUS
DOCUMENT NUMBER: 82:26785
TITLE: Lack of toxicity and carcinogenicity of some commonly used cutaneous agents
AUTHOR(S): Stenback, Frej; Shubik, Philippe
CORPORATE SOURCE: Med. Cent., Univ. Nebraska, Omaha, NE, USA
SOURCE: Toxicology and Applied Pharmacology (1974), 30(1), 7-13
CODEN: TXAPA9; ISSN: 0041-008X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Repeated applications of the cutaneous agents, benzophenone (I) [119-61-9], **propylene glycol** [**57-55-6**], isopropyl myristate [**110-27-0**], resorcinol (II) [108-46-3], 2-ethyl-1,3-hexanediol [**94-96-2**], p-aminobenzoic acid [150-13-0], and pyrogallol [87-66-1] to the skin of mice for their life-span did not significantly increase the tumor incidence and mortality as compared with controls. Skin lesions, slight **inflammation** and ulceration were observed, but no persistent cutaneous abnormalities occurred. Thus, a carcinogenic or toxic potential which would affect the use of these agents in man was not detected.

=> => d stat que l39
L2 2232 SEA FILE=REGISTRY ABB=ON PLU=ON GLYCEROL(L)ETHYLHEXAN? OR TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR

HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
L5 215163 SEA FILE=HCAPLUS ABB=ON PLU=ON AEROSOLS/CV OR AEROSOL? OR MIST OR SPRAY
L6 4600 SEA FILE=REGISTRY ABB=ON PLU=ON NONENAMIDE OR OCTAMIDE OR DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR CAPSANTHIN OR UNDECANAMIDE OR PAAIPER
L7 10495 SEA FILE=REGISTRY ABB=ON PLU=ON CAPSAICIN OR DIBENZOXAZEPINE OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR CAPSCIUM OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L8 14988 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR NONENAMIDE OR OCTAMIDE OR DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR CAPSANTHIN OR UNDECANAMIDE OR PAAIPER
L9 13 SEA FILE=HCAPLUS ABB=ON PLU=ON PAAI?
L10 68025 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 OR CAPSAICIN OR DIBENZOXAZEPINE OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR CAPSCIUM OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L11 318578 SEA FILE=HCAPLUS ABB=ON PLU=ON INCAPACIT? OR INFLAM? OR L8 OR L9 OR L10
L33 1172689 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 OR GLYCEROL(L)ETHYLHEXAN? OR TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
L39 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L33(L)L11(L)L5

=> d ibib abs hitstr l39 1-8

L39 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:610072 HCAPLUS
DOCUMENT NUMBER: 141:135583
TITLE: Non-lethal temporary incapacitation formulation and novel solvent system
INVENTOR(S): Loghman-Adham, Kamran
PATENT ASSIGNEE(S): Zarc International, Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062641	A1	20040729	WO 2003-US611	20030110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2003-US611 20030110
AB A nonlethal temporarily **incapacitating** formulation having a new solvent system that has reduced blow back longer hang time when used as an **aerosol spray.** The solvent and formulation are nontoxic, nonhazardous, nonflammable, highly stable, environmentally safe and able to withstand extreme operating temps. The solvent system is a mixture of propylene **glycerol** dicaprylate/caprate and

glycerol tris (2-**ethylhexanoate**) and is suitable for use for a wide range of automotive, household and industrial applications.

L39 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:532117 HCAPLUS
DOCUMENT NUMBER: 139:80652
TITLE: Non-lethal temporary incapacitation formulation and novel solvent system
INVENTOR(S): Loghman-Adham, Kamran
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003129138	A1	20030710	US 2002-36546	20020107

PRIORITY APPLN. INFO.: US 2002-36546 20020107

AB A nonlethal temporarily **incapacitating** formulation having a new solvent system that has reduced blow back longer hang time when used as an **aerosol spray.** The solvent and formulation are nontoxic, non-hazardous, nonflammable, highly stable, environmentally safe and able to withstand extreme operating temps. The solvent system is a mixture of propylene **glycerol** dicaprylate/caprate and **glycerol** tris(2-**ethylhexanoate**) and is suitable for use for a wide range of automotive, household and industrial applications.

L39 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:325921 HCAPLUS
DOCUMENT NUMBER: 136:320585
TITLE: Inflammatory responses and mucus secretion in rats with acute bronchiolitis induced by nickel chloride
AUTHOR(S): Ishihara, Yoko; Kyono, Hiroko; Serita, Fumio; Toya, Tadao; Kawashima, Hiroto; Miyasaka, Masayuki
CORPORATE SOURCE: Department of Hygiene and Public Health (I), School of Medicine, Tokyo Women's Medical University, Tokyo, 162-8666, Japan
SOURCE: Inhalation Toxicology (2002), 14(4), 417-430
CODEN: INHTE5; ISSN: 0895-8378
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of inhaled particulate matter in the workplace and outdoor environment on sensitive subpopulations are not sufficiently investigated in human and animal models. Thus, animal models for pulmonary diseases are necessary for appropriate risk assessment of toxic materials. The authors studied biochem. characteristics of an acute **inflammatory** process induced by inhalation of nickel chloride **aerosols** in rats. Acute bronchiolitis was induced by inhalation of nickel chloride **aerosols** for 5 days in Wistar rats according to the method described by **Kyono** et al. (1999). Deterioration and recovery from **inflammatory** responses were evaluated by analyzing markers of **inflammation** in bronchoalveolar lavage (BAL) fluid. Exptl. animals were sacrificed during and after the nickel **aerosol** exposure period. The number of neutrophils markedly increased to .apprx.0.5 + 103 cells/μL BAL fluid during nickel **aerosol** exposure, accompanied by increase of total protein, soluble L-selectin,

cytokine-induced neutrophil chemoattractant/growth-regulated gene products (CINC/GRO), elastolytic activity, trypsin inhibitory capacity, β-glucuronidase activity, fucose, and sialic acid in BAL fluid compared with those of the control group. There was correlation between the number of leukocytes and soluble L-selectin concentration The number of pulmonary macrophages in BAL fluid decreased to .apprx.15% of those of the control group on the days of nickel **aerosol** exposure. The level of CINC/GRO recovered to that of the control group on day 3 after cessation of the nickel **aerosol** exposure. However, other **inflammatory** markers remained at the elevated levels. Changes in the markers of **inflammation** during and after the nickel **aerosol** exposure were consistent with previously reported morphol. findings. The results indicated that this animal model is potentially useful as an acute bronchiolitis model.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:177237 HCAPLUS
DOCUMENT NUMBER: 126:196164
TITLE: Chemical and elemental comparison of two formulations of oleoresin capsicum
AUTHOR(S): Haas, Js; Whipple, Re; Grant, Pm; Andresen, Bd; Volpe, Am; Pelkey, Ge
CORPORATE SOURCE: Forensic Science Center, Lawrence Livermore National Laboratory, Livermore, CA, 94550, USA
SOURCE: Science & Justice (1997), 37(1), 15-24
CODEN: SJUSFE; ISSN: 1355-0306
PUBLISHER: Forensic Science Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In-custody deaths following the application of pepper spray weaponry by law enforcement personnel have increased in California over the last few years. Oleoresin capsicum (OC), an oily extract of hot peppers, is the active ingredient in the spray, but little detailed information on product mixts. is available. Since OC exts. contain a multitude of natural compds. at irregular concns., there could be considerable variation in overall chemical composition among the different formulations of both "natural" and "synthetic" OC prepns. This was confirmed by organic and inorg. analyses performed on OC sprays produced by two manufacturers licensed for distribution within the state of California. The results indicated that the differences could lead to considerable inconsistency in weapon effectiveness, and suggested that more comprehensive studies are warranted.

IT **111-01-3**, 2,6,10,15,19,23-Hexamethyltetracosane
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**pepper spray** chemical and elemental composition)

RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



L39 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1988:637046 HCAPLUS
DOCUMENT NUMBER: 109:237046
TITLE: Foam-producing analgesic and anti-inflammatory aerosols
INVENTOR(S): Nakagawa, Akira; Saiki, Toshihiko; Miyata, Satoru; Masuda, Kenji; Oguri, Kunio; Mekata, Satoshi; Teramoto, Keiichiro
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan; Osaka Aerosol Industry Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63119420	A2	19880524	JP 1986-266428	19861108
JP 07078019	B4	19950823		
PRIORITY APPLN. INFO.:			JP 1986-266428	19861108

AB Aerosols producing analgesic and anti-inflammatory foams contain inflammation inhibitors 0.3-15.0, surfactants 0.1-5.0, H2O 3.0-20.0, powders 0.1-5.0, and propellants 60.0-90.0% by weight An aerosol was prepared consisting of l-menthol 3.7, dl-camphor 0.3, Me salicylate 1.6, glycol salicylate 0.7, eucalyptus oil 0.4, squalane 0.3, 1,3-butylene glycol 0.5, polyoxyethylene polyoxypropylene cetyl ether 1.0, EtOH 2.0, H2O 8.5, talc 1.0, and freon-114 80% by weight l-Menthol, dl-camphor, Me salicylate, glycol salicylate, eucalyptus oil, squalane, and 1,3-butylene glycol were mixed and heated to 50° to give a uniform solution To this solution were added polyoxyethylene polyoxypropylene cetyl ether, EtOH, water, and talc, and the mixture was emulsified. The whole emulsion was packed in an aerosol container, and Freon-114 was added under pressure to give a foam-producing aerosol.

IT **111-01-3**, Squalane
RL: BIOL (Biological study)
(analgesic and anti-**inflammatory aerosols** containing)
RN 111-01-3 HCAPLUS
CN Tetracosane, 2,6,10,15,19,23-hexamethyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



L39 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:111089 HCAPLUS
DOCUMENT NUMBER: 86:111089
TITLE: Inflammation inhibitor for cosmetic preparations
INVENTOR(S): Moeller, Hinrich; Schnegelberger, Harald; Gloxhuber, Christian; Thimm, Hans J.
PATENT ASSIGNEE(S): Henkel und Cie. G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2526675	A1	19761230	DE 1975-2526675	19750614
NL 7605563	A	19761216	NL 1976-5563	19760524
GB 1549213	A	19790725	GB 1976-24194	19760611
CH 621062	A	19810115	CH 1976-7544	19760614

PRIORITY APPLN. INFO.: DE 1975-2526675 A 19750614

GI



I



II

AB Cyclic acetals and ketals of aromatic aldehydes and ketones were prepared and used as **inflammation** inhibitors in sunscreen and sunburn-preventing compns. For example, 2,2,4-trimethyl-1,3-pentanediol [144-19-4] was treated with 34.8 g formaldehyde [50-00-0] in the presence of p-toluenesulfonic acid to give 128 g 4-isopropyl-5,5-dimethyl-1,3-dioxane (I) [3583-00-4]. Five other compds. were prepared similarly. 2-Methyl-4-propyl-5-ethyl-1,3-dioxane (II) [61920-23-8] was prepared from acetaldehyde [75-07-0], 2-ethyl-1,3-hexanediol [**94-96-2**], and triethyl orthoformate in the presence of the catalyst, and 41 other compds. were prepared similarly. These compds. decreased carrageenin- and dextran-induced rat paw edema and UV-induced edema and erythema in mice and guinea pigs, resp. A sunscreen emulsion was prepared from glycerol monostearate (20), stearic acid (70), oleic acid (30), cetyl alc. (20), 2-ethyl-2,5,5-trimethyl-4-isopropyl-1,3-dioxane [6290-33-1] (40), and Ph salicylate (40 g) in 800 g H2O. The emulsion was packaged as an **aerosol**, with an 80:20 emulsion/propellant ratio.

L39 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:112210 HCAPLUS
DOCUMENT NUMBER: 78:112210
TITLE: Resins containing highly dispersed asbestos
INVENTOR(S): Iida, Akira
PATENT ASSIGNEE(S): Taniguchi, Toru
SOURCE: Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47036008	B4	19720909	JP 1969-4401	19690123

AB PVC [**9002-86-2**], nylon 11 [**25587-80-8**], and ABS [9003-56-9] granules were adsorbed onto asbestos fibers (oOr >20) in an aqueous suspension and dried to give filled resin granules. For example, 12 kg PVC (passing 325 mesh sieve) was gradually added to a suspension of 3 kg chrysotile [12001-29-5] (oOr 45) in 75 l. water under stirring and **spray**-dried in vacuo to give 14.3 kg PVC granules containing 20% asbestos fiber.

L39 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:31588 HCAPLUS
DOCUMENT NUMBER: 78:31588
TITLE: Forming corrosion-preventing coatings on metallic surfaces
INVENTOR(S): Scheiber, Werner; Aalrust, Per
PATENT ASSIGNEE(S): Metallgesellschaft A.-G.
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2117218	A	19721019	DE 1971-2117218	19710408

PRIORITY APPLN. INFO.: DE 1971-2117218 19710408

AB Phosphated steel sheets (usually coated with a phenolic primer) are electrostatically coated with a powder containing an epoxy, a blowing agent, and polyethylene [9002-88-4], nylon 11 [**25035-04-5**], or PVC [**9002-86-2**] and heated to prepare a foamed coating which protects against corrosion, absorbs sound, and has good resistance to aging, wear, and temperature extremes. A protective coating on aluminum [7429-90-5] primed with poly(vinyl butyral) is prepared similarly with a powdered epoxy containing a blowing agent. The coated metals are especially useful as automobile parts. Thus, phosphated steel is electrostatically coated with powdered polyethylene (d. 0.915) containing an azodicarbonamide-ZnO mixture 8, an epoxy 10, and phthalanyl peroxide 2% and heated at 210.deg. for 7 min to give a 3.4 mm coating of nonporous foam which provides >1000 hr of corrosion protection in a salt **spray** test.

=> => => d stat que l41
L1 21941 SEA FILE=REGISTRY ABB=ON PLU=ON PROPYLENE(L)GLYCOL OR CAPRYL OR CAPAX OR KENKEL OR EDENOL OR HODAG OR INOLEX OR LEXOL OR LIPO OR LIPON? OR MIGL? OR STEPAN OR NEOBEE OR TRIVENT OR UNITOL? OR UPI
L2 2232 SEA FILE=REGISTRY ABB=ON PLU=ON GLYCEROL(L)ETHYLHEXAN? OR TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
L3 484872 SEA FILE=HCAPLUS ABB=ON PLU=ON L1 OR PROPYLENE(2A)GLYCOL OR ?CAPRYL? OR CAPAX OR KENKEL OR EDENOL OR HODAG OR INOLEX OR LEXOL OR LIPO OR LIPON? OR MIGL? OR STEPAN OR NEOBEE OR TRIVENT OR UNITOL? OR UPI
L5 215163 SEA FILE=HCAPLUS ABB=ON PLU=ON AEROSOLS/CV OR AEROSOL? OR MIST OR SPRAY
L6 4600 SEA FILE=REGISTRY ABB=ON PLU=ON NONENAMIDE OR OCTAMIDE OR DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR CAPSANTHIN OR UNDECANAMIDE OR PAAIPER
L7 10495 SEA FILE=REGISTRY ABB=ON PLU=ON CAPSAICIN OR DIBENZOXAZEPINE OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR CAPSCIUM OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L8 14988 SEA FILE=HCAPLUS ABB=ON PLU=ON L6 OR NONENAMIDE OR OCTAMIDE OR DECAMIDE OR DECENAMIDE OR HOMOCAPSAICIN OR CAROTEN OR CAPSANTHIN OR UNDECANAMIDE OR PAAIPER
L9 13 SEA FILE=HCAPLUS ABB=ON PLU=ON PAAI?
L10 68025 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 OR CAPSAICIN OR DIBENZOXAZE

```
                PINE OR CHLOROACETOPHENONE OR CHLOROBENZALMALONONITRILE OR
                CAPSCIUM OR OLEORESIN OR PAPRIKA OR CAPSICUM OR PEPPER
L11       318578 SEA FILE=HCAPLUS ABB=ON  PLU=ON  INCAPACIT? OR INFLAM? OR L8
                OR L9 OR L10
L33      1172689 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L2 OR GLYCEROL(L)ETHYLHEXAN?
                OR TRIOCTANOIN OR ETHYLHEXAN? OR GLYCERIN(L)ESTER OR KYO? OR
                HEXALAN OR NIKKO OR NISSHIN OR NOMCORT OR TRIVENT
L34          138 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3 AND L33 AND L5 AND L11
L35           58 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L34 AND PD=<FEBRUARY 24, 2002

L37           39 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L)L33(L)L11
L38           39 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L37 NOT L35
L39            8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L33(L)L11(L)L5
L40           40 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3(L)L5(L)L11
L41           36 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L40 NOT (L38 OR L39)


=> d ibib abs hitstr l41 1-36

L41  ANSWER 1 OF 36  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:823128  HCAPLUS
DOCUMENT NUMBER:          143:216673
TITLE:                    Formulations and methods for treating rhinosinusitis
                          comprising a steroidal anti-inflammatory agent
INVENTOR(S):              Chaudry, Imtiaz
PATENT ASSIGNEE(S):       Dey, L.P., USA
SOURCE:                   U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.
                          Ser. No. 657,550.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2005180925         A1    20050818    US 2005-78263            20050312
     US 2004208830         A1    20041021    US 2003-414682           20030416
     US 2004208831         A1    20041021    US 2003-414756           20030416
     US 2004209852         A1    20041021    US 2003-657550           20030904
     US 2006039871         A1    20060223    US 2005-250256           20051014
     US 2006051299         A1    20060309    US 2005-250220           20051014
     US 2006051300         A1    20060309    US 2005-250925           20051014
PRIORITY APPLN. INFO.:                       US 2003-414682       A2  20030416
                                             US 2003-414756       A2  20030416
                                             US 2003-657550       A2  20030904
                                             WO 2004-EP3314       A1  20040329
                                             WO 2004-EP3315       A1  20040329
                                             WO 2004-EP3316       A1  20040329
```

AB The invention involves methods and formulations for treating or preventing rhinosinusitis, including but not limited to, bacterial-induced, viral-induced and/or fungus-induced rhinosinusitis in mammals, and/or rhinosinusitis not induced by an infective agent, such as bacteria, fungus or virus. In one embodiment, the formulation of the present invention comprises an anti-inflammatory agent (e.g. fluticasone propionate) having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent. Thus, a prophetic example for treating symptoms associated with rhinosinusitis contained amphotericin B about 2.0 to 100.0 mg/mL, neomycin sulfate about 5.0 to 100.0 mg/mL, fluticasone propionate about 0.25 to 1.0 mg/mL,

Polysorbate 80 about 0.1 to 1.0 mg/mL, and water to 100%.
IT **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nasal **spray** formulations containing steroidal anti-**inflammatory** agent for treating rhinosinusitis)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L41 ANSWER 2 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:706415 HCAPLUS
DOCUMENT NUMBER: 137:386715
TITLE: A liquid charge affecting non-lethally people and animals for aerosol self-defense means
INVENTOR(S): Lyapishev, V. M.; Samoryadov, A. V.; Tuzhikova, M. V.
PATENT ASSIGNEE(S): Tsentral'nyi Nauchno-Issledovatel'skii Institut Tochnogo Mashinostroeniya, Russia; Gosudarstvennoe Unitarnoe Predpriyatie Nauchno-Proizvodstvennyi Tsentr "TsNIITOChMASh-1"
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2179963	C1	20020227	RU 2000-114019	20000605

PRIORITY APPLN. INFO.: RU 2000-114019 20000605
AB A liquid for an aerosol container used as self-defense means contains natural extract of red pepper (oleoresin capsicum), a nondrying or semidrying liquid natural vegetable oil and monoat. aliphatic alc. or its mixture with a diat. aliphatic alc. The charge is an efficient lacrimator.
IT **57-55-6**, **Propylene glycol**, uses
RL: TEM (Technical or engineered material use); USES (Uses)
(in **pepper spray** lacrimator)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



L41 ANSWER 3 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:654368 HCAPLUS
DOCUMENT NUMBER: 137:174980
TITLE: Anti-inflammatory aerosols
INVENTOR(S): Matsumura, Toshiro
PATENT ASSIGNEE(S): Toyo Aerosol Industry Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002241309	A2	20020828	JP 2001-43583	20010220

PRIORITY APPLN. INFO.: JP 2001-43583 20010220

AB The title **aerosols** comprise (1) a stock solution containing anti-**inflammatory** agents 0.1-5 %, alcs. 10-90 %, and water balance to 100 % and (2) propellants containing ≥ 10 % di-Me ether to enhance the solubility of the anti-**inflammatories.** For example, a stock solution was formulated containing indomethacin 1, isopropanol 5, **propylene glycol** 40, l-menthol 3, POE POP cetyl ether 1, ethoxylated hydrogenated castor oil 1, propylene carbonate 5, hexyl laurate 5, and distilled water 39 %. A propellant contained LPG 30 % and di-Me ether 70 %. The **aerosol** contained the above stock solution and propellant at the ratio of 90 to 10. The **aerosol** was stable for more than 12 mo.

IT **57-55-6, Propylene glycol**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-**inflammatory aerosols**)

RN 57-55-6 HCAPLUS

CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



L41 ANSWER 4 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:923625 HCAPLUS

DOCUMENT NUMBER: 136:58810

TITLE: Pharmaceutical anti-inflammatory aerosol formulation containing a hydrofluoroalkane propellant

INVENTOR(S): Armour, Duncan Robert; Brown, David; Congreve, Miles Stuart; Gore, Paul Martin; Green, Darren Victor Steven; Holman, Stuart; Jack, Torquil Iain MacLean; Mason, Andrew McMurtrie; Morriss, Karen; Ramsden, Nigel Grahame; Thomas, Marian; Ward, Peter

PATENT ASSIGNEE(S): Glaxo Group Limited, UK; et al.

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095925	A1	20011220	WO 2001-GB2613	20010615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289539 A1 20030312 EP 2001-938435 20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004503505 T2 20040205 JP 2002-510103 20010615
PRIORITY APPLN. INFO.: GB 2000-14881 A 20000616
WO 2001-GB2613 W 20010615

AB The present invention relates to a pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant having dissolved therein particulate (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid (I) or a salt or solvate thereof. Methods and uses of the formulation in the treatment of respiratory disorders are also described, as are canisters and metered dose inhalers containing said formulation. For example, I was prepared, formulated as aerosol containing 1% I, 10% ethanol, and 1,1,1,2-tetrafluoroethane up to 100% (by weight), and the formulation was filled into an aluminum canister, to obtain a metered dose inhaler with about 120 actuations.

IT **57-55-6**, **Propylene glycol**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and **aerosol** formulation of anti-**inflammatory** leucyl-tyrosine derivative for treatment of respiratory disorders)

RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:923588 HCAPLUS
DOCUMENT NUMBER: 136:42861
TITLE: Pharmaceutical anti-inflammatory aerosol formulation containing piperidinylcarbonyloxy propanoic acid derivative
INVENTOR(S): Armour, Duncan Robert; Brown, David; Congreve, Miles Stuart; Gore, Paul Martin; Green, Darren Victor Steven; Holman, Stuart; Jack, Torquil Iain MacLean; Keeling, Steven Philip; Mason, Andrew McMurtrie; Morriss, Karen; Ramsden, Nigel Grahame; Thomas, Marian; Ward, Peter
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095881	A1	20011220	WO 2001-GB2634	20010615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289499	A1	20030312	EP 2001-938449		20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004503488	T2	20040205	JP 2002-510060		20010615
US 2004039021	A1	20040226	US 2003-311556		20030821
PRIORITY APPLN. INFO.:			GB 2000-14849	A	20000616
			WO 2001-GB2634	W	20010615

AB The present invention relates to a pharmaceutical aerosol formulation comprising a hydrofluoroalkane (HFA) propellant having suspended therein particulate (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino] propanoic acid (I) or a salt or solvate. Methods and uses of the formulation in the treatment of respiratory disorders are also described, as are canisters and metered-dose inhalers containing the formulation. Thus, I was prepared and filled into an aluminum canister containing I 1 and 1,1,2,2-tetrfluoroethane to 100%.

IT **110-27-0**, Isopropyl myristate **9002-92-0**, Polyethylene glycol lauryl ether **9004-98-2**, Polyethylene glycol oleyl ether **9005-65-6**, Polyethylene glycol Sorbitan monooleate **31566-31-1**, Glyceryl monostearate **106392-12-5**, Pluronic
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical anti-**inflammatory aerosol** formulation containing piperidinylcarbonyloxy propanoic acid derivative)

RN 110-27-0 HCAPLUS
CN Tetradecanoic acid, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 9002-92-0 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-dodecyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9004-98-2 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α-(9Z)-9-octadecenyl-ω-hydroxy- (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.

(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 31566-31-1 HCAPLUS
CN Octadecanoic acid, monoester with 1,2,3-propanetriol (9CI) (CA INDEX NAME)

CM 1

CRN 57-11-4
CMF C18 H36 O2



CM 2

CRN 56-81-5
CMF C3 H8 O3



RN 106392-12-5 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, block (9CI) (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:873187 HCAPLUS
DOCUMENT NUMBER: 136:11167
TITLE: Anti-inflammatory analgesic aerosols

INVENTOR(S): Sayama, Yoshikatsu; Obata, Kazuo; Kondo, Hiroaki
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan; Mikasa Seiyaku Co., Ltd.; Koike Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001335468	A2	20011204	JP 2000-156834	20000526
PRIORITY APPLN. INFO.:			JP 2000-156834	20000526

AB This invention relates to anti-inflammatory analgesic aerosols which provide cooling and refreshing foams upon spraying. The aerosols comprise nonsteroidal anti-inflammatory analgesics 0.1-10, l-menthol 0.3-5, viscosity enhancers 0.01-1, surfactants 1-10, lower alcs. 30-70, and water 10-60 %; and liquefied petroleum gas propellants. An aerosol solution contained ketoprofen 2, l-menthol 2, Na polyacrylate 0.05, polyoxyethylene polyoxypropylene cetyl ether 5, ethanol 40, methylparaben 0.1, and distilled water 50.85 %. A spray preparation comprised the above solution and isobutane at the weight ratio of 40 to 60.

IT **9087-53-0**, Polyoxyethylene polyoxypropylene cetyl ether
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-**inflammatory** analgesic **aerosols** with improved adhesion)

RN 9087-53-0 HCAPLUS
CN Oxirane, methyl-, polymer with oxirane, hexadecyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 36653-82-4
CMF C16 H34 O



CM 2

CRN 9003-11-6
CMF (C3 H6 O . C2 H4 O)x
CCI PMS

CM 3

CRN 75-56-9
CMF C3 H6 O



CM 4

CRN 75-21-8
CMF C2 H4 O

L41 ANSWER 7 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:741543 HCAPLUS
DOCUMENT NUMBER: 135:293962
TITLE: Pharmaceutical composition and method for control and treatment of cutaneous inflammation
INVENTOR(S): Dobbs, Michael R.; McArthur, T. Reid
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 5 pp., Cont. of U.S. Ser. No. 876,893, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6300326	B1	20011009	US 2000-631165	20000803
PRIORITY APPLN. INFO.:			US 1994-333831 B1	19941102
			US 1997-876893 B1	19970616

AB A composition for treating cutaneous **inflammation** by topical application comprises a range of percentages of anti-infective solvent, water, an emollient agent, and anti-**inflammatory**/anti-pruritic agents. The composition is sufficiently viscous to be applied as a **spray.** There is also disclosed a method of treating the dermal areas of mammals using the composition as a topical medication. Thus, approx. 171 g of triamcinolone acetonide, 113.6 kg denatured alc., 227.1 kg **propylene glycol**, 5.68 kg dimethyldimethyl hydantoin, and 788.95 kg purified water was used to prepare a topical pharmaceutical. Antipruritic and anti-**inflammatory** activity of the composition in dogs was studied.
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 8 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:369691 HCAPLUS
DOCUMENT NUMBER: 134:357597
TITLE: Anti-inflammatory aerosol compositions
INVENTOR(S): Matsumura, Toshiro; Suzuki, Mie; Ogata, Ken
PATENT ASSIGNEE(S): Toyo Aerosol Industry Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 2001139492 A2 20010522 JP 1999-321457 19991111
PRIORITY APPLN. INFO.: JP 1999-321457 19991111
AB This invention relates to an **aerosol** comprising (1) an undild. solution containing nonsteroidal anti-**inflammatories** 0.5-2.5 % and monohydric lower alcs. 30-85 % and (2) propellants. The **aerosol** composition is filled in a container which has an actuator. An anti-**inflammatory** solution was formulated ketoprofen 0.3, ethanol 30, **propylene glycol** 1, cetanol 0.5, palmitic acid 0.3, iso-Pr myristate 0.1, dimethylpolysiloxane 0.1, ethoxylated hydrogenated castor oil 0.2, xanthan gum 0.1, citric acid 0.1, and water q.s. to 100 %. An **aerosol** contained the above solution 50 and liquefied petroleum gas 50 %.

L41 ANSWER 9 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:592577 HCAPLUS
DOCUMENT NUMBER: 133:172191
TITLE: Aerosol compositions of HMG-CoA reductase inhibitors for inhibiting inflammation associated with pulmonary disease
INVENTOR(S): Harlan, John M.; Winn, Robert K.; Liu, Li
PATENT ASSIGNEE(S): University of Washington, USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048626	A2	20000824	WO 2000-US4124	20000217
WO 2000048626	A3	20001207		
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001006656	A1	20010705	US 1999-251707	19990217
PRIORITY APPLN. INFO.:			US 1999-251707	A2 19990217

AB The present invention provides an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitor. The HMG-CoA reductase inhibitor can be, for example, a statin such as lovastatin, pravastatin, simvastatin, cerivastatin, fluvastatin, atorvastatin or mevastatin. The invention also provides a method of treating a pulmonary disease with an aerosol formulation of a HMG-CoA reductase inhibitor. An example is given showing inhibition of cell adhesion by lovastatin.
IT **79902-63-9**, Simvastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**aerosol** compns. of HMG-CoA reductase inhibitors for inhibiting **inflammation** associated with pulmonary disease)
RN 79902-63-9 HCAPLUS
CN Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-

naphthalenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 10 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:104531 HCAPLUS
DOCUMENT NUMBER: 130:144216
TITLE: Non-irritating capsaicin formulations and applicators therefor
INVENTOR(S): Holt, Stephen D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 635,149.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869533	A	19990209	US 1998-106834	19980630
US 5854291	A	19981229	US 1996-635149	19960423
PRIORITY APPLN. INFO.:			US 1996-635149 A2	19960423

AB A delivery system for applying a formula containing **capsaicin** together with another ingredient to neutralize the discomfort resulting from the application of **capsaicin** to the skin which involves the topical application of **capsaicin** by use of patches, use of second skin, use of **sprays** and includes a unique method for applying the formulation using laser on the epidermis. A composition contained deionized water 81.00, **propylene glycol** 5.00, glycerin 3.00, polyethylene glycol 1.00, butylene glycol 1.00, triethanolamine 0.60, inositol 0.20, Me paraben 0.10, Pr paraben 0.10, carbomer 940 0.30, DL-panthenol 1.00, nettle extract 0.50, yarrow extract 0.50, horsetail extract 0.50, birch extract 0.50, rosemary extract 0.50, horsetail extract 0.50, ginger extract 0.50, chamomile extract 0.50, birch extract 0.50, lavender extract 0.50, bergamot extract 0.50, **capsaicin** 0.025, coltsfoot extract 0.50, and comfrey extract 0.50%.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 11 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:221018 HCAPLUS

DOCUMENT NUMBER: 128:286372
TITLE: Topical medicament containing diclofenac
INVENTOR(S): Mueller, Gerhard
PATENT ASSIGNEE(S): Kade Pharmazeutische Fabrik G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 834312	A1	19980408	EP 1997-117282	19971006
EP 834312	B1	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19641259	A1	19980416	DE 1996-19641259	19961007
AT 230594	E	20030115	AT 1997-117282	19971006
PT 834312	T	20030430	PT 1997-117282	19971006
ES 2189910	T3	20030716	ES 1997-117282	19971006

PRIORITY APPLN. INFO.: DE 1996-19641259 A 19961007

AB A topical anti-**inflammatory** and analgesic composition contains diclofenac or a salt thereof, an aqueous solvent, and ≥1 phospholipid as solubilizer. The composition is stable and well tolerated, and allows rapid penetration of diclofenac through the skin. Thus, a **spray** contained diclofenac Na 50.0, DL-α-tocopherol 0.3, phenoxyethanol 1.0, lecithin 30.0, **propylene glycol** 80.0, NaH2PO4 buffer (pH 6.3) 100.0, diethylene glycol monoethyl ether 300.0, and water 438.7 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 12 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:146650 HCAPLUS
DOCUMENT NUMBER: 128:196691
TITLE: Analgesic lotion for hemorrhoids and method of making such lotion
INVENTOR(S): Ivy, Jeffery Wade; Payne, Curtis Emery; Burda, Christopher Dominic
PATENT ASSIGNEE(S): Au Pharmaceuticals, Inc., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5720962	A	19980224	US 1995-539063	19951004
WO 9834628	A1	19980813	WO 1997-GB338	19970205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

AU 9716122 A1 19980826 AU 1997-16122 19970205
PRIORITY APPLN. INFO.: US 1995-539063 A 19951004
WO 1997-GB338 A 19970205

AB This invention relates to an externally applied lotion that causes irritation or mild **inflammation** of the skin or mucous membranes for the purpose of relieving pain in hemorrhoids and the method of making such lotion. The formulation of the present invention contains ingredients to perform the five functions of vasoconstrictor, astringent, analgesic, antipruritic, and anesthetic. An alternate embodiment of the invention provides a formulation of the invention having a suitable viscosity to enable the lotion to be applied by a **spray** applicator directly to the site of application. A lotion comprises 9.0000-11.0000 parts hamamelis water; 0.0045-0.0055 parts epinephrine·HCl; 0.0900-0.1100 parts menthol crystals; 4.0653-4.9687 parts aloe powder; 64.2907-78.5775 parts purified water; 0.3499-0.4277 parts carbomer; 4.0000-4.8888 parts **propylene glycol**; 0.1000-0.1222 parts methylparaben; 0.1000-0.1222 parts propylparaben; 0.1000-0.1222 parts tetrasodium EDTA; 0.7000-0.8555 parts DEA cetyl phosphate; 1.0000-1.2222 parts stearic acid; 0.2500-0.3055 parts glyceryl stearate; 0.2500-0.3055 parts PEG 100 stearate; 5.0000-6.1111 parts C12-15-alkyl benzoate; 0.1000-0.1222 parts jojoba oil; 0.2000-0.2444 parts ginseng; 0.2000-0.2444 parts imidazolidinyl urea; and 0.2000-0.2444 parts triethanolamine.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 13 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:516322 HCAPLUS
DOCUMENT NUMBER: 127:126673
TITLE: Hydrocortisone spray for topical administration
INVENTOR(S): Weder, Hans Georg; Weder, Marc Antoine
PATENT ASSIGNEE(S): Vesifact Ag, Switz.; Weder, Hans Georg; Weder, Marc Antoine
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721428	A1	19970619	WO 1996-CH434	19961209
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2238263	AA	19970619	CA 1996-2238263	19961209
AU 9676899	A1	19970703	AU 1996-76899	19961209
EP 866689	A1	19980930	EP 1996-939798	19961209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: CH 1995-3499 A 19951212
WO 1996-CH434 W 19961209

AB A homogeneous nanodispersion of hydrocortisone in a lipophilic base comprising a partial ester of polyoxyethylenesorbitan with a fatty acid, a phospholipid, and a neutral oil is provided for dermal application as a **spray** for treatment of **inflammatory** diseases of the skin. A suitable dispersion contained Lipoid S100 0.063, EtOH 0.625, polysorbate 20 1.750, polysorbate 80 1.000, polysorbate 60 0.175, hydrocortisone base micro BP88 0.105, **Miglyol** 812 0.750, phenoxyethanol 0.602, and water 94.930 weight%.

L41 ANSWER 14 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:237922 HCAPLUS
DOCUMENT NUMBER: 124:281824
TITLE: Lachrymator aerosol formulations containing capsicum oleoresins
INVENTOR(S): Abbott, Joe L.; Andrade, Michael S.
PATENT ASSIGNEE(S): Enviro Pac International, USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5500205	A	19960319	US 1994-200449	19940223

PRIORITY APPLN. INFO.: US 1994-200449 19940223

AB Aerosol lachrymator formulations are provided having all natural pepper exts. as the active ingredient. The lachrymator formulations are useful in self-defense devices. The formulations are non-toxic and have a broader spectrum of activity than man-made lachrymators. These aerosol formulations rely on a carbon dioxide propellant, which is generated in situ. An aerosol comprises 3 component mixture; (1) component A containing oleoresin capsicum 1.2g (1.5 million Heat Units), Tween 80 2.4, benzyl alc. 0.96, isopropanol 17.976, and citric acid 1.675g, (2) component B containing NaHCO3 2.065 and water 17.736g, and (3) component C containing water 2.08 and isopropanol 2.08g.

IT **9005-65-6**, Polyoxyethylene sorbitan monooleate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lachrymator **aerosol** formulations containing **capsicum oleoresins**)

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L41 ANSWER 15 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:981865 HCAPLUS
DOCUMENT NUMBER: 124:45341
TITLE: Protective effect of furosemide combined with non-steroidal anti-inflammatory drugs administered by inhalation route on guinea pigs anaphylaxis model
AUTHOR(S): Berti, F.; Rossoni, G.; Robuschi, M.; Mandelli, V.
CORPORATE SOURCE: Department of Pharmacology, University of Milan, Milan, Italy
SOURCE: Arzneimittel-Forschung (1995), 45(10), 1098-102
CODEN: ARZNAD; ISSN: 0004-4172
PUBLISHER: Cantor
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The exposure of ovalbumin sensitized guinea pig to an **aerosol** of the specific antigen causes a respiratory crisis in approx. 100 s (dyspnea time) associated with a substantial increase in blood concentration of both histamine (from 27.5 ± 1.8 ng/mL to 1570 ± 26 ng/mL, n = 8) and thromboxane B2 (TXB2, from 0.52 ± 0.03 ng/mL to 18.1 ± 0.6 ng/mL; n = 8). The **aerosol** treatment of the animals (20 min) with

furosemide (CAS **54-31-9**, frusemide, FRU), nimesulide (CAS 51803-78-2, NIM), acetylsalicylic acid (CAS 50-78-2, ASA) and indomethacin (CAS 53-86-1, INDO) at the concns. of 1, 3, 10 and 30 mg/mL before ovalbumin challenge, brought about an attenuation of anaphylactic response. The rank order of potency for the prolongation of dyspnea time was FRU > NIM > ASA > INDO. In these expts. blood evaluation performed at the peak of the dyspnea time for histamine concentration in the treated animals indicated that whereas FRU (ED25 = 2.14 mg/mL (1.97-2.38)) and NIM (ED25 = 2.74 mg/mL (2.37-3.19)) were equiactive in reducing the release of histamine, ASA and INDO were devoid of this activity. On the contrary, the results obtained with ASA and INDO indicated a greater intrinsic activity in antagonizing TXB2 formation than that shown by the log-dose response curves of NIM and FRU. In another series of expts. the interaction of FRU with the other anti-**inflammatory** drugs in protecting guinea pig from immune bronchoconstriction has been evaluated using the combination two equiactive doses. The mixts. considered were FRU + NIM, FRU + INDO and FRU + ASA. The results obtained indicated that FRU interacts pos. with the three non-steroidal anti-**inflammatory** drugs in delaying the onset of the dyspneic crisis in guinea pig. However, when FRU was combined with NIM the gain obtained (209%) appeared superior to that reached when FRU was combined with ASA (180%) or INDO (126%).

L41 ANSWER 16 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:687000 HCAPLUS
DOCUMENT NUMBER: 123:77153
TITLE: Carboxamides as crystallization inhibitors for azole fungicide sprays.
INVENTOR(S): Wirth, Wolfgang; Wangermann, Klaus; Botta, Artur; Rosenfeld, Frank
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 33 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 4341986	A1	19950614	DE 1993-4341986		19931209
WO 9515685	A1	19950615	WO 1994-EP3926		19941128
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, NO, NZ, PL, RO, RU, SK, UA, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9510678	A1	19950627	AU 1995-10678		19941128
PRIORITY APPLN. INFO.:			DE 1993-4341986	A	19931209
			WO 1994-EP3926	W	19941128

OTHER SOURCE(S): CASREACT 123:77153; MARPAT 123:77153
AB The title carboxamides, prepared by known methods, are RCONR1R2 [R = H, (cyclo)alkyl, (cyclo)alkenyl, aryl, XCONR3R4, etc.; R1, R2 = H, (cyclo)alkyl, hydroxyalkyl, Ph, benzyl, etc.; X = alkylene, alkenylene; R3R4 = H, (cyclo)alkyl, alkenyl, Ph, benzyl, phenethyl; R1R2 and R3R4 = CH2CH2OCH2CH2, CH2CH2NR5CH2CH2; R5 = Me, Et]. Thus, ω-undecenic acid pyrrolidide stabilized a 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol spray.
IT **996-97-4P**
RL: MOA (Modifier or additive use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(preparation as crystallization inhibitor for azole fungicide **sprays**)
RN 996-97-4 HCAPLUS
CN Octanamide, N,N-diethyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L41 ANSWER 17 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:307265 HCAPLUS
DOCUMENT NUMBER: 120:307265
TITLE: Application of lipid microspheres to prepare a thromboxane A2 receptor antagonist aerosol for inhalation
AUTHOR(S): Takenaga, M.; Nakagawa, T.; Igarashi, R.; Mizushima, Y.
CORPORATE SOURCE: Sch. Med., St. Marianna Univ., Kawasaki, 216, Japan
SOURCE: Journal of Drug Targeting (1993), 1(4), 293-301
CODEN: JDTAEH; ISSN: 1061-186X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The Me ester of a new thromboxane A2 receptor antagonist, (+)S-145, i.e. (1R,2S,3S,4S)-(5Z)-7-(3-phenylsulfonyl-aminobicyclo[2,2,1]hept-2-yl)heptenoic acid, was incorporated into lipid microspheres (**lipo** S-145-Me) and its pharmacol. effect and tissue distribution were examined in guinea pigs following **aerosol** delivery. Bronchoconstrictive responses induced by i.v. injection of U46619 or the inhalation of ovalbumin were suppressed in a dose-dependent manner by **aerosol** inhalation of **lipo** S-145-Me, which was 3-10 times more potent that the unencapsulated calcium dihydrate of the original drug (S-1452). There was no significant difference in the airway tissue distribution of labeled **lipo** S-145-Me vs. S-1452 after 2 or 5 min of inhalation, but the encapsulated drug showed marked accumulation in the lungs after 30 min of inhalation. The in vitro uptake of **lipo** [14C] S-145-Me by fresh human neutrophils and an eosinophil cell line was resp. 7 times and 3.5 times higher than that of [14C] S-1452. These results suggest that **lipo** S-145-Me has the potential to be used as an inhalational antiasthma agent, and that its effect may be partly attributable to a for **inflammatory** cells which are responsible for allergic airway **inflammation.**

L41 ANSWER 18 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:173102 HCAPLUS
DOCUMENT NUMBER: 120:173102
TITLE: Aerosol compositions containing inflammable gases, lower alcohols, hydroxypropyl cellulose, and cell-activating compounds
INVENTOR(S): Nishida, Juichi; Ootsuka, Naomi
PATENT ASSIGNEE(S): Lion Corp, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 05262621	A2	19931012	JP 1992-65813	19920324

PRIORITY APPLN. INFO.: JP 1992-65813 19920324

AB Aerosol compns. contain inflammable gases and lower alc. solns. containing 0.01-30% by weight hydroxypropyl cellulose (I) and cell-activating compds. (which may have hair-restorative activity). The compns. show low combustibility, high safety, and improvement of effectiveness of cell-activating compds. Thus, an aerosol was prepared by mixing liquefied petroleum gas and a solution (prepared from pentadecanoic acid 3, tocopheryl acetate 0.2, Swertia herb extract 0.01, pantothenyl Et ether 0.5, I 10.0, sorbitan monolaurate 3.0, and EtOH to 100% by weight) at the weight ratio of gas/solution = 10/90.

IT **21482-12-2**
RL: BIOL (Biological study)
(**aerosol** compns. containing **inflammable** gases and lower alcs. and hydroxypropyl cellulose and, with high safety)

RN 21482-12-2 HCAPLUS

CN 3,6,9,12-Tetraoxapentadecane-1,14-diol, 2,5,8,11-tetramethyl- (9CI) (CA INDEX NAME)



L41 ANSWER 19 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:86479 HCAPLUS

DOCUMENT NUMBER: 120:86479

TITLE: Aerosol-type nonsteroidal anti-inflammatory compositions

INVENTOR(S): Oowada, Ryoichi

PATENT ASSIGNEE(S): Osaka Eyazoole Kogyo Kk, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05279250	A2	19931026	JP 1992-79516	19920401
JP 3302995	B2	20020715		

PRIORITY APPLN. INFO.: JP 1992-79516 19920401

AB The title compns., which form foams or gels, contain ≥70 weight% (based on total liquid weight) polyalcs. and nonsteroidal anti-**inflammatory** agents. The compns. are less irritating than conventional **mist**-forming **aerosols**. **Propylene glycol** 94, bufexamac 1, cetyl alc. 5 weight%, and propellants were mixed to give foam-forming **aerosol**, which was applied to the nasal membrane without irritation.

IT **57-55-6**, **Propylene glycol**, biological studies
RL: BIOL (Biological study)
(nonsteroidal anti-**inflammatory aerosols** containing,

foam- or gel-forming, with no irritation)
RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (8CI, 9CI) (CA INDEX NAME)



L41 ANSWER 20 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:578274 HCAPLUS
DOCUMENT NUMBER: 113:178274
TITLE: Aerosol compositions for pharmaceuticals and cosmetics
INVENTOR(S): Akita, Shigeki; Oguri, Kunio
PATENT ASSIGNEE(S): Osaka Aerosol Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02032190	A2	19900201	JP 1988-181754	19880722
JP 2729244	B2	19980318		

PRIORITY APPLN. INFO.: JP 1988-181754 19880722
AB An **aerosol** useful in pharmaceutical and cosmetic prepns. contain water 30-60, EtOH and/or isoPrOH 20-60, Me2O 11-40, a physiol. active agent 0.1-12, and an inhibitor of volatility with high ignition temperature 0.1-10% by weight The discharge amount from the **aerosol** is 0.1-0.5 g/s at 25°. The **spray** is not flammable and not wasted by scattering. An anti-**inflammatory**, analgesic **aerosol** composition was prepared consisting of camphor 3.0, methanol 3.0, Me salicylate 2.5, glycol salicylate 1.5, **propylene glycol** 5.0 g, a 99% undenatured alc. 20.0, isoPrOH 5.0, water 30.0, Me2O 27.0, and liquefied petroleum gas 3.0 mL.

L41 ANSWER 21 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:164952 HCAPLUS
DOCUMENT NUMBER: 112:164952
TITLE: Stable anti-inflammatory analgesic topical pharmaceutical preparations containing salicylate esters
INVENTOR(S): Nakagawa, Akira; Miyata, Satoru; Saiki, Toshihiko; Masuda, Kenji; Sakai, Kenzo
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01294625	A2	19891128	JP 1988-123275	19880519
JP 07103031	B4	19951108		

PRIORITY APPLN. INFO.: JP 1988-123275 19880519

AB Anti-**inflammatory** analgesic topical prepns. contain carboxyvinyl polymers as stabilizers. l-Menthol 2.5, glycol salicylate (I) 1.0, squalane 0.6, **propylene glycol** 0.6, poly(oxyethylene)-poly(oxypropylene) cetyl ether 1.0, talc 1.0, EtOH 2.5, carboxyvinyl polymer 0.02, H2O 8.28, and Freon-114 82.5% by weight were mixed. to give an **aerosol**, which was preserved at 40° for 3 mo to show 95.3% residual I, vs. 83.9% for the control prepds. without the carboxyvinyl polymer.

L41 ANSWER 22 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:44065 HCAPLUS
DOCUMENT NUMBER: 108:44065
TITLE: Aqueous, nonstinging, antiinflammatory steroid formulations for nasal administration
INVENTOR(S): Benjamin, Eric Joel; Anik, Shabbir Tyabji; Lin, Ya Yun Tracy
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 246652	A2	19871125	EP 1987-107416	19870521
EP 246652	A3	19880203		
EP 246652	B1	19910717		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4782047	A	19881101	US 1986-866171	19860522
DK 8702586	A	19871123	DK 1987-2586	19870521
DK 175238	B1	20040719		
FI 8702231	A	19871123	FI 1987-2231	19870521
FI 88459	B	19930215		
FI 88459	C	19930525		
NO 8702127	A	19871123	NO 1987-2127	19870521
NO 173365	B	19930830		
NO 173365	C	19931208		
AU 8773273	A1	19871126	AU 1987-73273	19870521
AU 609718	B2	19910509		
JP 62283927	A2	19871209	JP 1987-126846	19870521
JP 2521291	B2	19960807		
ZA 8703663	A	19881228	ZA 1987-3663	19870521
AT 65183	E	19910815	AT 1987-107416	19870521
CA 1288048	A1	19910827	CA 1987-537690	19870521
IL 82615	A1	19911121	IL 1987-82615	19870521
ES 2031467	T3	19921216	ES 1987-107416	19870521
US 4983595	A	19910108	US 1988-247008	19880920

PRIORITY APPLN. INFO.:
US 1986-866171 A 19860522
EP 1987-107416 A 19870521

AB Aqueous antiinflammatory steroid formulations, which are useful for treatment of **inflammation** of the nasal mucosa without stinging, contain 0.01-0.05% antiinflammatory steroid, 2-10% **propylene glycol**, 10-25% PEG 400, and 1-4% Polysorbate 20. A nasal **spray** contained flunisolide hemihydrate 0.025, **propylene glycol** 5.0, PEG 400 20.0, Polysorbate 20 2.50, benzalkonium chloride 0.035, Na2EDTA 0.01, BHT 0.01, citric acid 0.005, Na citrate dihydrate 0.00765, sorbitol 2.00, and water to 100%; the pH was adjusted

to 5.2. In a one month intranasal toxicity study in rabbits, no adverse reactions were seen using this formulation.

L41 ANSWER 23 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:419991 HCAPLUS
DOCUMENT NUMBER: 105:19991
TITLE: Ozone-induced change in bronchial reactivity to methacholine and airway inflammation in humans
AUTHOR(S): Seltzer, Janet; Bigby, Barbara G.; Stulbarg, Michael; Holtzman, Michael J.; Nadel, Jay A.; Ueki, Iris F.; Leikauf, George D.; Goetzl, Edward J.; Boushey, Homer A.
CORPORATE SOURCE: Cardiovasc. Res. Inst., Univ. California, San Francisco, CA, 94143, USA
SOURCE: Journal of Applied Physiology (1986), 60(4), 1321-6
CODEN: JAPHEV; ISSN: 8750-7587
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The increase in airway responsiveness induced by O3 exposure in dogs is associated with airway epithelial **inflammation**, as evidenced by an increase in the number of neutrophils (polymorphonuclear leukocytes) found in epithelial biopsies and in bronchoalveolar lavage fluid. Ten healthy, human subjects were investigated as to whether O3-induced hyperresponsiveness was similarly associated with airway **inflammation** by examining changes in the types of cells recovered in bronchoalveolar lavage fluid obtained after exposure to air or to O3 (0.4 or 0.6 ppm). The concns. of cyclooxygenase [39391-18-9] and lipoxygenase [**9029-60-1**] metabolites of arachidonic acid [506-32-1] in lavage fluid was measured. Plus, airway responsiveness to inhaled methacholine [55-92-5] **aerosol** before and after each exposure and performed bronchoalveolar lavage 3 h later was measured. More neutrophils in the lavage fluid from O3-exposed subjects, especially in those in whom O3 exposure produced an increase in airway responsiveness was found. Also significant increases in the concns. of prostaglandins, F2α [551-11-1] and thromboxane B2 [54397-85-2] in lavage fluid from O3-exposed subjects were found. Thus, in human subjects O3-induced hyperresponsiveness to methacholine is associated with an influx of neutrophils into the airways and with changes in the levels of some cyclooxygenase metabolites of arachidonic acid.

L41 ANSWER 24 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:598027 HCAPLUS
DOCUMENT NUMBER: 95:198027
TITLE: Enhancement by prostacyclin of the contractility of the guinea pig airways smooth muscle
AUTHOR(S): Vargaftig, B. Boris; Lefort, Jean
CORPORATE SOURCE: Unite Venins, Inst. Pasteur, Paris, 75015, Fr.
SOURCE: European Journal of Pharmacology (1981), 74(2-3), 141-8
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB **Aerosol** PGI2 (I) [35121-78-9] potentiated the increase in pulmonary resistance to inflation induced by serotonin [50-67-9], PGF2α [551-11-1], acetylcholine [51-84-3], and histamine [51-45-6] in the guinea-pig. This was not due to a reflex, nor to further production of prostaglandin (PG) cyclooxygenase derivs. I and PGF2α induced contraction of the parenchyma lung strip of the guinea-pig, which could be inhibited by polyphloretin phosphate [9014-72-6] and by PGE1 [**745-65-3**]. Since PGF2α failed to potentiate the bronchial responses to acetylcholine, histamine or serotonin, under conditions where I was effective, the in vitro similarities between the 2 PGs cannot explain the in vivo results. The ability of I to potentiate bronchial responses was not shared by the other PGs. Since the latter are either bronchoconstrictor agents by themselves (PGF2α and PGD2), or bronchodilators (PGE1, PGE2), the hypothesis is proposed that I potentiates the responses of the bronchi to various agonists by a mechanism similar to that which accounts for the potentiation of acute **inflammation** and pain by PGE1 and PGE2, the latter being ineffective in enhancing the bronchial responses because of the associated bronchodilator activity.

L41 ANSWER 25 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:548520 HCAPLUS
DOCUMENT NUMBER: 93:148520
TITLE: Flavored table salt
PATENT ASSIGNEE(S): Sato Shokuhin Kogyo K. K., Japan
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 55016624	B4	19800506	JP 1972-88165		19720901
PRIORITY APPLN. INFO.:			JP 1972-88165	A	19720901

AB NaCl containing water-soluble, high-mol.-weight binders is **spray**-dried and adsorbed with organic flavoring materials to yield flavored table salts. The binder improves flow and increases adsorbancy of the salts to the organic flavoring materials. Thus, 990 g NaCl was dissolved in 3 L water; to this was added 15 g guar gum [9000-30-0] and the solution was **spray**-dried. The salt (800 g) was sprayed with 200 g red **pepper** extract (100 g red **pepper** extracted with a mixture containing 150 g EtOH and 150 g **propylene glycol**) and dried to yield 1000 g of free-flowing salt.

L41 ANSWER 26 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:534002 HCAPLUS
DOCUMENT NUMBER: 93:134002
TITLE: Polyamide-based powder coating materials
PATENT ASSIGNEE(S): Polymer Corp., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55065263	A2	19800516	JP 1979-111817	19790903
JP 62059155	B4	19871209		
US 4248977	A	19810203	US 1978-958523	19781107
CA 1121933	A1	19820413	CA 1979-337153	19791005

PRIORITY APPLN. INFO.: US 1978-958523 A 19781107

AB Comps. of polyamides 100, epoxy resins 2-5, and vinyl acetal polymers 1-10 parts are extruded, chilled, and ground to give powder coating materials having good adhesion to substrates. Thus, a composition of Rilsan BMNO (nylon 11) [**25035-04-5**] 100, Epon 1001 (I) [**25068-38-6**] 7, Mowital B30H (II) 3, $CaCO_3$ 20, and TiO_2 8 parts was extruded at 200°, pelletized, chilled, and ground to 60 mesh passing. A degreased steel plate was preheated at 302° and immersed in a fluidized bed of the above powder to form a 0.2-mm coating having salt-water **spray** resistance >1000 h, compared with <24 h for a similar composition without I and II.

L41 ANSWER 27 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:485053 HCAPLUS
DOCUMENT NUMBER: 89:85053
TITLE: The role of mediators, irritants and allergens in causing mucin secretion from the trachea
AUTHOR(S): Richardson, P. S.; Phipps, R. J.; Balfre, K.; Hall, R. L.
CORPORATE SOURCE: Dep. Physiol., St. George's Hosp. Med. Sch., London, UK
SOURCE: Ciba Foundation Symposium (1978), 54(Respir. Tract Mucus), 111-31
CODEN: CIBSB4; ISSN: 0300-5208
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Histamine acid phosphate [51-74-1] given to cats (**aerosol** into the lungs) and geese (solution directly applied to the trachea) increased mucin secretion by the trachea. Prostaglandins (A2 [13345-50-1], E1 [**745-65-3**], E2 [363-24-6], F1α [745-62-0], and F2α [551-11-1]) increased mucin secretion in both species. 5-Hydroxytryptamine [50-67-9] failed to stimulate mucin output in cats. Ammonia and cigarette smoke both increased mucin secretion in cats by a combination of local and reflex mechanisms. O-chlorobenzilidine malononitrile [**2698-41-1**] increased secretion by the goose trachea entirely by a local mechanism. Expts. in which sensitized cats were challenged by various routes have given equivocal results on whether anaphylaxis increases airway mucin secretion. Irritants caused mucin secretion both by reflexes and local mechanisms, the mechanisms for the latter due perhaps to the release of pharmacol. mediators.

L41 ANSWER 28 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1978:461129 HCAPLUS
DOCUMENT NUMBER: 89:61129
TITLE: Anticorrosive slurry coating materials
INVENTOR(S): Ichimura, Yutaka
PATENT ASSIGNEE(S): Dai Nippon Toryo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53028631	A2	19780317	JP 1976-103286	19760830
PRIORITY APPLN. INFO.:			JP 1976-103286 A	19760830

AB Dispersions of 20-40 parts thermoplastic resin powder and 60-80 parts powdered Zn in H2O are useful as anticorrosive coating materials for metals. Thus, a composition of 30-μ nylon 11 [**25035-04-5**] (softening temperature 186°) 30, powdered Zn 70, H2O 30, **propylene glycol** 10, polyethylene glycol nonylphenyl ether 1, and monoethanolamine 0.5 part was emulsified, applied to a polished steel pipe to 80 μ, dried, and baked 20 min at 250° to give coatings having good salt water-**spray** resistance and postformability.

L41 ANSWER 29 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:177081 HCAPLUS
DOCUMENT NUMBER: 88:177081
TITLE: Fire hazards of some medicinal aerosols
AUTHOR(S): Prikhod'ko, L. S.; Kurchenko, L. S.; Besklinskaya, L. A.; Dumcheva, L. I.
CORPORATE SOURCE: Khar'k. Nauchno-Issled. Khim.-Farm. Inst., Kharkov, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1977), 11(8), 72-4
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The flash point, ignition temperature, and temperature of spontaneous combustion were determined for 16 oils and solns. used as carriers in medicinal aerosols. These included olive oil, lavender oil, camphetone, ephatine, camphomene, liviane, and inhalipt. The temperature of spontaneous combustion for these prepns. was 394, 251, 260, 404, 360, 239, and 507°, resp. The presence of 50% freon in the aerosol carrier did not decrease and, in some cases increased, the flammability of oil or solution
IT **9005-65-6**
RL: BIOL (Biological study)
(in **aerosols**, **inflammability** of)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L41 ANSWER 30 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1978:94831 HCAPLUS
DOCUMENT NUMBER: 88:94831
TITLE: Inflammation-inhibiting, topically applicable pharmaceutical preparation
INVENTOR(S): Rovee, David; Marvel, John; Mezick, James

PATENT ASSIGNEE(S): Johnson and Johnson, USA
SOURCE: Ger. Offen., 37 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2721831	A1	19771124	DE 1977-2721831	19770513
US 4185100	A	19800122	US 1977-788453	19770420
CA 1101334	A1	19810519	CA 1977-277688	19770504
FR 2394293	A1	19790112	FR 1977-13724	19770505
FR 2394293	B1	19800620		
BE 854472	A1	19771110	BE 1977-177453	19770510
GB 1544351	A	19790419	GB 1977-19637	19770510
AU 7725073	A1	19781116	AU 1977-25073	19770511
AU 512371	B2	19801009		
NL 7705276	A	19771115	NL 1977-5276	19770512
NL 190049	B	19930517		
NL 190049	C	19931018		
JP 52145525	A2	19771203	JP 1977-53783	19770512
ZA 7702842	A	19781227	ZA 1977-2842	19770512
AT 7703412	A	19801115	AT 1977-3412	19770512
AT 362869	B	19810625		
US 4282216	A	19810804	US 1979-64311	19790806
US 4360518	A	19821123	US 1981-244569	19810317
US 4473565	A	19840925	US 1982-442997	19821119
US 4579844	A	19860401	US 1984-592142	19840322

PRIORITY APPLN. INFO.:
US 1976-685942 A 19760513
US 1977-788453 A 19770420
US 1979-64311 A3 19790806
US 1982-442997 A3 19821119

GI



I



II

AB Topical antiinflammatory compns. of high activity contain a corticosteroid and a prostaglandin synthetase-inhibiting nonsteroidal compound from the classes of acetylsalicylates, hydratropic acid derivs., pyrazolone derivs., fenamic acid derivs., aroyl-substituted pyrroles, and substituted arylacetohydroxamic acids. Thus, a **propylene glycol** -EtOH-based preparation containing both triamcinolone acetonide (I) [76-25-5] and

suprofen (II) [40828-46-4] was more effective against exptl. skin **inflammations** in mice than were similar prepns. containing either drug alone. Formulations are given for topical creams, solns., gels, salves, powders, **aerosols**, and impregnated adhesive plasters for use with the drugs, and the effects of several types of formulations themselves on the effectiveness of the drugs are described.

L41 ANSWER 31 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:155709 HCAPLUS
DOCUMENT NUMBER: 84:155709
TITLE: Aerosol nasal spray composition
INVENTOR(S): Lapidus, Herbert; Mackles, Leonard
PATENT ASSIGNEE(S): Bristol-Myers Co., Can.
SOURCE: Can., 14 pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 982942	A1	19760203	CA 1970-96153	19701021
PRIORITY APPLN. INFO.:			US 1970-21532 A	19700320

AB A self-propelling powder or liquid composition intended for inhalation therapy containing a pharmaceutically active material, a readily vaporizable propellant liquid, and a hydrophobic oil for reducing the irritating blast effect associated with nasal **aerosol** propellants is reported. The hydrophobic oil contains from 12-40 C atoms, is selected from the group consisting of higher fatty alcs., higher fatty acid esters, and hydrocarbon oils, and comprises from .apprx.5-90% by weight of the composition E.g., an **aerosol** composition contained chlorpheniramine stearate [7586-63-2] 0.7, phenylephrine palmitate [7645-08-1] 1.0, menthol [**89-78-1**] 0.3, oleic acid [112-80-1] 3.0, iso-Pr myristate [**110-27-0**] 55.0, and 40:60 Freon 12-Freon 114 40.0% by weight

L41 ANSWER 32 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:491852 HCAPLUS
DOCUMENT NUMBER: 83:91852
TITLE: Acute toxicity of certain synthetic varnishes
AUTHOR(S): Bielski, Janusz; Mrozikiewisz, Aleksander; Banaszkiewicz, Waclaw; Przyborowski, Henryk
CORPORATE SOURCE: Dep. Hyg. Labor Prot., Sch. Agric., Poznan, Pol.
SOURCE: Acta Physiologica Polonica (1975), 26(1), 25-31
CODEN: APYPAY; ISSN: 0044-6033
DOCUMENT TYPE: Journal
LANGUAGE: Polish

AB Histopathol. changes of varying intensity were observed in the tissues of rats exposed for 72 hr to **sprays** (20,000 mg/m3 air) of the synthetic varnishes, Polimal 110 [**9042-67-5**], Chemolak [9042-13-1], and Plastlak [9042-66-4]. Polimal 110, a polyester varnish, was the most toxic, and produced intraparenchymatous **inflammation** in the lungs, emphysema, and tissue congestion, as well as liver steatosis and congestion and kidney damage. However, all **sprays** contained varnish concns. greater than those occurring in regular usage.

L41 ANSWER 33 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:534856 HCAPLUS
DOCUMENT NUMBER: 81:134856
TITLE: Aromatic oleoresin emulsion

INVENTOR(S): Quesnel, Peter G.; Lambrou, Andreas; Walker, Edwin Stanley
PATENT ASSIGNEE(S): Bush Boake Allen Ltd.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2348004	A1	19740502	DE 1973-2348004	19730924
ZA 7307306	A	19740828	ZA 1973-7306	19730913
AU 7360388	A1	19750320	AU 1973-60388	19730918
FI 55290	C	19790710	FI 1973-2916	19730919
FI 55290	B	19790330		
CH 591816	A	19770930	CH 1973-13614	19730921
BE 805207	A1	19740116	BE 1973-135948	19730924
FR 2199945	A1	19740419	FR 1973-34189	19730924
US 3906116	A	19750916	US 1973-400169	19730924
SE 394584	B	19770704	SE 1973-12981	19730924
NO 138928	C	19781213	NO 1973-3744	19730924
NO 138928	B	19780904		
NL 7313171	A	19740327	NL 1973-13171	19730925
JP 49085275	A2	19740815	JP 1973-107076	19730925
AT 7308262	A	19760515	AT 1973-8262	19730925
AT 334724	B	19760210		
GB 1451448	A	19761006	GB 1972-44220	19731002

PRIORITY APPLN. INFO.: GB 1972-44220 A 19720925

AB An emulsion of aromatic **oleoresin** was prepared by diluting **pepper**, turmeric, cinnamon, mushroom, or ginger with 0.25-1.25 parts by weight of EtOH, PrOH, or **propylene glycol**, admixing with an emulsion stabilizer and an edible or essential oil, and emulsifying. The emulsion is then encapsulated or **spray** dried for use in soups, sauces, vinegar, pickles, and meat products.

L41 ANSWER 34 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:407261 HCAPLUS
DOCUMENT NUMBER: 73:7261
TITLE: Aerosol borates composition to treat inflammations of the skin
PATENT ASSIGNEE(S): Aerosol Maatschappij Holland N. V.
SOURCE: Neth. Appl., 5 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6811874		19700224	NL	19680820

AB The **aerosol** compns. contain a propellant and a boric acid triester of a C1-6 aliphatic alc. The concentration of ester (or mixture of esters) is 1-60 weight % calculated on the total weight of the composition Difluoroethane, ethane, CO2, or N is a suitable propellant. The compns. are especially active against infective **inflammations** of the skin, e.g., athlete's foot or paronychia. A typical-composition contains Et3BO3 20, scopolamine 0.0025, **propylene glycol** 4.0, iso-PrOH

25.4975, Freon 11 20.0, and Freon 12 30.0%.

L41 ANSWER 35 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1966:51232 HCAPLUS
DOCUMENT NUMBER: 64:51232
ORIGINAL REFERENCE NO.: 64:9521c-d
TITLE: Stabilized fluocinolone acetonide compositions
INVENTOR(S): Chapman, George T.; Senior, Norman; Woodman, Michael; Pearce, Jaqueline S. D.
PATENT ASSIGNEE(S): Imperial Chemical Industries Ltd.
SOURCE: 5 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1013180		19651215	GB	19621030

AB The decomposition of fluocinolone acetonide (6α,9α-difluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione) (I) in anti-**inflammatory** compns. is prevented by the addition of citric acid (II), preferably in quantities <1% of the compns. The compns. are made up with conventional excipients and may also contain antibiotics, e.g. neomycin. Thus, a cream was made by blending, at 60-5°, stearic acid 10, sorbitan monostearate 5.2, poly(oxyethylene) sorbitan monostearate 2.8, sorbitan monoleate 1.0, Me p-hydroxybenzoate 0.18, Pr p-hydroxybenzoate 0.08, II 0.01, thiomersalate 0.002, I 0.025, **propylene glycol** 5, and H2O 76 parts. Similarly, compns. containing I and II were made in the form of lotions, ointments, and **aerosol spray** solns.

L41 ANSWER 36 OF 36 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1962:79695 HCAPLUS
DOCUMENT NUMBER: 56:79695
ORIGINAL REFERENCE NO.: 56:15619i,15620a-b
TITLE: Preparation protecting the skin against ultraviolet rays
INVENTOR(S): Hach, Vladimir; Seda, Miroslav; Veris, Otomar; Borovicka, Milos; Kakac, Bohumil; Volek, Frantisek
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 98951		19610315	CS	19591215

PRIORITY APPLN. INFO.: CS 19591215

AB The combination of C1-18 alkyl ethers of α-naphthol with azulenes, especially guaiazulene, gives a preparation with a high absorption power at 2900-3000 A. which show the highest irritant and **inflammatory** effects on human skin. Alkyl ethers of α-naphthol are highly stable against sun radiation and chemical influences. The active component is dispersed in a liquid, semisolid, or pasty substance. Thus, Bu α-naphthyl ether (I) 1.0, guaiazulene 0.1, perfume 0.1, and liquid paraffin up to 100 g. were mixed at room temperature and stored in brown glass bottles. Similarly, Et α-naphthyl ether 2.0, perfume 0.5, and olive oil up to 100 g. were

mixed and charged to **aerosol** bottles. To the mixture of polyethylene glycol 80.0 and **propylene glycol** 17.0 was added at 40-50° I 2.0 g.; this mixture was homogenized, cooled to room temperature, 1.0 g. perfume added, and the product stored in glass bottles.

=>